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ABSTRACT 
Treatment of lead poisoning relies primarily on chelation therapy. The 
sodium salt of (R,S)-2,3-dimercapto-l-propanesulfonic acid (DMPS, DimavalL ®) 
is a water-soluble analogue of British Anti-Lewisite (BAL). Its oral dosage form is 
considered effective for the diagnosis and treatment of mercury poisoning 
(Aposhian et a!., 1995). In adults, therapeutically successful attempts have been 
reported for the treatment of chronic lead poisoning with DMPS (Anatovskaya, 
1962). In children having chronic lead poisoning, the efficacy of DMPS was noted 
following a 5-day therapy (Chisholm & Thomas, 1985). 
Despite its current use in chelation therapy for the treatment of lead 
poisoning, detailed chemical characterization and/or investigation of the resulting 
complexes has not been fully investigated. DMPS and its complexes with lead are 
electro active, consequently have been investigated using electro analytical 
techniques. This present work was designed with the aim of (a) investigating the 
in-vitro complexing behavior of DMPS with lead at simulated physiological 
conditions, (b) in-vivo investigation of the chelation therapy of low and highly 
exposed subjects (workers). 
Electroanalytical techniques including: Voltammetry at the Dropping 
Mercury electrode, Differential Pulse Polarography (DPP), Anodic Stripping 
Voltammetry (ASV), and Cathodic Stripping Voltammetry (CSV), have been 
employed for investigating the complexing properties ofDMPS. 
1 
Application of the methods suggested by Deford-Hume and Shuman-
Woodward for measuring stability constants of metal complexes, showed that the 
formed Pb:DMPS complex could be a labile coordination complex having a 
formation constant ofKf= 2.66xI04• 
In addition, the results demonstrated that the Pb:DMPS species was much 
weaker than that formed between Pb2+ and EDTA (Kf = 1.25xI018). This may 
indicate that the mobilized lead from soft tissues and bone after chelation may have 
involved mechanisms other than complex formation. 
The in-vitro results demonstrated that electroanalytical techniques proved to 
be highly sensitive and selective for investigating both lead as well as DMPS levels 
in biological fluids. However, after chelation optimizing the media to enhance 
selectivity was necessary. 
Upon titration of DMPS versus lead or alternatively lead versus DMPS, the 
results showed that lead did not form a stable coordination complex. However, a 
compound with enough stability was formed which mobilized lead from body 
stores as demonstrated by levels of lead in urine measured after a single oral dose 
of DMPS (100 mg/ 3 capsules). Additionally, after dosing of exposed subjects 
classified as having low and high lead body burden, in-vivo findings showed that 
lead was substantially chelated after dosing with 100 mg DMPS/ 3 capsules. 
However, the lead-DMPS complex was not detected in urine and hence was 
regarded as a labile coordination complex. The latter finding compared well with 
in-vitro studies. 
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CHAPTER I 
INTRODUCTION 
Lead is a ubiquitous metal, soft with silvery gray color (atomic weight 207.19, 
m. p. 327.5 °C). The metal is resistant to corrosion and this property together with its ease 
of handling has led to its widespread use for thousands of years. Lead exists as the metal 
and as its compounds, both inorganic and organic, which enter the environment either 
from natural sources, or through various industrial processes e.g. mining, smelting, 
recycling, or waste disposal (Tsuchiya 1985). Techniques for shaping and smelting lead 
have been known for thousands of years. It is not only one of the oldest metals known, 
but it has also been investigated more and for a longer time than almost all other metals 
(Greenwood et aI., 1984). In spite of the growing awareness and evidence about the 
sources, risks, causes and effects of lead on various body organs, cases of lead poisoning 
still continue to occur in many localities, in particular, among occupationally exposed 
workers, and in certain selected child populations (Mahaffey et aI., 1985). Battery 
workers constitute one occupational group with a high risk of developing chronic lead 
pOIsomng. 
1.2. Lead in the Environment 
The transportation and distribution of lead from fixed, mobile and natural 
resources are primarily via air. Airborne lead can contribute to human exposure via 
contamination of food, water and dust, as well as through direct inhalation. 
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Lead deposited in water, whether from air or through run-off from soil, partitions 
rapidly between sediments and the aqueous phase, depending upon the pH, salt content. 
and the presence of organic chelating agents. However, generally lead remains localized 
because of its poor solubility in water, except at low pH. 
Generally, in non-smoking populations, the major source of exposure is from food 
and water. Airborne lead may contribute significantly to human exposure, depending 
upon factors such as: use of tobacco, occupation or proximity to lead smelters. In 
children, the main source of exposure to lead is from food, air, dust, soil and water, 
particularly since hand to mouth activity is common at ages one and half to three years. 
Levels of lead found in the air, water and soil/dust vary widely depending on the 
degree of industrial development, urbanization and lifestyle factors. Ambient air levels 
vary depending on the area. In the vicinity of lead smelters, air lead levels have been 
reported to be higher than in cities where leaded petrol is no longer in use. Lead intake 
from air can therefore vary from less than 4 Jlg/day to more than 200 Jlg/day 
(IPCS/WHO, 1995). Lead concentrations in drinking water may reach as high as 100 
Jlg/l. However, if samples were taken from the water source, levels may be as low as 5 
Jlg/I (IPCS/WHO, 1995). 
Exposure to lead from dietary intake depends upon many lifestyle factors, 
including: foodstuffs consumed, food processing technology, use of lead solder, lead 
levels in water and the use of lead-glazed ceramics. 
Additionally, in some regions lead is used as a medical remedy and in certain 
areas is used in cosmetic preparations. 
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Lead in dust and soil remains the major source of exposure in children and 
infants. A number of factors may contribute to the level of exposure such as domestic 
conditions, use of lead based paints, and lead in petrol or urban density (US EPA, 1986a). 
In infant and children, lead in soil and dust constitute a major source of exposure in 
addition to behavioral characteristics that, among other factors, contribute to lead intake 
by this age group (Marlowe et ai., 1982). In adult populations, inhalation remains the 
dominant pathway of occupational exposure. 
Workers in industries that produce, refine, use or dispose of lead and its 
compounds, may absorb as much as 400 /-lg of lead during a typical (8 hour) working day. 
In-addition exposure via food and water may constitute an additional burden (US EPA, 
1989). 
1.3. Sources of Lead Exposure in Jordan 
Although progress for the control of occupational lead exposure has undoubtedly 
been made world wide, the condition is not yet nationally noticeable. Furthermore, in the 
past few years, measures have been taken to determine the permissible food and water 
lead levels. These levels must comply with international standards. The Jordanian 
Ministry of Health central laboratories conduct this particular test on regular basis. In 
children, lead exposure accounts for less than 1 % of total cases of lead toxicity reported 
(Ministry of Health, 1995). Khalil, and Co-workers, (1994) measured blood lead levels in 
children under the age of five (n = 486). 
In-spite of these results, use of leaded gasoline (98% of total gasoline) remains the 
main source of exposure in non-occupationally exposed individuals. 
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Although, most industries in Jordan do comply with the World Health 
Organization (WHO) standards for blood lead levels of 40 ~g/dl in occupationally 
exposed workers the majority of cases of lead poisoning reported to medical centers are 
due to occupational exposure to lead and/or its compounds. At the present time there are 
no accurate records of lead exposed subjects in Jordan. Information on lead exposed 
workers has been documented only in the past few years. However, it is believed that the 
main source of exposure to lead is among workers in battery manufacture. Evaluations 
suggest that the current lead exposure at battery manufacture plants is a major health 
concern. 
In Jordan, manufacture of lead storage batteries accounts for the largest 
consumption of lead most of which has required re-smelting. Production of lead storage 
batteries involves the use of both metallic lead, in the form of lead-antimony alloy, as 
well as oxide(s) of lead in almost equal amounts. Metallic lead is used in the production 
of grids, whereas lead oxide(s) are used for plate pasting. Secondary smelting involves 
four main stages: handling and preparation of scrap (battery breaking), furnace melting, 
refining and casting. The processes that generate lead fumes or dust include: casting 
grids of metallic lead or lead alloy, pasting the interstices of the grid with lead oxide paste 
and assembling batteries using gas welding. Therefore, lead exposure can occur at each 
stage with various degrees of exposure. Lack of industrial hygiene expertise, regulation, 
and workers education remain the major factors in increased occupational lead poisoning. 
In Jordan there are three battery plants employing 160 workers with a mean of 
14.5 working years. These workers now undergo biannual medical assessment. 
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Further clinical and biochemical investigations are conducted on workers with 
blood lead concentration above the WHO permissible level of 40 Jlg/dl. About 20% of 
routinely examined blood lead samples are above this WHO level. Symptoms reported 
by workers vary from mild abdominal pain (40%), constipation (95%), fatigue (85%), 
joint pain (80%), loss of appetite (35%) and lack of concentration (17%) to discoloration 
of the gingival margins (65%) (Ministry of Health, Annual Report 1999, Jordan). 
However, severe cases of acute lead poisoning are extremely rare, although one to two 
cases may occur annually due to acute exposure to lead fumes. Because of its physical 
and chemical properties, lead is used in a wide variety of industries and trades other than 
battery manufacture. These include, among others, manufacture and use of cables, 
pigments, petrol (gasoline) additives, solder and steel products. 
1 .4. Physiology of Lead. 
The potential for inorganic lead exposure varies widely with a number of factors 
including the route of exposure. In humans, lead is absorbed following inhalation or 
ingestion whereas percutaneous absorption is minimal. Up to 50% of the inhaled lead 
may be absorbed, and influenced by its chemical speciation, particle size, and solubility in 
body fluids (IpeS/WHO, 1995). 
It is well known that once lead is absorbed, it is not distributed homogeneously 
through out the body. Blood and soft tissue initially contain most of the absorbed lead, 
while a slower redistribution to bone occurs later. The half-life of lead in blood and soft 
tissue is about 30-36 days, while bone effectively serves as an endogenous reservoir of 
lead, with considerably longer half-life (27 years). 
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In children the retention of lead in body stores is much greater than in adults 
(Marcus et aI., 1985c). Blood lead is distributed between the plasma and the erythrocytes. 
At normal concentration, around 95% of blood lead is contained within the erythrocytes. 
The capacity of erythrocytes to bind lead is about 50 Ilg/dl of whole blood. Above this 
level, a rapid increase in plasma lead concentration occurs and levels as high as 100 Ilg/dl 
have been reported (Mantan and Cook 1984). Lead has greater affinity to bind to fetal 
hemoglobin as compared to adult hemoglobin (Ong and Lee 1980). With continued 
exposure, the initial loosely deposited lead in bone becomes fixed as inert lead phosphate. 
Ponds, et aI., (1991) postulated that lead starts to accumulate in the human 
skeleton during fetal development and continues to about 60 years of age. Because 
absorption of battery lead from the gastrointestinal tract is minimal (less than 5%), most 
ingested lead passes through the intestine and is excreted via faeces. Excretion of lead is 
very slow, even when excessive lead intake is stopped. Age as well as exposure 
characteristics have an impact on the amount of lead excreted (US EPA, 1986a). 
1.5. Clinical Picture of Lead Poisoning 
The clinical symptoms of lead poisoning are non-specific and hence, the disease 
has been called the silent disease. Furthermore, there may be an absence of clinical 
symptoms in some subjects with blood lead concentrations exceeding 100 Ilg/dl, while 
symptoms may be present in others at concentrations as low as 40 Ilg/dl (Pagliuca et aI., 
1990). Symptoms of lead poisoning tend to follow a sequential pattern. 
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At low blood lead concentrations, subtle neurological symptoms including fatigue, 
irritability, lack of concentration and coordination are observed. At higher concentrations 
aching joints and limb muscles will develop, together with colicky abdominal pain 
preceded by severe constipation and often accompanied by vomiting (Lilis et aI., 1977). 
Pallor appears at a relatively late stage, accompanied by severe anaemia. Anaemia 
has been associated with lead exposure as a consequence of inhibition of haem 
biosynthesis, the red blood cells are microcytic and hypochromic, as in iron deficiency, 
and usually there are increased numbers of reticulocytes with basophilic stippling, which 
result from the inhibition of the enzyme pyrimidine-5-nucleotidase (Pagliuca et aI., 1975; 
1990). In-addition, to clinical conditions other than lead poisoning, basophilic stippling 
of the erythrocytes has been associated with infection, red cell injury by haemolytic 
chemicals, and other types of anaemia. Grandjean, et aI., (1989a) demonstrated that the 
deficiency may persist for a considerable time after cessation of exposure and this may be 
attributed to the failure of the erythropoietic system to compensate. However, Graziano, 
et aI., (1991) postulated that inhibition of the erythropoietin hormone, which normally 
regulates the formation of erythrocytes, is also involved affecting the reserve capacity for 
erythropoiesis. 
The ancient Greek physicians reported toxic effects of lead on the nervous system. 
More recently, Stollery, et aI., 1989, studied the effect of lead on occupationally exposed 
workers and the results showed a significant decrease in performance on a battery of tests. 
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Of these tests, sensory and motor reaction times, memory, attention, verbal 
reasoning and spatial processing are affected. Peripheral nerve palsies resulting in wrist 
drop have been rarely seen in adult workers. 
Blue lines in the gingival margins have been described in highly exposed subjects 
with blood lead levels ranging between 100 to 200 Jlgldi. These lines are thought to 
consist of lead sulfide precipitates due to the interaction of hydrogen sulfide with lead. 
Furthermore, lead exerts toxic effects on various other organs such as bone. Bone lead is 
transferred to other target organs as well as blood. There is evidence that a complex 
interaction between lead and bone components i.e., minerals, cells and extracellular 
matrix occurs which affects its homeostasis. 
It has been suggested that lead may affect the cardiovascular system. For 
example, studies such as the British Regional Heart Study (BRRS) and the National 
Health and Nutrition Examination Survey (US NHANES II), (Shaper et aI., 1981) 
focused on the impact of blood lead levels on systolic and diastolic blood pressure taking 
into consideration potential confounding factors e.g. age, alcohol consumption, smoking 
and town of residence. They concluded that at a low blood lead level of 1.45 Jlg/dl, there 
was no significant correlation between lead and blood pressure. Although when blood 
lead levels were doubled, there was a weak association (Pocock et aI., 1988). 
1 .6 Occupational Exposure 
Occupational exposure to lead fumes at levels, which result in poisoning, still 
occur in many countries (Verrula & Noah 1990). 
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In the occupational setting, there were only concerns for the identification of late 
stage, highly symptomatic cases of lead poisoning resulting in crippling neurological 
manifestations of lead toxicity such as palsy and encephalopathy (Lin-Fu 1985). In many 
countries occupational lead exposure is entirely unregulated and no monitoring of 
exposure exists. Therefore, significant lead exposure is not limited to traditional heavy 
industries (Kaye 1987). Most occupational standards are based on the level of airborne 
lead only, however this route of exposure doesn't fully reflect the total daily exposure of 
workers, particularly exposure may occur from other sources such as food, water 
alcoholic beverages and dusts. 
1 .7. Diagnosis of Lead Poisoning 
Until recently, occupational physicians seemed unable to decide whether the 
initial biochemical changes observed at the onset of exposure to lead were an adaptation 
phenomenon or whether they indicate an early stage of lead poisoning (Buchet et ai., 
1980). Methodological difficulties in measuring lead and the different porphyrins in 
biological fluids, together with the complex dynamics of lead absorption, distribution, 
and excretion were probable factors responsible for the lack of positive correlation 
between lead levels and other biochemical indicators of lead exposure. 
However, measurement of the blood lead concentration remains the most 
commonly used indicator of exposure for assessing lead body burden. Therefore, 
diagnosis of lead poisoning relies primarily on the clinical and laboratory findings. 
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The clinical picture, duration of exposure and the time of sampling are considered 
exceedingly valuable criteria, not only for diagnosis, but also for assessing the degree of 
exposure particularly among occupationally exposed subjects. 
1.8. Biochemical Effects of Lead 
Blood lead (BPb) is distributed between the plasma and the erythrocyte. There is 
evidence that erythrocytes have the capacity to bind lead up to 50 Ilg/dl, and consequently 
lead levels in whole blood increase with the increase of lead in the erythrocytes (Manton 
& Cook 1984). Above this level a fairly rapid increase in plasma levels occurs, therefore, 
the proportion of "free" ionized blood lead is considered important in relation to its 
biological activity. Lead exerts toxic effects on the erythroid cells, where it can affect the 
activity of a number of enzymes essential for the haem biosynthetic pathway. Although 
little is known about the time sequence of the reported biochemical disturbances, there is 
evidence indicating that these changes are directly related to the level of exposure. 
Figure 1.1 illustrates that the normal haem biosynthetic pathway consists of eight 
steps, each of which is catalyzed by a specific enzyme. The resulting compound from 
step 1 comprises two steps; the first is the reaction between pyridoxal phosphate with 
glycine to produce the activated glycine. In the second step the activated glycine reacts 
with succinyl CoA to produce 8-Aminolaevulinic Acid (ALA). The second reaction is 
catalyzed by ALA synthetase (ALA-S) (Barltrop 1975). 
Step 2 to 5 take place in the cytosol and begin by the condensation of two 
molecules of ALA to yield porphobilinogen (PBG), the monopyrrole precursor of 
porphyrins and haem. 
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This step is catalyzed by 0- aminolaevulenic acid dehydratase (ALA-D). In step 3 
and 4, four porphobilinogen moities are linked to give the tetrapyrrol rings of 
uroporphyrinogen. This step is catalyzed by uroporphyrinogen I synthetase. In step 5 the 
four acetic acid side chains are decarboxylated by the action of uroporphyrinogen 
decarboxylase to produce coproporphyrins I and III. 
In step 6 two propionic acid side chains of coproporphyrinogen III undergo 
decarboxylation and oxidation by the action of coproporphyrinogen oxidase to form vinyl 
groups, thus producing protoporphyrinogen. Step 7, is where six hydrogen atoms are 
removed by the action of protoporphyrinogen oxidase to produce protoporphyrin IX. 
Step 8, involves the chelation of ferrous iron with protoporphyrin to form haem. This 
reaction is catalysed by ferrochelatase. 
Lead prevents the conversion of ALA to porphobilinogen and coproporphyrinogen 
III to protoporphyrin IX by inhibiting the activity of ALA dehydratase (ALA-D) and 
coproporphyrinogen oxidase. It also interferes with the conversion of protoporphyrin to 
haem through the inhibition of ferrochelatase. An increase in urinary excretion of ALA 
and coproporphyrins reflect the outcome of this inhibition (Moore et aI., 1987). The 
inhibition of ferrochelatase, leads to the accumulation of protoporphyrin in the red blood 
cells. ALA-D is the only enzyme of the haem biosynthesis pathway, which is cytosolic 
while the others are in the mitochondria. 
Because it is cytosolic and is easily accessible, ALA-D is the most commonly 
investigated enzyme (Mushak 1989; Hirata 1996) lead poisoning. 
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Direct biochemical evidence indicates that ALA-D is the most sensitive index for 
exposure to lead, and its inhibition is therefore observed even in cases of low lead 
exposure. As mentioned above, the effect of lead on ferrochelatase is to inhibit the 
incorporation of ferrous iron into protoporphyrin. Zinc ions become non-enzymically 
located at the center of the tetrapyrrole ring, forming zinc protoporphyrin (ZPP). 
Increased concentrations of ZPP in erthyrocytes may be measured in subjects with 
exposure to lead. 
12 
Cell 
Mitochondria 
Glycine + succinyl CoA 
ALA Synthatase 
Negative 
Aminolaevulinic acid ALA ..... 
Feedback 
Haem 
F errochelatase 
Protopophyrin IX 
t 
Protoporphyrinogen 
oxidase 
I 
Protoporphyrinogen 
Coproporphyrino-
gen oxidase 
Cytosol 
. ..................... ............................................................................ ... ~ ALA 
ALA 
dehydratase 
• Porphyrinogen (PBG) · ................. ~ PBG 
PBG deaminase 
Uroporphyrinogen 
synthetase 
Uroporphyrinogen III ............. ~ Uroporphyrin 
Uroporphyrinogen 
decarboxy lase 
Coproporphyrinogen 
'--__________ ~ __________ --L ......... ~ Coproporph. 
o Enzymes not depressed by lead 
D Enzymes depressed by lead 
Figure 1.1. Haem Biosynthetic pathway showing the enzymes depressed and 
not affected by lead 
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When a subject is first exposed to lead, the blood lead concentration rises and the 
ALA-D activity falls within days, whereas the rise in urinary ALA and coproporphyrin III 
levels are not detected until at least 2-6 weeks post exposure (Meredith et aI., 1978). 
Accumulation of zinc protoporphyrin is even slower and takes about 2-4 months. Both 
coproporphyrin in urine and zinc protoporphyrin (ZPP) in blood have been investigated as 
possible biomarkers for lead exposure. The results of ZPP could be confounded by 
concurrent iron deficiency anemia. Therefore, measurements of urinary coproporphyrin 
and ZPP in blood have limited usefulness as biological indicators of environmental 
exposure particularly at blood lead levels below 25 J.lg/dl (Marcus et aI., 1987 and Al-
Saleh et aI., 1992). 
Other studies have demonstrated that upon the removal of lead exposed subjects 
from the site of exposure, a dramatic fall in urinary ALA and coproporphyrin III levels 
were observed, while zinc protoporphyrin levels fell after few weeks. Conflicting results 
have been reported with regards to ALA-D activity. Some believe that the activity of 
ALA-D may even remain depressed for many years following the removal of exposed 
subjects (Granick et aI., 1973). In-addition to haem inhibition, lead also interferes with 
the sodium-ATPase pump, thus causing increased fragility and decreased survival of red 
blood cells (Hasan et aI., 1967). 
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1 .9. Treatment of Lead Poisoning 
The mainstay therapy in the management of lead poisoning is based on chelation. 
Generally, the aim of chelation is to remove the toxic metal ions from hard and/or soft 
tissue. This can be achieved when the chelating agent exerts higher affinity to the metal 
ions than the affinity of the metal for biological molecules. 
Several factors may contribute to the biological and/or clinical effectiveness of a 
chelating agent (ligand). These include: (a) high affinity of the ligand towards the toxic 
metal ion (b) low toxicity (c) limited interactions with essential biological molecules (d) 
penetration of the ligand to tissues where the metal is deposited (e) rapid elimination of 
the ligand-metal complex via the kidney (f) and specificity. Greenwood et aI., 1984, 
evaluated the chelating agents used in the treatment of lead poisoning in both humans and 
animals (Table 1.1). 
These include: 
(1) Calcium disodium ethylenediaminetetra acid, known as EDTA. 
(2) Dimercapto-chelating agents: 
(a) dithiol, 2,3-dimercaptopropanol known as BAL. 
(b) meso 2,3-dimercaptosuccinic acid known as DMSA. 
(c) sodium 2,3-dimercaptopropane-l-sulfonic acid known as DMPS. 
(3) D-penicillamine. 
15 
Table 1.1. Comp~rison Properties of Common Chelating Agents 
Stability of 
Chelating Agent I Specificity I Pharmacokinetics I Chelating 
Dimercaptol 
(2,3-Dimercapto-
propanol) 
(BAL) 
Meso-2,3-
Dimercapto 
Succinic Acid 
(DMSA) 
D-Penicillamine 
EDTA and 
Na2CaEDTA 
2,3-Dimercapto-l-
Propane Sulfonic 
Acid 
mM~ 
Useful antidote in 
arsenic, mercury, 
and lead poisoning 
It has status FDA 
orphan drug for 
lead poisoning. 
Useful antidote in 
arsenic, lead & 
mercury poisoning 
Efficient chelator 
of many divalent 
and trivalent 
metals in vivo. 
Efficient chelator 
for Mercury, Lead 
and Arsenic 
Readily absorbed, 
metabolized and excreted by 
kidney within four hours. It 
interacts directly with metals 
in blood and tissue fluids and 
reactivated cellular 
sulfhydryl containing 
enzymes. 
57% was found in gastric 
tissue. Excreted as 16% in 
urine, 70% in faeces, 1.6% 
as CO2. 
It is readily absorbed from 
the gut. Resistant to 
metabolic degradation. 
EDT A penetrates cell 
membrane relatively poorly, 
thus considered an 
extracellular chelator. 
It binds to plasma protein 
and eliminated by kidney 
Agent 
Unstable in aqueous 
solution, dispensed in 
10% solution in 
peanut oil. 
Remarkably stable 
for dimercapto 
compounds, 
especially at acidic 
pH. 
Unknown 
Remarkably stable 
Remarkably stable 
for dimercapto 
compounds at acidic 
pH. 
16 
Toxicity and Adverse 
Effects 
Cardiovascular, Headache, 
Nausea, Vomiting, 
Lacrimation, Salivation, 
Parethesis & pain. It has a high 
cellular toxicity. 
Relatively non-toxic agent for 
treatment of metal poisoning 
has less cellular toxicity than 
BAL, since it is more polar. 
D-isomer is relatively non-
toxic compound. Pyridoxine 
deficiency is a toxic effect of 
L-isomer. Acute allergic 
reaction, Bone narrow-toxicity 
resulting in a plastic anemia, 
autoimmune disease. 
EDT A is toxic to kidney in 
high doses. Chills, Fever, 
Nausea, Vomiting, Allergic 
reaction may occur.. 
Allergic reaction to DMPS are 
rare, Nausea, Weakness, 
Vertigo and itching. 
Dosage 
form 
Given LV., 
I.M. 
Effective 
when given 
orally. 
Given orally 
Slow 
intravenus 
infusion or 
intramuscularl y 
Effective 
when given 
orally. 
Remarks 
Increases the 
excretion of 
endogenous 
trace elements 
Increases the 
excretion of 
endogenous 
copper 
(clinically not 
important). No 
serious side 
effects were 
observed. 
Chelation of 
essential calcium 
in vivo 
circumvented by 
using 
Na2CaEDTA 
Increase Cu2+ 
Mn2+ and Al J+ 
excretion 
1.9.1. Calcium Disodium Edetate (CaNa2EDT A) 
Calcium disodium edetate (EDT A), which belongs to the polyaminocarboxylic 
acid family, was introduced in the 1950's for the treatment of lead poisoning, particularly 
in cases of asymptomatic lead poisoning in children (Schoen 1993). It has been also used 
extensively as a tool for the diagnosis of lead poisoning to support the decision as to 
whether chelation therapy should be initiated, particularly in childhood poisoning 
(Chisholm 1987 & 1992). It is usually administered by slow intravenous infusion simply 
because its oral absorption from the gastrointestinal tract is very poor. 
The distribution of EDT A is mainly extracellular. It forms a 1: 1 coordination 
complex with lead (Figure 1.2) via the formation of 4 coordination bonds (kr = 1.2x 1 018). 
EDT A is insoluble in water with a fairly small volume of distribution. Fifty percent of 
this complex is eliminated via the renal system within 1 hour while ninety five percent is 
excreted after 24 hours. Treatment with EDT A has been shown to produce a rapid fall in 
blood lead levels, and a consequent increase in urinary excretion of lead (Piomelli et aI., 
1984). Although EDT A has proven to be effective in the treatment of acute lead 
poisoning, toxicity to the renal tubules has led to a reduction in its use. Additionally, in a 
study conducted by Cory-Slechta (1987) on rats, EDT A proved to be ineffective in 
depleting lead from the brain, however it may result in further redistribution to plasma, 
kidney and the brain. In spite of EDTA's effectiveness in reducing blood lead 
concentrations, its use is limited due to low gastrointestinal absorption, non-specificity 
and the need for higher dosage which may cause proximal tubule toxicity as a 
consequence of the release of lead in the kidney during its excretion (Moe! and Kumar 
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1982; Khan et aI., 1983; Klaassen 1996). Additionally, other side effects of minor 
importance include, malaise, fatigue, chills, fever, myalgias, headache and urinary 
frequency and urgency. Depletion of endogenous metals such as zinc, iron and 
manganese were observed following chronic therapy (Chisholm &Thomas et aI., 1985), 
but the amounts excreted are relatively low and are not of clinical concern particularly 
during a short period of therapy (Mc Neil 1995). 
o 0 
II II 
-O_C C - 0- Na+ 
H22 '- j CH2 _ CH2 bH2 
N "N/ 
H2C / ................... Ph " CH2 
t_o/ ~o_t 
~ ~ 
Figure 1.2. Lead Complex with EDT A. 
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1.9.2. Dimercapto Chelating Agents 
Although chelation therapy with dimercapto agents was initiated 50 years ago 
during World War II, its indication for use in asymptomatic children and adults remains 
controversial. It is debatable if chelation therapy should be initiated based on blood lead 
level whether or not there are symptoms. Therapy using chelating agents is mostly made 
on clinical judgment. 
Table 1.2. Structural Similarities between Dimercapto Chelating Agents. 
Compound Structure 
H H H 
2,3-dimercapto-l-propanol H_d_t_ ~_OH 
(BAL) ~ ~ ~ 
I I 
H H 
0 H H 0 
Meso 2,3-dimercaptosuccinic II I I II 
HO-C-C-C-C-OH 
acid (DMSA) ~ I S 
I I 
H H 
H H H 
Sodium 2,3-Dimercapto -I- I I I 
H-C-C-C S03· Na+ 
propanesulfonic acid I I I S S H 
I I (DMPS) H H 
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a. 2,3-Dimercapto-l-propanol (BAL) 
Dimercaprol or British Anti Lewisite is a well-established chelating agent for 
heavy metals. It has been employed for the treatment of inorganic and elemental mercury 
poisoning and arsenic poisoning. BAL has been used in combination with EDT A in cases 
of lead poisoning. BAL was initially used in W orld War II for mustard and Lewisite gas 
intoxication. It is a relatively colorless liquid with a sulfur odor. It is highly lipid soluble 
with low water solubility and is not very stable in aqueous solutions. Because of its high 
lipid solubility, it distributes intracellularly and extracellularly. BAL enters the cells 
particularly the erythrocytes and also passes the blood brain barrier. 
Endogenously, metals are bound to sulfhydryl groups in protein systems. BAL 
has a greater affinity for metals and successfully acts as a competitor with the formation 
of a stable heterocyclic metal-ligand complex, which results in decreased toxicity. BAL 
has been successfully used in combination with EDT A, particularly in children with lead 
encephalopathy showing significant increase in urinary excretion of lead (Chisholm 
1992). The onset of action of BAL is within 30 minutes following its administration. 
Excretion of the complex formed occurs within 4-6 hours, via the biliary and renal 
systems (Chisholm 1990). 
Additionally, BAL has proven to be successful in the removal of arsenical 
compounds through the formation of a stable 5-membered ring via combination with 
sulfhydryl (SH) groups (Peters et ai., 1945). However, its effectiveness is limited in 
humans since it causes an increase of the lead in the brain (Hoover & Aposhian 1983). 
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b. Meso 2,3-Dimercaptosuccinic acid (DMSA) 
Meso 2,3-dimercaptosuccinic acid (DMSA) is considered one of the most 
effective oral chelating agents for lead poisoning. It is relatively selective, hydrophilic 
and an analogue to British Anti-Lewisite (BAL). Very little is known about its 
physiochemical properties, despite the extensive biological studies on DMSA (Rivera, et 
aI., 1989). DMSA is a weak tetraprotic acid containing two carboxylic acid groups and 
two sulfhydryl groups. Values of the four protonation constants have been determined 
potentiometrically using a glass electrode (Anderegy et aI., 1970 and Lenz et aI., 1965). 
Table 1.3. Protonation Constants of Meso - DMSA. 
Interaction 
Meso-DMSA 
(T = 20°C) 
Meso-DMSA 
(T = 23°C) 
Racemic-DMSA 
Bpr : protonation constant 
p: number of ligands 
r: number of protons 
Species 
n 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Log Bpr 
r 
1 12.8 
2 22.25 
3 26.80 
4 29.96 
1 10.79 
2 19.68 
3 23.16 
4 25.87 
1 11.00 
2 20.61 
3 24.57 
4 26.82 
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Reference 
(Anderegy, 1970) 
(Anderegy, 1970) 
(Anderegy, 1970) 
(Anderegy, 1970) 
(Lenz, 1965) 
(Lenz, 1965) 
(Lenz, 1965) 
(Lenz, 1965) 
(Anderegy, 1970) 
(Anderegy, 1970) 
(Anderegy, 1970) 
(Anderegy, 1970) 
DMSA is available as a white crystalline powder and exists in two forms: the 
meso and DL forms. The two forms possess different physical and chemical properties. 
The meso form (m.p. 210-211 °C) is sparingly soluble in water, and soluble in basic 
aqueous solution. The DL form (m.p. 120-125°C) is readily soluble in distilled water and 
rearranges to meso form when heated above its melting point. At acidic pH values 
DMSA is stable but decomposes in basic solutions (Aposhian et aI., 1982). 
The racemic form of DMSA has been successfully used in the treatment of lead 
poisoning in children and adults (Graziano et aI., 1985; Graziano et aI., 1991). The US 
Food and Drug Administration (FDA 1991) has approved the use ofDMSA, as an orphan 
drug for the treatment of lead poisoning in children. 
DMSA causes an increase in trace metal excretion such as arsenic and mercury 
(Lenz et aI., 1981). It reduces lead concentrations of the blood, brain, and kidney without 
redistributing lead from bone (Cory-Slechta 1988). Another advantage of DMSA over 
other dimercapto chelating agents, it is the least toxic based on i.p. LDso determination in 
mice (Table 1.4) and other animals (Aposhian et aI., 1984). 
Table 1.4. LD50 determination i.p. in mice (Aposhian et 01., 1984). 
Compound LDso 95%, confidence 
Mmol/kg interval 
BAL 1.48 1.11 1.97 
DMPS 6.53 5.49 7.71 
Meso-DMSA 13.73 11.36 15.22 
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Absorption of DMSA following an oral dose is rapid but incomplete. Both blood 
and plasma data fit a two-compartment model and exhibit an apparent elimination half-
life of approximately 48 hours. The volume of distribution of DMSA is fairly small with 
the majority of the drug remaining in the plasma (McNeil, Inc., Consumer Products 
1992). DMSA appears to be rapidly and extensively metabolized in man to form a mixed 
disulfide with L-cysteine (Mairorino et aI., 1989). The kidney rapidly excretes DMSA 
and 75% of the renal excretion occurs within the first 24 hours. 90% of the DMSA is 
excreted as the mixed DMSA cysteine disulfide, with the remaining 10% is excreted as 
unaltered drug. The majority of mixed disulfide consists of DMSA linked to two 
molecules of L-cysteine, while the remaining disulfide contains only one cysteine per 
DMSA molecule. The peak excretion of the altered DMSA occurs within two hours post 
ingestion (Aposhian et aI., 1989). 
Side effects associated with DMSA are of minor importance and include rashes, 
nausea, vomiting, febrile reactions, transient elevation in aminotransferase, alkaline 
phosphatase activity and reversible leukopenia (Mann et aI., 1991; Grandjean et aI., 
1991). 
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c. Sodium 2,3- Dimercapto -1-propanesulfonic acid (DMPS) 
DMPS was introduced for the treatment of heavy metal poisoning in the 1950s in 
the Soviet Union under the name of Unithiol (Petrunkin 1959). The compound gained 
popularity in the Western world in mid seventies following its success in countries such 
as China and Japan. DMPS is a water-soluble analog of dimercaprol (BAL) 
demonstrating lower toxicity than dimercaprol and EDT A. It is a white, crystalline 
powder of a racemic mixture of sodium 2,3-dimercapto-1-propane sulfonic acid. Its 
therapeutic advantages over to BAL and EDT A have included: 
(1) Low toxicity, as measured in mice (Aposhian et aI., 1984). 
(2) It is orally administered and readily available. 
(3) Unlike BAL or EDTA, DMPS does not cause mobilization and or 
redistribution of mercury (Berlin and Norberg 1965), lead (Cory-Slechta et 
aI., 1987) or arsenic (Aposhian et aI., 1984) to the brain. 
Experimental as well as clinical evidence pertaining to this compound has 
demonstrated that it is a safe oral chelating agent when used for the treatment of chronic 
lead poisoning, arsenic, organic and inorganic mercury poisoning (Chisholm & Thomas 
1985; Campbell et aI., 1986). Anatovskaya (1962) used DMPS for the treatment of 
chronically exposed lead poisoned adult subjects. Its use for the management of 
childhood lead poisoning has been limited due to some dermatological manifestations 
(Stevens-Johnson Syndrome) following an 8-day therapy (Chisholm et aI., 1990). 
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DMPS forms stable complexes with heavy metal ions, which are similar to those 
of dimercaprol except in the case of Cd-DMPS complex (Casa 1979; Planas-Bhone & 
Gabard 1980). In humans, 60% of 14C-DMPS is absorbed following an oral dose, which 
is double the absorption rate as compared to rats. When the binding of 14C_DMPS to 
plasma protein was measured by equilibrium dialysis, it was found to reach 90% in 
humans and 70% in dogs (Wiedemann et aI., 1982). Furthermore, DMPS is oxidised to 
DMPS tetrasulfide via an intermediate compound (Luganskii & Loboda 1960). Chisholm 
and Thomas (1985) investigated the effectiveness of DMPS in lowering blood lead 
concentrations and the extent of urinary excretion in lead poisoned children. They 
concluded that following a 5-day course of 200 or 400 mg per m3 surface, there was a 
significant decrease in blood lead concentrations and an increase urinary excretion 
without altering the concentrations of essential metal ions such as zinc and copper in 
plasma. Additionally, urinary excretion was not dose dependent. Furthermore, Maiorino, 
et aI., 1991 investigated the pharmacokinetics of a single dose of DMPS (Dimaval) in 
blood and plasma of healthy volunteers, as shown in Table 1.5. 
Table 1.5. Pharmacokinetic parameters of total DMPS based on p.o. 
DMPS administration (Maiorino et al. I 1991). 
Parameter Cmax (JlMol/l) t max (b) AVC (uMol/l) t1l2(b) 
Blood Mean 11.9 3.7 148 9.1 
±SE 1.5 0.7 11 1.3 
Plasma Mean 25.3 3.4 318 9.9 
±SE 3.0 0.6 21 1.6 
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Hurlburt and Co-workers (1994) investigated the pharmacokinetics of 3.0 mg/kg 
of DMPS following intravenous dose in five healthy volunteers. They concluded that 
DMPS is rapidly transformed to the disulfide formes), within 15 minutes following 
administration; only 12% of the total DMPS was present as the parent drug (unaltered 
form). After 96 hours, only 12% was excreted via the kidney, and 880/0 was excreted as 
the disulfide metabolite (altered form). Furthermore, the elimination half-life (tl/2) of the 
total DMPS (unaltered and altered) was 20 hours, while the t1/2 of the unaltered form was 
1.8 hours. They also concluded that the elimination of both forms was primarily via the 
kidney. 
The sodium salt of DMPS was found to promote the excretion of mercury via the 
kidney in human volunteers (Clarkson et aI., 1981; Mant et aI., 1985; Gonzalez-Ramirez 
et aI., 1995). Additionally, it has been used as a challenge test to determine the body 
burden of mercury (Aaseth et aI., 1995). Once DMPS is given orally or intravenously, it 
is transformed rapidly to the oxidized species containing disulfide bonds (Maiorino et aI., 
1991; Hurlburt et aI., 1994). However, there were, minimal amounts of the altered form 
of DMPS in red blood cells. This is probably the case with other cells as the environment 
in the cytosol is reducing whereas that of blood is oxidizing (Maiorino et aI., 1991). The 
altered form of DMPS was detected 60 hr and 96 hr in the blood or plasma and urine 
respectively, after the administration of a single intravenous dose (Hurlbut et aI., 1994). 
In plasma, the altered DMPS species were found to be in the DMPS disulfide 
form. In a separate study an oral dose of 300 mg of DMPS was administered to healthy 
volunteers. Twelve hours after dosing, 62.5% of the total DMPS was bound to proteins, 
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while the remaining 36.6% consisted of non-protein associated DMPS disulfides and 
0.9% was present as the unaltered DMPS. From the protein bound fraction, 84% was the 
DMPS-albumin complex and 16% were a higher molecular weight protein complex. In-
vitro DMPS-albumin complex was broken by dithiothreitol indicating that the DMPS was 
bound via disulfide linkage. Furthermore, and after 9 hours of DMPS administration, 
10% of the total urinary DMPS was unchanged drug and 90% was in the altered form. 
Urinary DMPS disulfides have included: acyclic polymeric DMPS disulfide (97%), 
DMPS-cysteine (1 :2) mixed disulfide (2.5%) and (0.5%) in cyclic DMPS disulfide 
(Maiorino et aI., 1996). 
1.9.3. D-penicillamine 
D-penicillamine is a D-B-B-dimethyl cysteine known as Cuprimine; which has 
been approved for the treatment of Wilson disease, cystinuria and severe rheumatoid 
arthritis. D-penicillamine was the only oral chelating agent used until the introduction of 
DMSA and DMPS for heavy metal poisoning. D-penicillamine has been used in less 
severe symptomatic inorganic and mercury inhalation exposure, but its use has been 
limited due to some side effects. It is well known that D-penicillamine causes an increase 
in the absorption of lead from the gastrointestinal tract (Goldfrank et aI., 1998). 
In animal experiments, D-penicillamine was found to have a lower mobilizing 
effect if compared with EDTA and BAL (Hammond 1971). D-penicillamine is readily 
but incompletely absorbed after oral administration. About 50% of an oral dose is 
excreted in the urine after 48 hours with 10% as unchanged drug, up to 25% as cysteine-
penicillamine disulphide, 15% as penicillamine disulphide, and less than 10% as S-
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excreted in the urine after 48 hours with 10% as unchanged drug, up to 25% as cysteine-
penicillamine disulphide, 150/0 as penicillamine disulphide, and less than 10% as S-
methyl-D-penicillamine; about 35% of an oral dose is eliminated in the faeces in 3 days. 
Following intravenous administration, about 80% of the dose is excreted in the urine in 
24 hours. Plasma half-life is about 2 to 4 hours (Perrett et aI., 1981). 
H 
H.s. d COOH 
I 
Figure 1.3. Structural Formula of D-penicillamine. 
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1.10. Analytical Methods for Trace Determination of Lead and DMPS in 
Biological Matrices 
1.10.1 . Lead Analysis in Biological Fluids 
a. Body Fluids as Matrices for the Analysis of Lead 
It is well known that inhaled lead eventually reaches the blood stream (lPCS, 
1996). Consequently the haematopoetic system is considered the most important 
transport system in determining the distribution of metal to various body organs 
(Klaassen 1996). Other factors are cellular membrane permeability, availability of 
intracellular ligands and possible perfusion rates of the various organs, which play a 
significant role in lead distribution and/or accumulation and excretion. 
Once lead is present in the blood, it occurs in three forms: one fraction is bound 
to the erythrocyte; the second is bound to plasma proteins and the third is in the free 
ionized diffusible form. 
Of the three forms, lead binds mainly to the erythrocyte (Facchetti et al 1983). 
The remaining fraction occurs in the plasma mostly bound to plasma albumin and 
globulins, while some occurs in the plasma water as free ionized lead. The protein bound 
lead is regarded as inactive lead and is carried passively to the bones where it 
accumulates with sustained exposure (Facchetti et aI., 1983). Protein binding therefore, is 
a factor that must be accounted for when measurements are made in biological fluids. 
The ionized free lead found in the plasma is considered the active lead and is 
responsible for the direct toxic effects which lead induces in soft tissues. 
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The determination of lead concentrations in the three blood fractions is significant 
smce each carries different biological and toxicological implications. Of particular 
importance in the evaluation of occupational exposure is the plasma fraction since it has 
valuable information about toxicity, absorption kinetics, and distribution and excretion 
rates. 
It has been proposed that the ionized plasma lead levels directly affect the 
concentration of lead in the other blood fractions and other tissues. Accordingly, it 
affects lead levels in the erythrocytes, intracellular fluid, urine, soft tissue and bones. 
Two important factors were observed following to the proposed metabolic model which 
must be considered for the diagnosis of the occupationally exposed workers: 
(A) The sampling time; whether the sample is taken during exposure (non-steady 
state condition), or after cessation of exposure (steady state condition). 
(B) The sample preparation techniques prior to analysis that may give a value for 
free lead or total lead levels. 
Of great importance, however, is the way in which equilibrium binding is 
affected by factors such as disease states, diet, and administration of drugs. Any change 
in the degree of binding will represent a large percentage change in the unbound lead. 
The pathological factors that contribute to such disturbances in protein binding include 
liver and kidney diseases, as a result of high lead exposure. 
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Consequently, lead levels in blood must be interpreted with caution taking into 
consideration: (1) recent environmental exposure, (2) sample preparation prior to 
analysis, (3) other clinical laboratory tests, (4) clinical picture and (5) demography. 
Urine analysis is also useful where lead or other forms of lead compounds are 
extensively excreted via the kidney. Lead can be detected in urine for quite some time 
after it becomes undetectable in blood. Both pH and volume as well as sampling time are 
important factors in urine lead analysis. Urinary pH has a pronounced effect on the 
excretion of the lead. Low pH values may promote the re-absorption from the glomerular 
filtrate. Additionally, urine does not contain protein or lipids; it is thus regarded as a 
cleaner matrix to work with, and is occasionally introduced without pretreatment into the 
analytical system. 
b. Sampling I Sample Preservation and Pretreatment 
The first steps involved in trace metal analysis could act as a source of systematic 
errors and therefore constitute an important part of the analytical procedure. In order to 
avoid contamination by atmospheric dust, collection of a whole blood, plasma or urine 
sample must be strictly controlled and specified prior to assay. 
The type of sampling tube and the nature of the anticoagulant it contains can have 
dramatic effects on the results because of the risk of contamination. Control blank 
samples must be assayed parallel to authentic test samples. 
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Urine analysis is also useful where a drug or rapidly formed metabolite is 
extensively excreted into it, and drug metabolites may be measured after they have 
become undetectable in blood. Sample contamination using vials containing 
anticoagulants for procuring blood have shown unreliable results following the extraction 
with nitric acid (Nackowski et aI., 1977). Investigation of evacuated collected tubes 
containing sodium citrate, ethylenediaminetetraacetic acid-disodium salt or heparin 
showed that heparinized tubes were most convenient for the purpose (Herbert et aI., 
1982). 
Proper storage conditions of the heparinized blood sample at low temperature 
(9°C) and for limited time (3 days) were reported in preventing microbial degradation 
(Mitchell et aI., 1972). Collection into disposable teflon or quartz containers and storage 
at low temperature were assumed to be optimal (Facchetti et aI., 1983). 
Progress in sample pretreatment procedure paralleled the development of 
instrumental techniques adopted for determination of trace metals in biological fluids. 
Pre-concentration procedures, solvent extraction or the use of the expensive metexchange 
resin were employed prior to colorimetric or atomic absorption techniques. Complete 
destruction of organic matter was required in voltarnmetry, not only for separation and 
preconcentration purposes, but also for preventing complexation of the analyte with the 
residual organic matter prior to the measurement step. Flame atomic absorption and 
plasma emission may tolerate the presence of relatively large amounts of organic 
materials. 
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However, the need to remove organIc matter could be waived in neutron 
activation analysis and X-ray fluorescence methods. The reported sample pretreatment 
steps were thus modified. 
More generally, removal of organic matter applies to AAS. Low temperature dry 
ashing proved particularly inconvenient for blood because of its failure to completely ash 
the matrix. Wet ashing procedures using both high and low temperatures or pressures 
have also been suggested. These require the use of oxidizing mineral acids, which added 
potential contamination problems. Other ashing techniques with minimum contamination 
effects such as low-energy UV or high-energy irradiation of blood samples have been 
employed to decompose the organic matter, and to release the bound metals ions (Batley 
and Farrar 1978). In-addition, to photolytic methods, solid phase extraction technique has 
also been suggested (Djane et aI., 1997 and Smith et aI., 1998). 
c. Analysis of Lead by Spectrophotometric Techniques 
High sensitivity, specificity, precision, accuracy, legality (well established to stand 
up III court) (Skoog, West and Holler 1988), speed, cost and requirements of the 
specialized instrumentation are the main parameters that one should consider during the 
development of analytical method. Other factors such as minimum sample pretreatment 
steps, multi-element capability and the potential for automation are at present considered 
crucial and should also be taken in consideration. 
Atomic Absorption Spectroscopy (AAS) in both its flame and flameless modes is 
the most popular among spectrophotometric methods. 
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This is mainly due to the availability of instrumentation and ease of operation 
coupled with good precision and high sample throughput. Furthermore, AAS IS 
employed when there is need to analyze large number of samples particularly In 
environmental or surveillance studies (Taylor et aI., 1983). Other spectrometric 
techniques such as Neutron Activation Analysis (NAA), X-ray Fluorescence (XRF) and 
Isotope Dilution Mass Spectrometry (IDMS) have also been used for the analysis of trace 
metals in biological fluids. NAA and XRF are not used for routine analysis, but rather as 
reference methods. 
Thus, a wide range of methods has been used for the determination of lead in 
biological fluids. The complexity of the matrix, together with the low normal lead level 
and high contamination risks made direct spectrophotometric measurement difficult. 
(i) Flame Atomic Absorption Spectroscopy (FA AS) 
Although the flame atomic absorption method has several advantages including 
high precision and high sample throughput, it still has some drawbacks due to its 
complexity and low sensitivity particularly when trace concentrations are investigated. 
Some modifications have been introduced to improve this technique, with respect to its 
reproducibility, accuracy, precision, sensitivity and ease of operation but it is not widely 
used for this purpose. 
(ii) Electrothermal Atomic Absorption Spectrometry (ET AAS) 
This is currently a preferred measurement of lead. The flameless technique 
involves the incorporation of an electrothermal heated graphite furnace (OF) for 
atomization. 
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It is more sensitive by at least two to three orders of magnitude compared with 
F AAS (Reeder 1997 & Cheng et aI., 1997). ET AAS has been successfully employed for 
the analysis of lead in blood particularly in screening programs (Egila et aI., 1996). 
d. Analysis of Lead by Electroanalytical Techniques 
Electroanalytical methods, in particular stripping analysis are among the most 
sensitive for the determination of heavy metals in various matrices. They are inexpensive 
and require minimal sample pretreatment. In-addition, they permit determination of 
several analytes simultaneously at concentration levels in order of sub parts per billion. 
Due to these advantages, the scope of application has been increased particularly in the 
past ten years. Of the electroanalytical techniques, voltammetric methods have great 
merits for trace metal analysis in biological matrices. Voltammetry refers to a class of 
electroanalytical techniques in which the current at the working microelectrode is 
measured as a function of the applied potential. The applied potential electrolyses the 
analyte either by reduction or oxidation at the electrode surface. 
(i) Polarography (Voltammetry at the DME) 
Polarography is a subclass of voltammetry in which the working electrode is a 
dropping mercury electrode. Because of the special properties of the electrode, 
particularly its renewable surface and wide cathodic potential range, polarography has 
been widely used for the determination of many important reducible species. 
The excitation signal used in conventional DC polarography is a linearly 
increasing potential ramp. For a reduction, the initial potential is selected so that the 
reaction of interest does not take place. 
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The potential is then scanned cathodically while the current is measured. At a 
sufficiently negative potential, reduction of the analyte commences, the concentration 
gradient increases and the current rises rapidly to its limiting (diffusion controlled) value. 
At this slope, any analyte particle that arrives at the electrode surface will instantaneously 
undergo an electron transfer reaction. 
(ii) Pulse Voltammetry 
Voltammetric techniques, in pulse mode are aimed at lowering the detection 
limits of voltammetric measurement. By substantially increasing the ratio between the 
faradaic (when any analyte that oxidation-reduction occurred at the electrode) and 
nonfaradaic currents (a potential is applied to the electrode, if the potential is negative all 
the positive ions will be attracted to the electrode as a consequence current will result). 
Such techniques permit convenient quantitation down to the 0.1 Jlg/dl concentration level. 
Because of their greatly improved performance, modem pulse techniques have largely 
supplanted classical polarography in the analytical laboratory. The various pulse 
techniques are all based on a sampled current potential-step (chronoamperometric) 
experiment. A sequence of such potential steps, each with duration of about 50 ms, is 
applied onto the working electrode. After the potential is stepped, the charging current 
decays rapidly (exponentially) to a negligible value, while the faradaic increases to a 
maxima (oxidation-reduction). The difference between the various pulse voltammetric 
techniques is the excitation waveform and the current sampling regime. With normal-
pulse and differential-pulse voltammetry, one potential pulse is applied for each drop of 
mercury when the DME is used. 
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By controlling the drop time (with a mechanical knocker), the pulse is 
synchronized with the maximum growth of the mercury drop. At this point, near the end 
of the drop lifetime, the faradaic current reaches its maximum value, while the 
contribution of the charging current is minimal. 
(iii) Normal-Pulse Voltammetry 
Normal-pulse voltammetry consists of a series of pulses of increasing amplitude 
applied to successive drops at a preselected time near the of each drop lifetime. Such a 
normal-pulse is shown in Figure 1.4. Between the pulses, the electrode is kept at a 
constant (base) potential at which no reaction of the analyte occurs. The amplitude of the 
pulse increases linearly with each drop. The current is measured about 40 ms after the 
pulse is applied, at which time the contribution of the charging current is nearly zero. 
The resulting voltammogram has sigmoidal shape. 
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Figure 1.4. Time dependence of the working electrode potential In 
Normal Pulse Polarography. 
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Normal pulse polarography is 5-10 times more sensitive than DC polarography. 
In-addition, normal pulse polarography may be advantageous when using solid electrodes. 
In particular, by maintaining a low initial potential during most of the operation, it is 
possible to alleviate surface fouling problems (due to adsorbed reaction products). 
A related technique, reverse-pulse voltammetry, has a pulse sequence, which is a 
mirror image of that of normal-pulse voltammetry. In this case, the initial potential is on 
the plateau of the wave (i.e., where reduction occurs), and a series of positive-going 
pulses of decreasing amplitude is applied. 
(iv) Differential-Pulse Polarography 
Differential-pulse voltammetry IS an extremely useful technique for 
measunng trace levels of orgamc and inorganic speCIes. In differential-pulse 
polarography, fixed-magnitude pulses-superimposed on a linear potential ramp is applied 
to the working electrode at a time just before the end of the drop. 
When the potential of the pulse becomes sufficiently cathodic, the reactant (ox) 
present in the solution starts to be reduced. The current is sampled for a short period (up 
to '" 1 00 ms) at a fixed time after the application of the pulse. 
It is assumed that the pulse time is short enough for the surface area of the 
mercury drop to be practically constant during the pulse (Figure 1.5. A). To fulfill this 
requirement, the pulse is applied when the drop size is already quite large (e.g. 450/0 of 
final size). If the current is measured always at the same time during application of each 
pulse, a wave-like shape (Figure 1.5 B) will result. 
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Figure 1.5. (A) Mercury drop with time, and 
(8) The resultant current-voltage curve in a wave-like 
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The current is sampled twice, just before the pulse application and again late in 
the pulse life as shown in Figure 1.6. 
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Figure 1.6. The change of potential of the working electrode with time 
in DPP. The Current is sampled at the times indicated by 
dots. 
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The first current is instrumentally subtracted from the second, and the current 
difference [~t = t(t2) - t (tl)] is plotted vs. the applied potential. The resulting 
differential-pulse voltammogram consists of current peaks, the height of which is directly 
proportional to the concentration of the corresponding analytes. 
The peak potential (Ep) can be used to identify the species, as it occurs near the 
polarographic half-wave potential: 
Ep = E1I2 - ~E2 
The differential-pulse operation results in a very effective correction of the 
charging background current. The charging current contribution to the differential current 
is negligible. 
The peak shaped response of differential pulse measurements results also in 
improved resolution between species with similar redox potentials. In various situations, 
peaks separated by 50 m V may be measured. Such quantitation depends not only upon 
the corresponding peak potentials, but also on the width of the peak. 
The peak shaped response, coupled with the flat background current, makes the 
technique particularly useful for analysis of mixtures. The selection of the pulse 
amplitude and potential scan rate usually requires a trade off among sensitivity, 
resolution, and speed. For example, larger pulse amplitude results in larger and broader 
peaks. Pulse amplitude of 25-50 mY, coupled with a -5 mV/s scan rate, and is 
commonly employed. Irreversible redox systems results in lower and boarder current 
peaks (i.e., inferior sensitivity and resolution) compared with those predicted for 
reversible systems. 
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In-addition to improvements in sensitivity and resolution, the technique can 
provide information about the chemical form in which the analyte appears (oxidation 
states, complexation, etc.). 
The pulse repetition time is - 1 s, and the pulse duration is - 50 ms. The amplitude 
of the applied potential LlEp is usually not more than 50 m V. In this variant of the 
method, the current is measured before and after the application of each pulse. At the 
point indicated schematically in Figure 1.7 the difference (Llt) is recorded. 
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Figure 1.7. Mercury drop electrode with the current is sampled twice. 
Once before the potential is applied and another just 
before the drop is dislodged. 
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The change of the potential with time from a lower to a more cathodic potential as 
shown in Figure 1.8, the difference ~l on the applied potential E has a peak profile. 
Pulse polarography and Voltammetry appear to be very powerful techniques for 
solving various physiochemical problems and are also sensitive and efficient in analysis 
because of their inherent sensitivity and selectivity towards both organic and inorganic 
analytes. 
-£ 
Figure 1.S. The dependence of the current on potential in DPP. 
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(v) Stripping Analysis 
Stripping analysis IS an extremely sensitive electrochemical technique for 
measuring trace metals. Its remarkable sensitivity is attributed to the combination of an 
effective preconcentration step with advanced measurement procedures that generates an 
extremely favorable signal-to-background ratio. Since the metals are preconcentrated 
into the electrode by factors of 100-1000, detection limits are lowered by 2-3 orders of 
magnitude compared to solution phase voltammetric measurements. Hence, four to six 
metals can be measured simultaneously in various matrices at concentration levels down 
to 0.01 J.lg/I utilizing relatively inexpensive instrumentation. The ability to obtain such 
low detection limits strongly depends on the degree to which contamination can be 
minimized. Expertise in ultratrace chemistry is required. 
Essentially, stripping analysis is a two-step technique. The first, or deposition 
step, involves the electrolytic deposition of a small portion of the metal ions in solution 
into the mercury electrode to preconcentrate the metals. This is followed by the stripping 
step (the measurement step), which involves the dissolution (stripping) of the deposit. 
Different versions of stripping analysis can be employed, depending upon the nature of 
the deposition and measurement step. 
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(vi) Anodic Stripping Voltammetry (ASV). (Inverse Polarography) 
Although this technique was discovered in 1931 (Zbinden 1931), its use as an 
analytical method is relatively recent. ASV using (HMDE) measurement involves two 
distinct steps: first, the metal analyte is reduced (electrodeposited and simultaneously 
amalgamated) onto the working electrode, and secondly it is oxidized (stripping or 
electrolyzed) back into the electrolyte solution. The deposition process is considered as 
an effective electrochemical extraction. The analyte is concentrated at the working 
electrode to levels that are 100-1000 times higher than the test solution (Stegen et aI., 
1996; Zhou et aI., 1992; Ostapczuk 1992; Yen et aI., 1993). The analytical signal obtained 
in the electro-dissolution process generates an entire family of stripping techniques with 
varying sensitivities. 
The stripping step in linear scan of ASV involves the gradual and systematic 
reversal of the potential of the working electrode back into the anodic direction. The 
particular metal is thus re-oxidized back into solution when the oxidation potential 
reaches the standard potential of the metal/metal ion complex. The stripping current is 
thus measured as a function of the electrode potential. 
U sing the mercury film electrode (MFE), the stripping current generated by the 
metal oxidation at the MFE is proportional to the analyte concentration according to the 
following equation: 
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i n2.F2.A.I.CM2 
p = .................... Eq.l 
e 
Where: 
F = Faraday's constant 
A - Surface area of the electrode 
I - Mercury film thickness 
CM - Concentration of the metal analyte 
n - No. of electrons transferred. 
The peak current for the stripping process at the MFE, assuming thin films «1 Own 
thick) and slow scan rate (l V min-I), occurs at a peak potential Ep (Wang et aI., 1985). 
Ep= o 2.3RT nja / v E + Log ...................... Eq.2 
nF RTD 
Where: 
EO = Standard potential of the metal/metal ion 
a = Thickness of the diffusion layer 
D = Diffusion coefficient of the metal ion 
R, T, n, F have their normal definitions 
It has been shown that the total current recorded (It) during the stripping process 
in Linear Scan Anodic Stripping Voltammetry (LSASV) is not directly proportional to the 
desired stripping reaction, according to the following equation: 
It = ip + Ibkgd = ip + (ic + ifr) .................... Eq. 3 
It represents the summation of the stripping current and the background current. 
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The latter results from the charging current (ic) plus a Faradaic current (ifr) 
attributable mainly to redox reactions of trace impurities present in the blank solutions as 
well as contributions from dissolved oxygen (Wang et aI., 1985). The varying magnitude 
of the background current is therefore the major drawback in LSASV and application of 
the technique in the analysis of trace metals in blood requires the introduction of a Blood 
Correction Factor (BCF) (Searl et aI., 1973): 
Anodic stripping voltammetry is a two-step technique. The first step is the 
deposition of the analyte onto the surface of the hanging mercury electrode to form an 
amalgam at a fixed potential that is sufficiently negative to reduce the metal ion. 
Mn+ + ne- ¢ M (Hg) ..................... Eq. 4 
In the second step, as the potential is taken to a more positive value, the 
deposited analyte is removed (stripped) from the electrode and reoxidized to Mn+ 
giving an analytical signal. 
M(Hg) ¢ Mn+ + ne- ..................... Eq. 5 
The pre-concentration step is carried out for a definite time under reproducible 
conditions (the solution may be stirred or the electrode may rotate at a constant speed) 
(Bond 1980). 
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The stripping current due to oxidation of each analyte is proportional to the 
concentration of the analyte in the analyzed as shown in the following equation 
(He inman et al., 1984): 
. - Kn312 A D1I2 C 112 ~ - R R v .................... Eq. 6 
Where K: constant 
n: Number of electrons transferred per metal ion. 
A: Surface area of the electrode (cm2). 
D: Diffusion coefficient of the metal in mercury in cm2 Is. 
C: The concentration of the metal in the electrode in molelcm . 
v: The scan rate in vis 
Voltammetric techniques have been applied to so many differing fields of analysis, 
principally because of the high reproducibility and very high sensitivity. 
(vii) Differential Pulse Anodic Stripping Voltammetry (DPASV) 
DPASV was developed to increase the sensitivity of ASV. It offers better 
differentiation of faradaic current signal. In DP ASV pulses of equal amplitude are 
superimposed on an anodic potential scan. The pulses have amplitude of 10-100 m V and 
about 69 ms duration and a repetition rate of 0.5-5 seconds. The ramp potential does not 
change significantly during the pulse life. So the current is sampled twice just before the 
pulse and almost at the end of the pulse. The final signal is the difference between these 
two current values (Wang et aI., 1985). 
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The overall sensitivity of stripping voltammetry depends on the stripping step 
itself and the deposition time, but it is limited by the purity of the reactant and sampling 
(Riely et a!., 1987). The typical detection limits of the DP ASV are 10-6 - 10-9 mollL. 
ASV is used to investigate metal organic interaction taking advantage of its high 
sensitivity and selectivity for easily reduced metal species. Conditional stability constants 
can be determined by compleximetric titrations followed by anodic stripping 
voltammetric measurement. 
1.11. Measurement of Chelating Agents in Body Fluids 
Sensitive, selective and specific methods for the measurement of chelating agents 
such as CaEDT A, dimercapto-chelating agents and D-penicillamine are scarce in the 
literature. Consequently, investigation of the disposition of chelating agents has relied 
upon indirect measurement of lead excreted after the administration of a specified dose of 
the compound. 
Direct investigation of either the free chelating agent, its metabolites, degradation 
products, altered forms or complexed form has not been fully undertaken. In particular, 
the use of analytical techniques which offer the major advantage of detecting lead in 
addition to the different species of the chelates in body fluids have not yet been 
investigated. 
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a. In-Vitro Studies Pertaining to Lead-Mercapto Complexes 
In spite of the fact that lead-EDT A complexes have been extensively investigated, 
few reports dealt exclusively with the characterization and/or identification of lead-
mercapto complexes. In particular, in-vitro studies of lead complexes with either DMSA 
or DMPS have never been investigated using polarographic techniques with mercury 
electrode, either static mercury drop or hanging mercury drop electrode. Of great 
importance is the investigation of the selectivity and specificity of mercapto chelating 
agents towards lead and competition with other endogenous metal ions such as Cu2+, and 
Zn2+. This can be investigated by measuring the formation constants of metal complexes 
using one of the following techniques. 
(A) Polarographic techniques including either DPP at the dropping mercury 
electrode, or DP ASV at the hanging mercury drop electrode. 
(B) Spectrophotometric methods. 
(C) Potentiometric methods. 
Shortly after the development of dimercatpo chelating agents it became obvious that 
the knowledge of the types of metal complexes formed by these chelating agents, as well 
as their stabilities were important in the development of new and more effective drugs for 
metal poisoning. It has been claimed that the greater the stability constant for a given 
complex, the greater the mobilization of that metal ion from poisoned tissues. Several 
attempts were made toward the measurement of the stability constants of metal 
complexes of dimercapto-chelating agents using different techniques involving 
potentiometry and spectroscopy. 
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Since polarography can be utilized for the measurement of low concentrations of 
various analytes such as metal ions, ligands and/or compounds, polarographic methods 
for the determination of stability constants have been found to be useful, in particular 
when the stability constant of a complex is too low to allow potentiometric measurements 
(Bond et aI., 1972). Each of the above techniques has its advantages and disadvantages, 
which should be recognized before its application. 
If the formation constant is known for a given system, then it is possible to 
calculate the equilibrium concentration or activities of species existing in the system, 
under a certain set of experimental conditions. Such exact knowledge of composition is 
essential for the interpretation of kinetic and biological interactions (Dwyer et aI., 1964). 
1.12. Methods for determination of urinary DMSA and DMPS 
Several procedures have been developed to quantify DMSA in biological fluids, 
many of which turned out to be non-specific and inappropriate once applied to a complex 
media where more than one species containing a sulfhydryl group is present. 
Therefore, a sensitive and specific assay was developed using gas chromatography 
(OC) to determine DMSA in the urine. Samples were first reduced electrochemically to 
liberate DMSA present as disulfide. DMSA was then extracted into ethyl acetate. 
The organic phase was evaporated and DMSA was derivatized by forming its 
trimethylsilyl (TMS) derivative. The DMSA-TMS derivative was then quantified by OC 
using flame ionization detector (Knudsen et aI., 1988). DP polarography can be used for 
determination of DMSA since it has a reducible group, which is the carboxylic acid. 
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However, derivatization-using bromobimane has been attempted for the 
determination ofDMSA in urine. Bromobimane reacts with the thiol groups ofDMPS or 
DMSA. Bromobimane was used to form highly fluorescent bimane derivative. Neither 
bromobimane nor DMSA fluoresce independently, but once bromobimane reacts with 
thiol groups it will fluoresce and give a high analytical signal at picomole amounts. 
Aposhian et aI., (1992) developed this assay to evaluate the extent of urinary excretion of 
the altered and unaltered forms of DMSA. Similar reactions were observed following to 
the addition of DMPS to bromobimane and HPLC separation of the formed compounds. 
This led to the conclusion that both DMPS and DMSA formed mixed disulfide 
compounds (Maiorino et aI., 1986). 
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1.13. Formation Constants of Metal Complexes 
a. Definition and Importance 
Complexation reactions between a metal lOn, Mn+, and a ligand, L, with the 
maximum coordination number, p, can be expressed by the following equation: 
Mn+ + pL "¢ MLpn+ ........................ Eq. 7 
The formation constant (overall stability constant) is the equilibrium constant in a 
homogeneous solution. It describes the formation of a complex species from its solvated 
metal ions and an added ligand. The formation constant expression for the above reaction 
is given by: 
~ = [MLn+p]/([Mn+][L]p) .................... Eq. 8 
It is important to note that the magnitude of the formation constant gives an 
indication on the lability of the metal complexes and helps to evaluate the relative 
strength with which ligands compete for binding with metal ions concurrently present in 
the same matrix. 
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Since the above reaction may occur via a series of steps, it is possible to write a 
senes of p equilibrium expressions, in addition to the overall stability equilibrium 
expression, as follows: 
Mn+ + L ~ MLn+ ...... KI = [MLn+]/([Mn+][LD 
MLn+ + L ~ ML2n+ ...... K2 = [ML2n+]/([MLn+][LD 
ML2n+ + L ML3n+ ...... K3 = [ML3n+]/([ML2n+][LD 
ML(p_l)n+ + L MLpn+ ...... Kp = [MLpn+]/([MLn+p_d[LD Eq.9 
The constants K1, K2, ... , Kp are known as stepwise stability or formation 
constants (Crow, 1969). The overall stability constant ~ is the product of the stepwise 
stability constants as shown in the following: 
~ = K1• K2. K3 ...... Kp ................................. Eq. 10 
Determination of the formation constants of metal ligand complexe(s) provides 
information about the possibility of these reactions occurring in nature, including 
interactions with biological systems. They also shed light on the optimum conditions 
required for such reactions to occur. For a given system, when the formation constant is 
known, it is possible to calculate equilibrium concentrations or activities for species 
existing in the system under a certain set of experimental conditions. 
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b. Methods Used for the Determination of Formation Constants 
Many experimental approaches have been employed for the determination of 
formation constants. These include: potentiometry, ion exchange, polarography, 
spectrophotometry, polarimetry, conductometric titration, amperometry, freezing point, 
vapour pressure, and reaction kinetics (Rossotti et aI., 1961; Nancollas et aI., 1982). 
Electrochemical methods, especially polarography, play an important role for 
investigating the composition and stability of metal complexes, in addition to their 
mechanism of formation (Galus 1994). Appendix I contains the theoretical basis for 
calculating the formation constants using electroanalytical techniques. 
In many relevant studies, polarographic techniques have been used for the 
determination of the formation constants. These techniques offer possibilities for both 
quantitative and qualitative determinations of different species. In-addition, they have the 
advantage of high sensitivity detection and the ability to deal with micro-quantitative 
analysis. Many metals and organic compounds in addition to metal complexes are 
electro active and consequently give polarographic peaks due to their oxidation-reduction 
behavior at the working electrode. These include Pb2+, Ti+, Cd2+, Cu2+, Fe2+, In3+, Mn2+, 
Ni2+, Sb3+, Sn2+, Zn2+, azo, nitroso, nitro, carbonyl and sulfur containing compounds such 
as mercapto compounds. Cd2+, Pb2+ and Cu2+ complexes, in particular have been 
extensively investigated (Nancollas and Tonson 1982). Polarographic modes such as DC, 
DPP, ASV and CSV offer the possibility of quantitative and qualitative determination of 
different electroactive species. DPP can successfully be applied, its advantages is the 
high sensitivity compared with spectroscopic or potentiometric techniques. 
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DPP offers the following advantages for formation constants determination. 
Firstly, it can be used to determine formation constant of complexes that have low 
solubility (Nyholn and Wiknard 1989). Secondly, high sensitivity for the metal, the 
ligand and their corresponding complexes can be detected. Thirdly, in some cases, 
information about the intermediates formed during chemical reactions can be obtained. 
Fourthly, stepwise formation and overall conditional formation constants can be 
measured when high resolution between the metal, the ligand and the complex is 
demonstrated. When one needs to measure very low concentrations of electro active 
species, more sensitive techniques such as inverse polarography including ASV and CSV 
are required. Such techniques give limits of detection in the range of 10-10 to 10-12 M. 
Generally, when ASV is employed the analyte will be reduced at a negative 
potential, while oxidation will occur, we will scan the potential positively. This 
technique uses the Hanging Mercury Dropping Electrode (HMDE). When CSV is 
employed the analyte will be oxidized at a positive potential while we reduce it by 
applying a negative potential ramp. This technique uses the HMDE as well. In the 
Differential Pulse Polarography (DPP) the analyte will be reduced at the Dropping 
Mercury Electrode (DME) or the Static Mercury Electrode (fixed until we finish the 
cycle) then the drop changes (oxidation-reduction). 
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Study Objectives 
This introduction has shown that interactions between therapeutic chelators and 
lead are not fully understood. Thus, the present work aims at improving our 
understanding of the interaction between lead and the chelating agents, which are used in 
the treatment of lead poisoning. The study involves both in-vitro and in-vivo 
investigation. The in-vitro investigations focus on the development of analytical methods 
for the determination of lead and DMPS in biological fluids prior to the investigating 
complexing properties of lead with DMPS. 
The in-vivo investigations will involve workers who have been previously 
exposed to lead fumes in a lead acid battery manufacturing plant. The control and 
exposed subjects will be dosed with DMPS prior to blood harvesting at predetermined 
time points. Plasma and urine concentration-time profiles will be drawn and correlated 
with in-vitro results. 
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CHAPTER II 
IN-VITRO STUDIES 
2.1 . Instruments, Apparatus and Standard Methods 
2.1 .1 . Metrhom VA Trace Analyzer 
A Metrhom Electrochemical Analyzer (746 VA trace analyzer-
Switzerland) consisting of (1) A multi-mode electrode (MME) which may either 
operate a Dropping Mercury Electrode (DME), a Static Mercury Drop Electrode 
(SMDE), or a Hanging Mercury Drop Electrode (HMDE). In-addition, the MME 
stand has an auxiliary electrode (Ag/ AgCI) and a platinum electrode. (2) A 
computerized microprocessor operating via a piezoelectric keypad, and an LCD 
screen, which displays methods and routines, voltammograms and calibration 
graphs. The processor provides information prior to, during and after 
measurements are completed. 
The VA trace analyzer offers the following application modes: Direct 
current (DC), Differential pulse (DP), Square wave (SQW), Alternating current 
voltammetry of the first harmonic (AC!) and the second harmonic (AC2) types as 
well as Potentionmetric Stripping Analysis (PSA), Anodic and Cathodic stripping 
voltammetry in addition to Cyclic voltammetry coupled with a facility for 
background subtraction. (3) Electrochemical cells (capacity 5, 10, and 20 ml 
solution). 
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2.2. Chemicals, Standards and Reagents 
Chloroform, (HPLC grade) was obtained from May & Baker Ltd., 
(Dageham, England). Sodium hydroxide was purchased from Erbatron, Milan, 
Italy. Mineral acids such as HCI, H3P04, HCI04 and (HP03)n were supplied by 
BDH chemicals Ltd., (Poole, England), (Analar or Aristar grade). 
2,3-Dimercapto-1- propansulfonate sodium salt monohydrate (DMPS) Lot 
# 35H3535 was from Sigma Chemical Company, (P.O.Box 14508, St. Louis, MO, 
U.S.A). (C3H703S3Na) (Formula weight is 210.3 glmol). 
The following working reagents were prepared. 
1. Acetate buffer pH 5.0 (0.1 M) was prepared as follows: 67.8 ml acetic acid 
was mixed with 32.2 ml sodium acetate (0.1 M) and the pH adjusted to 5.0. 
2. 2,3-Dimercapto-1-propansulfonate-sodium salt monohydrate. 1 1.25 mg were 
dissolved in 10.0 ml of deionized water to make up a solution 4.88x10-3M. 
3. EDTA solution: 89.85 mg were dissolved in 50.00 ml of deionized water to 
make up a final concentration of 4.83 x 10-3 M solution. 
4. Perchloric acid 0.50 ml of perchloric acid (60%, sp.gr. = 1.53) was diluted to 
5.0 ml with deionized water to make up a final concentration (lM). 
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2.3. Preparation of Quality Control (QC) Samples 
Expired plasma and whole blood samples were obtained from the 
University of Jordan Hospital. Working quality control samples were prepared by 
spiking known concentrations of Pb2+ to make up dilute quality control samples in 
the concentration range of interest (Quality control samples were stored frozen at 
(-70°C) until assay and were employed for method validation). Additionally, 11 
samples were sent to the Trace Metals Laboratory, School of Biological Sciences, 
University of Surrey, Guildford, Surrey (Table 1.2) 1999. 
Table 2.1 Method Comparison between ASV & AAS*. 
Sample ASV AAS ASV AAS 
L1 L1 H1 H1 No. (J.lg/dl) (J.l9I/dl) (J.lg/dl) lilll/dl) 
1 13.88 13.86 71.23 71.08 
2 13.20 13.24 65.86 65.82 
3 12.20 12.21 78.56 78.45 
4 12.28 12.21 72.75 72.65 
5 11.09 11.17 70.16 70.17 
6 12.27 12.21 85.25 85.28 
7 11.67 11.59 76.28 76.17 
8 12.78 12.83 63.01 62.92 
9 9.42 9.31 71.23 71.08 
10 12.51 12.43 75.65 75.55 
11 11.84 11.79 75.65 75.55 
*AAS: Analysis was carried out at The Trace Metals Laboratory/ University of 
Surrey using Atomic Absorption Spectrophotometery. 
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2.4. Lead in whole Blood. 
Sample preparation for the determination of lead in blood 
The following procedure was adopted for the extraction of Pb2+ from 
blood. To a 500 /-ll blood sample, 4.0 ml aliquot of doubly distilled deionized 
water was added. The mixture was vortexed (30s), prior to the addition of 500 /-ll 
of HCI04 (60%, sp.gr. l.54, 9.194M). The solution was then sonicated for 10 
min. and centrifuged (4000 rpm/l0 min). The above solution was quantitatively 
decanted into a previously cleaned glass electrochemical cell 5.0 ml. After de-
aeration, the following instrumental settings were applied for recording the 
corresponding voltammograms pertaining to ASV mode (section 2.5.1). 
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2.5. Procedures and Results (In-Vitro Studies) 
2.5.1 . Instrumental Conditions and Modes Employed 
a. Differential Pulse Polarography (DPP) 
• Mode ................................... Differential Pulse 
• Working Electrode .................. Static Mercury Drop Electrode 
• Drop Size .............................. 9 
• U amplitude .............................. -100 (mV) 
• Sweep rate ............................. 24 (mV/s) 
• Measurement time .................... 20 (ms) 
• Pulse time ............................. .40 (ms) 
b. Anodic Stripping Voltammetry (ASV) 
• Mode .............................. Differential Pulse 
• Working Electrode ............. Hanging Mercury Drop Electrode 
• Drop size ......................... 5 
• U amplitude ......................... 100 (m V) 
• Sweep rate ....................... 13.33 (mV/s) 
• Accumulation time ............. 100 (s) 
• Accumulation Potential ....... -900 (mV) or - 800 (mV) 
• Potential Range (L1U) .......... -600 to 100 (mV) vs. Ag/AgCl 
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c. Cathodic Stripping Voltammetry (CSV) 
• Mode .......................... Differential Pulse 
• Working Electrode .......... Hanging Mercury Drop Electrode 
• Drop Size ..................... 9 
• U amplitude ..................... .1 00 (m V) 
• Sweep rate ..................... 24 (mV/s) 
• Accumulation time ........... 100 (s) 
• Accumulation Potential. .... -10 (m V) 
• Potential Range ~U ......... 0 to -900 (m V) vs. Ag/ Agel. 
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2.5.2. Analytical Method Development and Validation of Lead (II) 
in Biological Fluids using Electroanalytical Techniques 
a. Lead in the aqueous working matrix 
An electrochemical cell was previously soaked in a 1: 1 (water: HN03 (15 
M)) solution (3 days). 4.5 ml of doubly distilled deionized water was introduced. 
A 0.50 ml aqueous HCI04 aliquot was added to make a total volume of 5.0 ml. 
The mixture was vortexed and centrifuged at 4000 rpm. for 10 min. A series of 
voltammograms were recorded prior to and after the successive additions of lead 
concentrations ranging from 0.999 to 7.937 J..lg/dl in the measuring cell. The 
results are illustrated in the voltammograms shown in Figure 2.1. Peak heights 
and peak areas were evaluated and summarized in Table 2.1, and illustrated in 
Figure 2.2. The results gave a straight line in the range 0.999 to 7.937 J..lg/dl, and 
proved highly repeatable. The Y axis is represented by I1nA as the current 
measured by nano-ampere, while the X axis by U/m V as potential measured by 
millivolts. 
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Figure 2.1. 
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Representative voltammograms illustrating the ASV 
profiles after the successive additions of Pb2+ in an 
aqueous HCI04 media; in the concentrations ranging 
from (1) 0.999 to (8) 7.937 Jlg/dl. The results were 
typical of a total of 4 sets of voltammograms under 
these conditions. 
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Table 2.2. Peak areas and peak heights measured from the ASV 
voltammograms of Pb2+ in an aqueous HCI04 media. 
Pb2+ Concentration Peak area Peak height 
(kl-g/dl) (nA) (nA) 
No lead added 0.1664 1.696 
0.999 3.715 37.07 
1.996 7.594 74.81 
2.991 11.16 109.7 
3.984 15.04 147.9 
4.975 19.02 186.6 
5.964 22.7 223 .2 
6.951 26.18 257.5 
7.937 30.14 296.2 
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Figure 2.2. Calibration graphs for Pb2+ vs. (A) peak height (nA) 
and (8) peak areas (nA) in the concentrations ranging 
from 0.999 to 7.937 /-lg/dl. 
66 
b. Lead in whole blood. 
Peak areas and/or peak heights were measured to evaluate the analytical 
signals. In all cases, Pb2+ was determined using the standard addition technique. 
Figure 2.3 illustrates the voltammograms for control whole blood sample 
recorded after the successive additions of Pb2+ aliquots to make up the 
concentrations ranging from 0.999 to 99.099 ~g/dl in the measuring cell. The 
resulting data is summarized in Table 2.2 and shown in Figure 2.4 (peak areas and 
peak heights). The results showed a linear response in the range 0.999 to 99.099 
~g/dl at low concentration the voltammograms for the added lead were distorted 
by endogenous material. 
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Figure 2.3. (1) ASV profiles for a control whole blood extract,(2) 
to (17) after the successive additions of Pb2+ in the 
concentrations ranging from 0.999 to 99.099 J-Lg/dl. 
The results are represented above and show the 
value of I/nA over the range -600 to -100 V/mV. 
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Table 2.3. Peak areas and peak heights recorded from ASV 
voltammograms for a whole blood extract after the 
successive additions of Pb2+ to cover the 
concentration ranging from 0.999 to 99 .099 ~g/dl. 
" P"lb2+ , 
Peak area Peak height No. Coneentration 
a~df;d~(u@ldJ) . (nA) (nA) 
1 No lead added 0.160 1.48 
2 0.999 0.666 8.25 
3 1.996 1.358 15.56 
4 2.991 2.209 24.43 
5 3.984 3.086 33.37 
6 4.975 3.839 40.77 
7 5.964 4.789 50.24 
8 6.951 5.753 60.14 
9 7.937 6.762 70.24 
10 9.901 8.608 90.00 
1 1 19.608 18.730 187.60 
12 29.126 28.280 280.10 
13 38.462 38.230 375.80 
14 47.619 48.680 475.70 
15 65.421 69.010 670.90 
16 82.569 88.660 859.00 
17 99.099 107.600 1043.00 
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Figure 2.4. (A) Peak heights and (8) peak areas of lead for a 
control whole blood extract in the concentration 
ranging from 0.999 to 99. 099 ~g/ dl. 
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Signal Optimization 
Variation of the volume of HCI04 
A spiked normal whole blood sample containing 74.07 /-lg/dl was used to 
measure the recoveries of Pb2+ after precipitating the proteins using different 
volumes of HCI04 (60%, sp.gr. 1.54, 9.194 M). The volumes used were 0.25, 
0.50, 0.75, 1.00, 1.25 and 1.50 ml HCI04. In each case, the total volume was kept 
constant (5.0 ml). The results obtained are summarized in Table 2.3 and 
illustrated in Figure 2.5. 
The results illustrated that, in spite of the fact that the use of a 1.0 ml 
aliquot of HCI04 gave highest recovery; a 0.50 ml aliquot was employed since 
ionic strength was kept lower and gave a better peak shape. Consequently, a 0.50 
ml aliquot ofHCI04 was used in subsequent experiments. 
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Table 2.4. Summary of the recovery data CYo) measured from a 
spiked whole blood extract (74 .07 Jlg/dl) after 
deproteination with different volumes of concentrated 
HCI04 solution. 
Vol of PlCI04 N 
Recovery (%) calculated 
(ml) 
0.25 1 
0.50 3 
0.75 3 
l.00 3 
l.25 3 
l.50 3 
120.00 
80.00 
40.00 
From peak area 
20.99 
67.49 
68.44 
9l.54 
86.20 
95.23 
From peak height 
25 .09 
75.29 
75.45 
95.49 
87.40 
94.39 
~ From peak area 
-+- From peak height 
0.00 +-------.---,----,-----,--------,- ----,---...,...--------, 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 
Figure 2.5. 
vol. of HCI04 (ml) 
Profile of the recovery ("0) measured from peak areas 
and peak heights vs. the volume of HCI04 used for 
protein precipitation. 
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Linearity and Linear working range for measuring Lead in blood 
Lead in blood was measured using different blood samples; each was 
previously spiked into a standardized aliquot of a control blood sample containing 
2.9 ~gldl of lead. Lead in blood was evaluated in each spiked sample using the 
methods described earlier (section 2.4.1). The standard addition technique was 
employed for calculating the added concentrations ranging from 2.9 ~gldl to 
90.91 ~gldl. A representative standard addition graph corresponding to a spiked 
sample containing 56.60 ~gldl of lead is illustrated in Figure 2.6. 
Linearity was demonstrated both by the visual inspection and calculating 
the correlation coefficient between lead added and recovered. Figure 2.6 
illustrates the high correlation coefficient obtained (r = 0.9939). Successful 
measurement of Pb2+ in whole blood can thus be achieved using the standard 
addition technique. The calibration graph obtained by plotting Pb2+ 
concentrations (~g/dl) vs. the analytical signal obtained (nAmp) , linearity was 
demonstrated by obtaining the calibration graph. Further examination of the 
results obtained included plotting the analytical concentration of Pb2+ with those 
measured during the calibration graph or the standard addition technique. It is 
worth mentioning that a linear graph was observed (lead spiked compared with 
recovered). 
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Figure 2.6. (A) Representative ASV voltammograms measured 
from a whole blood extract previously spiked 
with 56.60 Jlg/dl and evaluated for Pb2+ using 
standard addition technique. 
(8) Standard addition curve ranging from 0.00 to 
300 ng Pb2+ additions. 
(e) Standard addition curve in the ranging from 
0.00 to 900 ng Pb2+ additions. 
These results were typical of a total of 4 sets. 
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Accuracy 
Table 2.4 summarizes the results obtained from the experiments designed 
to assess accuracy in order to detect the occurrence of systematic errors using 
spiked whole blood samples in the concentrations ranging from 9.90 to 90.91 
(~g/dl). Figure 2.7 clearly demonstrates the high correlation coefficient between 
the spiked and measured lead concentrations (r = 0.9933). The method 
demonstrated good accuracy. N = number of observations 
Absolute Error = Xmeasured -Xtrue 
R I · E Absolute Error 100 e atIve rror = x 
X true 
Table 2.5. Accuracy of the measured lead from previously spiked 
whole blood samples. (A) measured from peak height, 
(B) measured from peak area. 
IA) 
'AdCfed pb Measured Absolute Relative 
(ug/dl) N (Jlg/dl) Error Error 
9.90 4 11.48 l.58 15.96 
19.61 5 17.04 2.57 13.11 
38.46 7 36.10 2.36 6.14 
56.60 6 49.04 7.56 13.36 
74.07 4 69.12 4.95 6.68 
90.91 4 74.35 16.56 18.22 
(B) 
Addeo Pb Measured Absolute Relative 
(Jlg/dl) N (J,.tg/dl) Error Error 
9.90 4 9.67 0.23 2.32 
19.61 4 14.61 5.00 25.50 
38.46 4 33.46 5.00 13.00 
56.60 4 51.49 5.11 9.03 
74.07 3 64.89 9.l8 12.39 
90.91 3 68.53 22.38 24.62 
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Figure 2.7. Correlation between spiked (/-lg/dl) and measured 
(/-lg/dl) Lead in whole blood (A) from peak 
heights and (8) peak areas. 
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Sensitivity and Matrix Effects 
Calibration sensitivity was measured by recording ASV profiles after the 
successive additions of Pb2+ into the following solutions: 
(A) Aqueous HCI04 media. 
(B) An extract of a control blood sample whose analytical signal was initially 
measured and was employed for investigating the matrix effects. Using the 
standard addition techniques lead was spiked to make up the following 
concentration. 
(C) Blood samples were spiked, extracted and individually measured using the 
standard addition technique. 
Tables 2.6, 2.7 and Figure 2.8 summarize the results obtained. 
Table 2.6. Lead levels measured in (1) aqueous HCI04 
media (2) an extract of blood sample. 
Standard Addition Peak height (nAl IAqueous HCIO~ Control Blood pb2+ 
Matrix Extract 
pg/dl (1 ) (2) 
0.00 1.70 1.48 
0.99 37.07 8.25 
1.96 74.81 15.56 
3.85 147.90 33.37 
5.66 223.20 50.24 
7.41 296.20 70.24 
9.09 - 90.00 
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Table 2.7. Peak heights measured from individually 
extracted previously spiked blood samples. 
Lead concentration 
Jl9/dl 
0.00 
0.99 
1.96 
3.85 
5.66 
7.41 
9.09 
400 
350 
..., 300 
J: 
.~ 250 
(1) 
J: 200 
~ 
co 150 (1) 
Peak height 
Measured After 
Extraction 
nA 
-
3.48 
11.09 
23.89 
32.84 
48.16 
50.85 
y = 39.84 x - 1.7905 
R2 = 0.9994 
y = 9.7488 x - 1.8834 
R2 = 0.994 
EllA 
<>8 
oC 
a. 100 
50 
0 ir-::::::::::::::~==~~::::::::::~=:::::~==:~Y = 6.0704 x - 0.9148 R2 = 0.982 
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Pb Concentration (ug/dl) 
Figure 2.S. Peak heights (nA) measured during the evaluation of 
sensitivity and matrix effect (A) HCI04 solution. 
(8) blood extract (C) individually extracted blood 
samples. 
It is worth noting that since the recovery was relatively high (ranging from 87 
to 93), the decrease in the slope of the calibration graph measured from the extracts of 
blood could be due to matrix effects, which decreased the sensitivity. 
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Precision 
Method precision was also measured by evaluating standard deviations as 
well as Coefficient of Variance (CV%), as summarized in Table 2.8. Furthermore 
Figure 2.9 compares the precision measured by re-evaluating the data from either 
peak areas or peak heights. The results indicate that the CV% is around 10%. 
Table 2.8. Precision in the measurement of Lead in blood in the 
concentrations ranging from9. 90 to 90.91 Ilg/dl 
(A)Frorh peal< neight / 
, "x '<' " 
Pll~+ 
con c9Rf,atlo n , Mean concentration Standard CV 
Jl9/dl N measured Deviation % 
9.90 4 11.48 0.40 3.51 
19.61 5 17.04 2.57 15.09 
38.46 7 36.10 2.51 6.97 
56.60 6 49.04 5.51 11.23 
74.07 4 69.12 9.05 13 .09 
90.91 4 74.35 4.08 5.48 
(8) From peak area 
Pb2+ 
concentration Mean concentration Standard CV 
Jlg/dl N measured Deviation 0/0 
9.90 4 9.67 0.32 3.26 
19.61 5 14.61 2.85 19.52 
38.46 7 33.46 2.88 8.60 
56.60 6 51.49 9.57 18.59 
74.07 4 64.90 9.08 13.99 
90.91 4 68.53 3.45 5.03 
The results illustrate that acceptable precision was demonstrated (CV% 
ranged from 3.26 to 19.52) 
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Figure 2.9. CV% with the measured Lead levels in blood. 
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c. Lead (II) in Urine 
Sample preparation 
The following procedure was adopted for the determination of Pb2+ in 
unne. To 500 1-11 urine, 4.0 ml aliquot of doubly distilled deionized water was 
added. The mixture was vortexed for 30 seconds prior to the addition of 500 1-11 of 
HC104 (60%, sp.gr. 1.54, 9.194 M). The solution was then sonicated for 10 min. 
and centrifuged at 4000 rpm. for 10 min. and then quantitatively decanted into a 
previously cleaned glass electrochemical cell (5.0 ml). Peak areas and/or peak 
heights were measured from the ASV voltammograms to evaluate the analytical 
signals. Lead was determined using the standard addition technique. 
Linearity and Linear working range for measuring Lead in Urine 
Lead in urine was determined in spiked urine samples using the methods 
described above with the standard addition technique for calibration. 
Representative voltammograms are shown in Figure 2.10. 
The results indicate that using the method of standard addition; lead can 
successfully be measured from the urine matrix since linearity clearly 
demonstrated (r = 0.9997). 
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Pb added(og) Peak Area Peak Height 
0.00 3.02 35.31 
100.00 5.75 68.05 
200.00 8.38 95.83 
300.00 11.25 128.30 
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Figure 2.10. Representative ASV voltammograms measured a 
previously spiked urine sample (19. 61 ~gl dl) 
evaluated for Pb2+ using standard addition 
technique. Y axis = I/nA represents current 
(nano-Ampere); X axis = U/mV which represent 
potential (milliVolt). 
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Accuracy 
Table 2.9 summarizes the results obtained from the experiments designed 
to assess accuracy to detect the occurrence of systematic errors using spiked urine 
samples in the concentrations ranging from 19.61 to 90.91 /-lg/dl. Figure 2.11 
clearly demonstrates the high correlation coefficient obtained from spiked and 
measured lead concentrations in urine. Accuracy was further demonstrated by the 
low relative error 
Absolute Error = Xmeasured -Xtrue 
R I · E Absolute Error 100 e atlve rror = x 
X true 
n = number of observations 
Table 2.9. Accuracy of the measured lead from previously spiked 
urine samples. (A) measured from peak heights, (8) 
measured from peak areas. 
(A) 
Added Pb2+ · Measured Absolute Relative 
Jggfdl) N JggJdl) Error error 
19.61 3 21.57 l.96 10.01 
38.46 3 4l.11 2.65 6.89 
56.60 2 52.64 3.96 7.00 
74.07 3 76.08 2.01 2.71 
90.91 3 89.19 1.72 1.89 
(B) 
Added Pb2+ Measured Absolute Relative 
JggJdl) N JjlQ/dl) Error error 
19.61 3 20.74 1.13 5.75 
38.46 2 40.95 2.49 6.49 
56.60 3 51.35 5.25 9.28 
74.07 3 77.51 3.44 4.64 
90.91 2 77.51 3.42 3.76 
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Figure 2.11. Correlation between spiked and measured Lead in 
urine (Jlg/dl) from (A) peak heights and (8) peak 
areas. 
The results clearly demonstrate that the proposed method gave high 
correlation between the spiked and measured lead from the urine matrix. 
84 
Sensitivity and Matrix Effects 
Sensitivity was measured by recording ASV profiles after the successive 
additions of Pb2+ into the aqueous HCI04 media in the concentration ranging from 
0.99 to 9.09 Ilg/dl. This was compared with the results from urine samples, 
individually spiked, extracted and measured using the standard addition 
technique. Calibration sensitivities which are equated with the slopes of the 
calibration graphs, were measured for the following solutions: 
(A) Aqueous HCI04 solutions. 
(B) Individually spiked and extracted urine samples. 
Tables 2.10 and 2.11, summarize the results, which are further illustrated in 
Figure 2.12. 
Table 2.10. Peak heights versus concentrations spiked 
into aqueous HCI04 . 
Standard Addition Peak height (nA) 
Pb2+ Aqueous HCI04 Matrix 
J..lg/dl 
0.00 l.70 
0.99 37.07 
l.96 74.81 
3.85 147.90 
5.66 223.20 
7.41 296.20 
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Table 2.11. Peak heights measured from individually I spiked 
and extracted urine samples. 
~~ead$f(toncet(ttati€)n Peak height ~easured After 
J.lg/GH Extraction 
"/ 
,;; nA 
l.96 33.09 
3.85 56.88 
5.66 85.71 
7.41 11l.97 
9.09 142.04 
350 Y = 39.84x - 1.7905 
300 R2 = 0.9994 1m (A) 
...., 
250 
0(8) 
~ 
C) 
.- 200 Q) 
~ 
~ 150 
cu 
Q) 100 a.. y = 15.3x + 0.3478 
50 R2 = 0.9967 
0 
0 2 4 6 8 10 
pFl.) Concentration (ug/dl) 
Figure 2.12. Peak heights (nA) measured during the evaluation of 
sensitivity and matrix effects (A) from aqueous HCI04 
solution. (B) from individually extracted urine samples. 
The results clearly show that matrix effect is demonstrated in spite of the 
very small volume of urine sample employed and high dilution factor. The slope 
of the calibration graph measured from the urine matrix was much lower than that 
from the aqueous HCI04 media. 
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Precision 
Method precision for the determination of lead in urine was measured by 
evaluating standard deviations and their corresponding CV% Table 2.12. Figure 
2.13 compares the precision measured by re-evaluating the data from peak areas 
and peak heights. The results indicate that the CV% is around 10%. 
Table 2.12. Precision in the measurement of Lead in urine In 
the concentrations ranging from 19.61 to 90.91 
~g/dl. 
I(A) From peak heiQht 
Pb2+ I; 
-7; 
conS'en~r:ati(!)n , Mean concentration Standard CV 
" J;t~lefl . N measured deviation % 
19.61 4 21.57 1.78 8.27 
38.46 4 41.11 2.21 5.38 
56.60 4 52.64 3.38 6.43 
74.07 4 76.08 2.02 2.65 
90.91 4 89.19 6.56 7.35 
'B) From peak area 
Pb2+ 
concentration Mean concentration Standard CV 
J.!Qldl N measured deviation % 
19.61 4 20.74 1.87 9.01 
38.46 4 40.95 1.99 4.85 
56.60 4 51.35 4.12 8.03 
74.07 4 77.51 1.95 2.52 
90.91 4 94.33 15.42 16.35 
The results illustrate that good precision was obtained (range 2.52 to 16.35 
CV%) for peak areas, when lead was measured in the urine matrix. 
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Lead concentration (Jlg/dl) 
Figure 2.13. Precision, as CV'o, with measured Lead levels in 
urine. 
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2.5.3. Signal optimization for measuring Pb2+ in the urine matrix 
using: (a) Differential Pulse Polarography (DPP) 
(b) Anodic Stripping Voltammetry (ASV) 
(c) Cathodic Stripping Voltammetry (CSV) 
a. Measurement of Pb2+ in urine using DPP. 
The following data summarizes the DPP results of Pb2+ in the urine 
matrix. Figure 2.14 (A) illustrates the calibration data measured during the 
standard addition of Pb2+ into urine matrix using the instrumental parameters 
summarized in Figure 2.14 (B). 
Using the acetate buffer media (5.0 ml, pH 5) containing 50 III urine; the 
results showed that a relatively high sensitivity was obtained as demonstrated by 
the slope of the calibration graph (7.65 x 106 nAlM or 0.369/nAlllg/dl). The limit 
of detection (LOD) was calculated using the linear equation Y = b x + a 
Where a = intercept 
and Y (analytical signal calculating for LOD) = a + 3Sblank 
and Y LOD = b x + a ------- x = LOQ 
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b. Measurement of Pb2+ in urine using ASV mode. 
The data summarized in Figure 2.15 illustrate the ASV profiles and 
corresponding data for lead in urine measured from the acetate buffer media (5.0 
ml, pH 5). It is clear that a substantial increase in the sensitivity was recorded. 
This is demonstrated by the high slope of the calibration graph (3.88 x 108 nAIM 
or 18.73 nA/Jlg/dl). 
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c. Measurement of Pb2+ in urine using CSV mode. 
The following data summarize the CSV results of Pb2+ in the urine matrix 
(50 JlI urine spiked into 5.0 ml aliquot of acetate buffer pH 5). Figure 2.16 (A) 
illustrates the calibration data measured during the successive additions of Pb2+ 
into the urine matrix, using the instrumental conditions summarized in Figure 
2.l6 (B). The results showed 3 peaks at - 200 mY, - 400 mV and - 680 mY. 
There was a linear response to the added lead but there were no changes in the 
other peaks suggesting that these peaks correspond to endogenous compounds. 
Interestingly a small peak appeared at - 400 m V suggesting a small amount of 
endogenous lead (l x 10-4 M), which represent about the limit of detection for 
lead in urine matrix. 
The CSV profiles recorded illustrate that although linearity was 
demonstrated, however, CSV might not be specific since several interfering peaks 
appeared in the voltammogram. The main peak, which appeared at - 410 mV 
completely overlapped with that of the DMPS peak (Figure 2.20) 
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2.6. Method Development and Validation for DMPS in Biological 
Fluids using Electroanalytical Techniques. 
2.6.1. Electrochemical behavior of DMPS 
Using the following instrumental conditions, a cyclic voltammogram for 
DMPS was recorded: 
• Mode ............................... Cyclic 
• Working electrode ................. Hanging Mercury Drop Electrode 
• Drop Size ........................... 9 
• Ramp ................................ 0 -1000 (mV) 
• Sweep rate .......................... 5000 (mV/s) 
• Reverse Ramp ..................... 0.-1000 (mV) 
• Sweep rate .......................... 5000 (mV/s) 
DMPS was prepared at a concentration 3 .36x 10-5 M in an acetate buffer 
solution (PH 5.0, 0.10 M). The cyclic voltammograms (CV) obtained from (A) 
the background solution prior to DMPS addition and (B) the CV after the addition 
ofDMPS are shown in Figure 2.17. 
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-2 (A) 
-I 
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-a. CI (B) 
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Figure 2.17. Cyclic Voltammograms for (A) an acetate buffer 
solution (pH 5.0, 0.10 M) and (B) an acetate 
buffer solution containing DMPS (3.36xl0-5 M). 
Y axis = I/nA represents current (nano-Ampere) 
X axis = U/mV which represent potential (milliVolt). 
The above figure shows that DMPS has a cathodic potential wave 
appeared at - 486 mY, whereas the anodic wave appeared at - 445 mY. The 
oxidation-reduction behavior of DMPS seems irreversible, with a potential 
difference of ~Ep = 41 m V. 
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2.6.2. Signal Optimization for DMPS in aqueous solution. 
Variation of DMPS signal with concentration using: 
(a) DPP (b) ASV and (c) CSV 
The following procedures have been adopted: 
Q. Differential Pulse Polarography (DPP). 
• Mode ............................. Differential Pulse 
• Working electrode ............. Static Mercury Drop Electrode 
• Drop Size ........................ 9 
• U amplitude ....................... -100 (m V) 
• Sweep rate ..................... 24 (mV/s) 
• Measurement time ............ 20 (ms) 
• Pulse time ..................... .40 (ms) 
The above conditions have been optimized for measuring the analytical 
signal resulting from DPP mode. Figure 2.18 illustrates the resulting 
voltammograms. It is clear that peak signal is proportional with the DMPS 
concentration. 
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Figure 2.1S. DPP profiles for DMPS measured from aqueous 
solution in the concentrations ranging from (1) 
2.37xl0-5 M to (S) 1.S3xl0-4 . 
Y axis = I/JlA represents current (micro-Ampere) 
X axis = U/mV which represent potential (milliVolt) 
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b. Anodic Stripping Voltammetry (ASV) 
The following instrumental conditions have been adopted during the 
measurement of ASV profiles for DMPS: 
• Mode ................................ Differential Pulse 
• Working Electrode ................ Hanging Mercury Drop Electrode 
• Drop size ............................ 5 
• U amplitude ............................. 1 00 (m V) 
• Sweep rate .......................... 13.33 (mV/s) 
• Accumulation time ............... .1 00 (s) 
• Accumulation Potential .......... -900 (mV) or - 800 (mV) 
• Potential Range (L1U) ............. -600 to 100 (mV) versus Ag/AgCI 
The above conditions have been optimized for measuring the analytical 
signals resulting from ASV mode. Figure 2.19 illustrates the resulting 
voltammograms. Signals obtained are broad and less sensitive than DPP signals. 
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c. Cathodic Stripping Voltammetry (CSV) 
The following instrumental conditions have been adopted during the 
measurement of CSV profiles for DMPS: 
• Mode ................................... Differential Pulse 
• Working Electrode ................... Hanging Mercury Drop Electrode 
• Drop Size .............................. 9 
• U amplitude ........................... 100 (mV) 
• Sweep rate ............................. 24 (mV/s) 
• Accumulation time .................. .1 00 (s) 
• Accumulation Potential ............. -1 0 (m V) 
• Potential Range ~U .................. 0 to -900 (mV) vs. Ag/AgCI 
The above conditions have been optimized for measuring the analytical 
signals resulting from the CSV mode. Figure 2.20 illustrates the resulting 
voltammograms. It is clear that the signal is not linear over the concentration 
rangeof2.37 x 10-5 to 1.83 x 10-4 M. 
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2.6.3. Determination of DMPS in Plasma 
A 4.50 ml aliquot of water was spiked with a 0.50 ml (HP03)n (l M) into 
which a 5 ~l portion of EDT A solution (0.1 M) was added. Cathodic stripping 
voltammograms were recorded after three successive additions of DMPS solution 
(2.23 x 10-5 M) 40 ~l each. The resulting cathodic stripping voltammograms are 
illustrated in Figure 2.21. The above procedure was repeated for a solution 
containing 0.50 ml blank plasma (expired plasma) as illustrated in Figure 2.22. 
Figure 2.22 showed that linear curves were obtained for DMPS vs. 
concentration in plasma matrices. Addition of EDT A was necessary in order to 
free the Pb-DMPS complex, anticipated in authentic samples since Pb-EDTA 
forms a much stronger complex compared with that ofPb-DMPS. 
In order to compare several DMPS extraction procedures, two methods for 
protein precipitation were tried. In the first method, a 0.50 ml aliquot of plasma 
was added to an (HP03)n solution (0.50 ml), the mixture was vortexed (30s), 
centrifuged and decanted into an electrochemical cell. The mixture was then 
diluted with a 4.0 ml aliquot of deionized water (Figures. 2.23 & 2.25). 
In the second method, a 0.50 ml aliquot of plasma was added to 
acetonitrile (3.0 ml), the mixture was vortexed for 30 seconds, centrifuged at 4500 
rpm, for 10 min. and decanted. The supernatant was transferred into another tube, 
and the organic phase was evaporated under a stream of nitrogen. The residue was 
subsequently reconstituted with 4.5 ml water containing 0.50 ml (HP03)n as 
shown in Figure 2.24 and 2.26. 
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For each of the above final solutions, 5.0 JlI EDTA solution (0.1 M) was 
added prior to recording the cathodic stripping voltammograms, using the 
previously mentioned experimental conditions (2.4.4.2.c) 
The above procedure was adopted for measuring DMPS in plasma samples 
collected prior to and after dosing with DMPS. Representative voltammograms 
for the plasma samples collected at 0.00, and 2.50 hours post dosing are illustrated 
in Figures 2.23 to 2.26. 
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(C) Calibration curve. 
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2.6.4. Determination of DMPS in Urine 
5.0 ml acetate buffer (pH 5.6, 0.1 M) in which 50 ml of diluted urine 
(1: 1 00) was spiked. The earlier described voltammetric conditions (2.4.4.2) have 
been optimized for measuring the analytical signal for DMPS in urine matrix, 
resulting from DPP, ASV and CSV modes. Figures 2.27, 2.28 and 2.29 illustrate 
the resulting voltammograms together with their corresponding calibration data. 
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The above profiles illustrate that a linear curve having a high sensitivity 
(6.29 x 106 nA/M) was obtained. Furthermore, DMPS reduction peak appeared at 
- 462 m V, which is quite distinct from the lead reduction peak indicating that one 
can successfully measure DMPS in the presence of Pb2+ in authentic samples. 
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The relatively low sensitivity (4.70 x 106 nAIM) observed from the above 
results may be explained by the irreversible behavior of the DMPS redox couple. 
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Figures 2.20, 2.29 and 2.32 clearly demonstrate that linearity was only 
observed in the low DMPS concentrations, which ranged 1.65x10-7 to 6.58 x 10-7. 
At a relatively high DMPS concentration (10-6 M), deviation from linearity was 
observed. This may be due to the complex electrode process, which was 
predominated by an adsorption process. 
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Further experiments were carried out to study the voltammograms 
obtained from solutions containing free Pb2+, free DMPS and Pb-DMPS complex 
as anticipated in authentic samples. Consequently, lead levels were determined in 
the urine matrix using CSV and ASV modes, and the same was repeated for 
DMPS. For both Pb2+ and DMPS two media were investigated namely (A) 
acetate buffer (0.1 M, pH 5.6) in the presence of EDT A [Figures (2.30, 2.31, 2.32 
and 2.33)] and (B) perchloric acid media (1 M) [Figures (2.34, 2.35, 2.36 and 
2.37)]. 
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Figure 2.30. Cathodic Stripping Voltammograms of (1) acetate 
buffer solution (0.1 M, pH 5.6) containing EDTA 
(9.9xl0- 5 M) (2) above solution after the addition 
of 100 JlI urine, (3), (4) and (5) after successive 
additions of Pb2+ each 2.37xl0-7 M. 
Figure 2.30 illustrate that while EDTA did not show a peak in CSV, small 
background signals appeared in urine matrix at - 446 mV and -549 mY. These 
were regarded as insignificant signals. 
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Anodic Stripping Voltammograms of (0) acetate 
buffer solution (10 ml, 0.1 M, pH 5.6) containing 
EDTA (9.9x10- 5 M) (1) above solution after the 
addition of 100 III urine, (2), (3) and (4) after 
successive additions of Pb2+ each 2.37x10-7 M. 
From the above ASV profiles it is clear that in potential window scanned 
in the range - 800 to Zero m V, no significant peaks were recorded for the free 
lead ions. 
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Figure 2.32. Cathodic Stripping Voltammograms of (0) acetate 
buffer solution (10 ml, 0.1 M, pH 5.6) containing 
EDTA (9. 9x10-5 M) after the addition of 100 JlI 
urine, (I), (2), (3) and (4) after successive 
additions of DMPS each 1.65xl0-7 M. 
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Anodic Stripping Voltammograms of (0) acetate 
buffer solution (10 ml, 0.1 M, pH 5.6) containing 
EDTA (9.9xl0· 5 M) after the addition of 100 III 
urine, (1), (2), (3) and (4) after successive 
additions of DMPS each 1.65xl0-7 M. 
Figure 2.32 clearly demonstrated that by using CSV mode in the presence 
of EDTA, DMPS behaved linearly up to a maximum of 6.56xIO-7 M. At higher 
concentration there was a remarkable deviation from linearity (Figure 2.29). 
Figure 2.33, the ASV profiles showed that the ASV technique cannot be 
employed for the analysis of DMPS in biological matrix, since it gave a very 
insensitive peak in the presence of EDT A. 
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Figure 2.34. Cathodic Stripping Voltammograms of (0) perchloric 
acid solution (4.5 ml, 1.7 M) (1) after the addition 
of 500 ~I urine, (2), (3) and (4) after successive 
additions of Pb2+ volumes (25 ~I, 4.47xl0-7 M). 
Figure 2.34 illustrate the CSV profiles for lead addition in a perchloric 
acid solution (5 ml) containing 0.5 ml urine. It is clear that lead did not give a 
significant peak proportional to concentration. On the other hand, lead can be 
successfully determined in urine using perchloric acid media using the ASV mode 
(Figure 2.35). 
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Figure 2.35. Anodic Stripping Voltammograms of (0) perchloric 
acid solution (4.5 ml, 1.7 M) (1) after the 
addition of 500 JlI urine, (2), (3) and (4) after 
successive additions of Pb2+ volumes (25 JlI 
4.47xl0-7 M). 
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Figure 2.36. Anodic Stripping Voltammograms of (0) perchloric 
acid solution (4.5 ml, 1.7 M) after the addition of 
500 JlI urine, (1), (2), (3) and (4) after successive 
additions of DMPS volumes (25 JlI, 1.67xl0-6 M). 
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Figure 2.37. Cathodic Stripping Voltammograms of (0) perchloric 
acid solution (4.5 ml, 1.7 M) after the addition 
of 500 JlI urine, (1), (2), (3) and (4) after 
successive additions of DMPS volumes (25 JlI 
1.67x10-6 M). 
Figures 2.36 and 2.37 clearly demonstrate that the use of perchloric acid 
media is not recommended for the analysis ofDMPS in urine using CSV or ASV. 
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2.7. Complexometric Titration of DMPS versus Pb2+ followed by 
measuring DPP I ASV or CSV. 
Using the above instrumental conditions (section 2.4.1), peak heights 
and/or peak areas for Pb2+ were monitored after the successive additions of DMPS 
into an acetate buffer solution containing 1.43x 1 0-5 M Pb2+ (PH 5.6, 10.00 ml) . 
Table 2.13 summarizes the data pertaining to DMPS additions together with the 
resulting Pb:DMPS mole ratios in test solution. 
Table 2.13. Complexmetric titration of DMPS vs Pb2+ (1.43xl0-5 M) 
IT :w ~ .' ".' .~"" t~ Concentration Pb:DMPS Volume t,.:d) DMPS 
No. 
(4.802 K 10~3 M) DMPS [M] mole ratio 
1 10 4.8 X 10-6 1 :0.33 
2 20 9.60 X 10=5 1 :0.66 
3 30 1.44 X 10-5 1:1 
4 50 2.88 X 10:) 1 :2 
5 90 4.32 X 10:) 1:3 
6 120 5.76 X 10:) 1:4 
7 240 1.15 X 10-4 1 :8 
8 390 1.87 X 10-4 1: 13 
The resulting voltammograms measured using the three electroanalytical 
modes ofDPP, ASV and CSV are illustrated in Figures 2.38-2.40. 
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Overall addition (10 ul to 390 ul) of DMPS 
(4.802xl0- 3 M) into Pb2+ (1.43xl0- 5 M) using DPP 
technique. 
Together with Figure 2.14 and 2.27, the above figure clearly illustrate that 
while peak (I) correspond to the free DMPS, peak (II) correspond to free lead, the 
lead peak disappeared and two other peaks III and IV appeared after successive 
additions ofDMPS. 
It is interesting to note that the DMPS peak, which appears at - 461 m V 
(peak I), started appearing after the addition of higher DMPS levels (1 :3) 
Pb:DMPS. 
A further observation, showed that a constant signal corresponding to the 
formed complex was observed at - 515 m V (peak III). As anticipated, peak III 
was not increasing after the Pb2+ ions were totally complexed. 
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Overall addition (10 ul to 390 ul) of DMPS 
(4.802xl0- 3 M) into Pb2+ (1.43xl0- 5 M) using 
ASV technique. 
The above profiles indicate that, after the successive additions of DMPS, the 
ASV signals of lead, which overlapped with that of DMPS, decreased 
systematically while two new peaks appeared (I & II). These peaks may correspond 
to the formation of two complexes of Pb:DMPS, since they were increasing with 
increased DMPS concentration. 
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Figure 2.40. Overall addition (10 ul to 390 ul) of DMPS 
(4.802x10- 3 M) into Pb2+ (1.43x10- 5 M) using CSV 
technique. 
Figures 2.16 and 2.29, together with the above profiles (Figure 2.40) 
illustrate that at - 400 m V both DMPS and Pb2+ showed overlapping peaks. Peak 
A, however which appeared at - 540 m V, could be due to the signal 
corresponding to the Pb:DMPS complex (Figure 2.40). 
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2.B. Complexometric Titration of Pb2+ versus DMPS followed by 
measuring DPP I ASV or CSV. 
Using the above instrumental conditions (section 2.5.1), peak heights and 
or peak areas for Pb2+ were monitored after the successive additions of Pb2+ into 
acetate buffer solution (PH 5.6, 10.0 ml), containing 1.42xl0·5 M DMPS. Lead 
was added successively (in increasing amounts ranging from 10 1-11 to 450 1-11 
4.83xl0·3 M). After each addition, electroanalytical signals resulting from DPP, 
ASV and CSV modes were recorded. Table 2.14 summarizes the data pertaining 
to Pb2+ additions together with the resulting Pb:DMPS mole ratios in test solution. 
Table 2.14. Complexmetric titration of Pb2+ vs. DMPS (1.42x10- 5 M) 
g 
Vol;uOle(J,tI) Pb2+ Concentration Pb:DMPS :; 
No. 
(4.881)( 10.3 M) DMPS [M] mole ratio 
1 10 4.76 X 10.0 0.33:1 
2 20 9.52X 10.0 0.66:1 
3 30 1.43 X 10·:> 1:1 
4 60 2.84 X 10·:> 2:1 
5 90 4.25 X 10·:> 3:1 
6 180 8.43 X 10·) 6:1 
7 300 1.39 X 10.4 10: 1 
8 450 2.05 X 10-4 15: 1 
The resulting voltammograms measured using the three electro analytical 
modes ofDPP, ASV and CSV are illustrated in Figures 2.41-2.43. 
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Figure 2.41. Overall additions (10 ul to 450ul) of Pb2+ (4.83xl0- 3 
M) into DMPS (1.42xl0- 5 M) using DPP technique. 
Figures 2.14 and 2.27, in addition to the above profiles, illustrate that the 
DMPS peak decreased significantly after the successive additions of lead. Two 
new peaks (I) and (II) which appeared at - 510 m V and - 325 m V respectively 
may indicate the formation of two new complexes of Pb:DMPS. 
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Figure 2.42. Overall additions (10 JlI to 450ul) of Pb2+ 4.83xl0-3 
M) into DMPS (1.42xl0- 5 M) using ASV technique. 
The above Figure 2.42, together with Figures 2.15 and 2.28, indicate that 
using the ASV modes, one cannot discriminate between the analytical signals of 
the investigated species, DMPS or the formed complexes. This may be due to the 
very high sensitivity of measurement for the Pb2+ using ASV mode. The Pb2+ 
peak overlapped the anticipated peaks for the complexes. 
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Overall additions (10 ul to 450ul) of Pb2+ 
(4.83xl0- 3 M) into DMPS (1.42xl0- 5 M) using 
CSV technique. 
Figure 2.16 and 2.29, together with the above profiles clearly illustrate that 
at - 400 mY, both Pb2+ and DMPS showed overlapping peaks. Peaks I and II, 
which appeared at - 540 and - 260 mY, respectively clearly demonstrate the 
formation of new complexes formed between Pb2+ and DMPS (Figure 2.43). The 
high resolution, coupled by high sensitivity of CSV may successfully demonstrate 
the complex formation. 
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2.9. Optimization of the Electroanalytical signals for the 1: 1 
Pb: DMPS Complex. 
AI: 1 Pb:DMPS complex was prepared by adding equimolar amount of 
DMPS (2.41 x 10-3 M) and Pb2+ to acetate buffer solution. After de-aeration of 
10.0 ml aliquot of an acetate buffer solution (0.1 M, pH 5.6), electroanalytical 
signals pertaining to DPP, ASV and CSV were individually recorded after each 
successive addition of 1: 1 complex. Figures 2.44 to 2.46 illustrate the results 
obtained. 
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Figure 2.44. Differential Pulse Voltammograms recorded after the 
successive additions containing a 1: 1 complex of 
Pb:DMPS in an acetate buffer solution (2.41xl0- 3 M) 
(1) 10 JlI to (8) 800 Jll. 
The above profiles illustrate the linearity of the formed 1: 1 complex 
between lead and DMPS. 
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Figure 2.45. Anodic Stripping Voltammograms recorded after the 
successive additions containing a 1: 1 complex of 
Pb:DMPS in an acetate buffer solution 
(2.41x10- 3 M) (1) 10 JlI to (8) 800 Jll. 
The above ASV profiles illustrate that the formed complex( es) may be 
labile since both the Pb2+ and DMPS signals were increasing systematically after 
the standard addition of a solution containing 1: 1 Pb:DMPS complex. 
It may well be that the complex( es) could have dissociated at the electrode 
surface as a result of the applied -ve potentials during the scanning process. 
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Figure 2.46. Cathodic Stripping Voltammograms recorded after 
the successive additions containing a 1: 1 complex 
of Pb: DMPS in an acetate buffer solution 
(2.41xl0- 3) (1) 10 JlI to (8) 800 Jll. 
The above profiles clearly illustrate that the CSV mode is suitable for 
measuring the formed complexes) between Pb:DMPS. The complexes) may have 
remained stable during the measurement. 
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2.10. Variation of Pb2+ signal with deposition potential. 
To 10 ml acetate buffer (PH 5.6, 0.1 M ) containing Pb2+ at a 
concentration of 4.83 x 10-5 M, 100 J-li urine sample was added. Using the 
following experimental conditions, the analytical signals (peak height nA) were 
recorded after changing the deposition potentials in the range -100 to - 1500 mY. 
Experimental Conditions: 
• Mode ............................. Differential Pulse 
• Working Electrode ............ Hanging Mercury Drop Electrode 
• Drop size ......... '" ............ 5 
• U amplitude ......••................ .1 00 (m V) 
• Sweep rate ..................... .13.33 (mV/s) 
• Accumulation time ............ 100 (s) 
• Accumulation Potential ...... -900 (mV) or - 800 (mV) 
• Potential Range (~U) ......... -600 to 100 (mV) versus Ag/AgCI 
Table 2.15 summarizes the results obtained which are also shown in 
Figure 2.47. The experiment was repeated with a 1: 1 (Pb:DMPS) complex added 
at a concentration 4.83 x 10-5 M (Table 2.15 and Figure 2.48). The same 
procedure was repeated for an acetate buffer solution (PH 5.6, 0.1 M) containing a 
1: 1 Pb:EDTA complex (4.83 x 10-5 M) (Table 2.17 and Figure 2.49). Figure 2.50 
compares the ASV analytical signals obtained for the above three solutions 
containing the same molar concentration of (1) Pb2+ (4.83 x 10-5 M), (2) 
Pb:DMPS complex (4.83 x 10-5 M) and (3) Pb:EDTA (4.83 x 10-5 M). All were 
measured under the same experimental conditions in the urine matrix. 
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Table 2.15. Variation of Peak height (nA) with deposition 
potential (-mV) for Pb2+ (4.83xl0- 5 M) in a urine 
matrix. 
Deposition Potential E1/2 (mV) Peak Height (nA) 
0 -395 590.5 
100 -395 610.9 
200 -394 619.1 
300 -395 616.3 
350 -395 1066 
400 -395 2029 
425 -395 2483 
450 -395 4461 
475 -389 11480 
490 -386 14760 
500 -395 15200 
525 -385 16030 
600 -385 16080 
700 -384 15890 
800 -384 17140 
1000 -385 16990 
1500 -388 16770 
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Figure 2.47. 
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Variation of Peak height (nA) with deposition 
potential (-mV) for Pb2+ (4.83xl0- 5 M) in a urine 
matrix. 
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Table 2.16. Variation of Peak height (nA) with deposition 
potential (-mV) for Pb2+ (4.83xl0- 5 M) and DMPS 
(4.83xl0- 5 M) in a urine matrix. 
ESlposifion· Pof~ntial E1/2 (mV) Peak Height (nA) 
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Figure 2.48. 
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(4.83xl0- 5 M) in a urine matrix. 
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Table 2.17. Variation of Peak height (nA) with deposition 
potential (-mV) for Pb2+ (4.83x10- 5 M) and 
EDTA (4.83x10- 5 M) in a urine matrix. 
Deposition, Pet~ntial E1/2 (mV) Peak Height inA) 
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Variation of Peak height (nA) with deposition 
potential (-mV) for Pb2+ (4.83x10- 5 M) and EDTA 
(4.83x10- 5 M) in a urine matrix. 
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Figure 2.50. Comparison between the ASV analytical signals 
obtained from (1) free lead ions in a solution 
contains 4. 83xl 0-5 M Pb2+, (2) free lead ions in 
a solution contains Pb:DMPS complex 4.83xl0-5 
M and (3) free lead ions in a solution contains 
Pb:EDTA complex (4.83xl0- 5 M). 
Figures 2.47, 2.48, 2.49 and 2.50, clearly illustrate that while a Pb:EDT A 
complex is a stable complex having a dissociation potential at about -1300 m V 
versus Ag/ Agel reference electrode, Pb:DMPS behaved as if no complex has 
formed at all, or possibly a very labile complex has formed. 
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2.11. Relative stabilities of the Pb:DMPS and Pb:EDTA 
complexes. 
An equimolar amount of DMPS and Pb2+ (4.66 x 1 0-5 M) were 
added to a 10.1 ml test solution containing an acetate buffer (PH 5.0) into which 
100 III urine was previously spiked. An equimolar amount of EDT A was spiked 
to make up a concentration of 4.61 x10-5 M. Figures 2.51, 2.52 and 2.53 illustrate 
the results after recording the voltammograms using (a) DPP (b) ASV and (c) 
CSV modes. 
Relative stabilities of both Pb:EDTA and Pb:DMPS were investigated by 
initially spiking a 1: 1 Pb:DMPS complex as shown in Figure 2.51 into the urine 
matrix. While two peaks, appeared at - 310m V and at - 515 m V, these 
correspond to the Pb:DMPS complex. After the addition of an equimolar amount 
of EDT A, it was demonstrated that EDT A formed a complex with Pb2+ even 
though Pb2+ was associated with DMPS. The peak, which appeared at - 415 mV 
clearly demonstrated that it corresponds to the free DMPS. Consequently, 
Pb:EDTA complex, which has a formation constant of 1.13 x 1018 is more stable 
than that of Pb:DMPS. One should therefore, anticipate a very low stability 
constant for the Pb:DMPS. Figures 2.52 and 2.53, confirmed the above finding as 
demonstrated both by the ASV and CSV profiles obtained. 
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Figure 2.51. Differential Pulse Voltammograms illustrating (1) A 
blank DPP profile for the acetate buffer spiked 
with an aliquot of a control urine sample (100 JlI) 
,(2) DMPS spiked into (1) (4.70xl0- 5 M), (3) Pb2+ 
spiked into (2) (4.66xl0- 5 M) ,(4) EDTA spiked into 
(3) (4.61xl0- 5 M). 
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Figure 2.52. Anodic Stripping Voltammograms illustrating (1) A 
blank DPP profile for the acetate buffer spiked 
with an aliquot of a control urine sample (100 /-11) 
,(2) DMPS spiked into (1) (4.70xl0- 5 M), (3) Pb2+ 
spiked into (2) (4.66xl0- 5 M) ,(4) EDTA spiked into 
(3) (4.61xl0- 5 M). 
143 
." 
1 
:: = e_ 
I 
~ 
I 
11- (I) 
I 
a_ 
.. 
I 
!I-
I 
• i I I 
. ! I I I I I I I I , , , , , , , '1 , 
-391 mY 
2.31 )lA 
..... , 
-127 mV -256 mY 
6$ nA 197 nA 
.~ 
• I I I I I I I 
. , , , , , , 
-'''3 mV 
4.o.t J-lA 
(3) 
I , 
.. 
• H-
I 
., 
• 04-
I 
• ~-
I 
i--
.-
-128 mV 
170nA 
-388 mV 
2.15 J-lA 
(2) 
,; I I 
. ! I I I I I I I I , , , , , , , '! 
I 
::: 
W"I 
... -
I 
• 
... -
I 
, 
W"I 
; - -127 mV 
10' nA· 
--.. I I I I 
. , , , 
-J82 mV 
2.20 J-lA 
(4) 
I I I I I , , , , , I I . 
.. J , , 
-
Figure 2.53. Cathodic Stripping Voltammograms illustrating (1) A 
blank DPP profile for the acetate buffer spiked 
with an aliquot of a control urine sample (100 Ill) 
,(2) DMPS spiked into (1) (4.70xl0- 5 M), (3) Pb2+ 
spiked into (2) (4.66xl0- 5 M) ,(4) EDTA spiked into 
(3) (4.61xl0- 5 M). 
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2.12. Determination of the Formation Constants (Kf) for Pb: DMPS 
Complex. 
Investigations pertaining to the possibility of measuring formation of 
Pb:DMPS were initiated following the procedures of Shumann and Woodward's 
Method and of Deford-Hume (Appendix I). 
a. Shumann and Woodward's Method: 
Complexometric titrations followed by ASV measurements were 
conducted by titrating DMPS (4.77xl0-5 M) with Pb2+. After successive additions 
of J-li aliquots of Pb2+ (4.83x 1 0-3 M) the solution was stirred prior to ASV 
measurement. The increase in the lead signals was monitored in the two 
important regions of the titration curve, the region before the equivalence point 
was reached (A), the region after equivalence (B). Figure 2.54 (A) and (B) 
illustrate the voltammograms recorded in both regions. 
From the analytical signals and the calculated concentration of Pb2+ and 
the free ligand, attempts to measure the conditional formation constant were 
carried out in accordance with section 1.12-f. Tables 2.18 to 2.20 summarize the 
obtained results. 
The above procedure was repeated for another DMPS concentration 
(7.12x 10-5 M). A summary of the calculated Kds shown in Table 2.20. 
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Figure 2.54. Anodic Stripping Voltammogram of Pb2+ titration 
with DMPS; (A) before equivalence point and (8) 
after equivalence point. 
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The profiles illustrated in Figure 2.54 showed that in spite of the 
overlapping lead and DMPS peaks, it was already established that the lead 
analytical signal was 50 times more sensitive than that of DMPS. Consequently, 
the measurement in the analytical signals should give a small relative error. 
One can also conclude that while it is clear that curve (A), which 
illustrates the region before equivalence, shows that the complex signals increase 
with each successive addition of lead, curve (B) however shows that after the 
equivalence point a constant signal, which corresponds to the complex, was noted. 
Table 2.18. Stripping current versus CM/(CM-CL) for the titration 
of different DMPS concentration (A) 4.nxl0-5 M 
and (B) 7.12xl0- 5 M with Pb2+. 
(A) 
CM(t(i~) CM/(CM-CL) Current (l.JA) 
2.85 1.49 0.087 
3.09 1.84 0.143 
3.32 2.29 0.210 
3.56 2.94 0.307 
3.80 3.92 0.426 
(B) 
CM(105) CM/(CM-Cd Current O!~ 
3.30 0.86 0.045 
3.77 1.12 0.121 
4.00 1.28 0.162 
4.24 1.47 0.191 
4.47 1.68 0.237 
4.70 1.94 0.275 
4.94 2.26 0.311 
5.14 2.65 0.369 
5.40 3.13 0.452 
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Figure 2.55. Stripping current versus CM/(CM-CL) for the titration 
of different DMPS concentration (A) 4. nxlO-5 M 
and (8) 7.12xlO-5 M with Pb2+. 
Table 2.19. Stripping current versus CM for the titration of 
different DMPS concentration (A) 4. nxlO-5 M and 
(8) 7.12xlO-5 M with Pb(II). 
~A) 
CM(105) Current (IJA) 
5.2 1.109 
5.67 1.298 
6.60 1.684 
7.07 1.869 
7.53 2.034 
8.00 2.236 
8.46 2.435 
8.92 2.610 
9.38 2.824 
~B) 
CM(1()4) Current (IJA) 
0.759 1.498 
0.828 1.772 
0.896 2.114 
0.963 2.339 
1.03 2.601 
1.10 2.860 
1.16 3.145 
1.23 3.385 
1.30 3.714 
1.36 4.000 
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Figure 2.56. Stripping current versus CM for the titration of 
different DMPS concentration (A) 4.nxlO-5 M and 
(8) 7.12xlO-5 M with Pb(II). 
Table 2.20. Conditional formation constant of different DMPS 
concentrations (Shuman & Woodward calculations) . 
... ,r "L"''';'F~. ..... . ... ." . . , 
DMPS concentration 81 S2 (10-4) 
(M) 
4.77xl0-:l 0.1400 4.067 
7.12xl0-5 0.1685 4.087 
SI = Slope of the line before equivalence (Figure 2.55) 
S2 = Slope of the line after equivalence (Figure 2.56) 
K f= Conditional Formation Constant. 
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Kr Average 
Kr 
2.901xl04 2.664x 104 
2.426x 104 
b. The Method of Deford - Hume. 
Complexometric titrations followed by DPP measurements were 
conducted by titrating Pb2+ (2.40x 1 0-5 M) with DMPS. After each addition (~l 
aliquots) of DMPS, the analytical signal was measured. Figure 2.S7 (A) illustrate 
the recorded profiles during the successive additions until a 1: 1 Pb:DMPS 
complex was obtained. Excess DMPS was subsequently added until a Pb:DMPS 
ratio of 1 :45 was obtained [Figure 2.57 (B)]. Table 2.21 (A) and (B), summarize 
the measured analytical signals during the above titration. 
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Figure 2.57. Differential Pulse Voltammograms of Pb2+:DMPS 
after the addition of various ligand concentration 
ranging between: (A) 4.7ge-M to 2.4e-5M into 
2.40e-5M Pb2+ and (8) 4.76e-5M to 3.97e-4M 
into a 9.64e-6M Pb2+. 
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Table 2.21. Variation of peak current with the addition of ligand 
concentrations: (A) (4.7ge-6 to 2.4e-5) M into a 
2.40e-5M Pb2+and (B) 4.76e-5M to 3.97e-4M into a 
9.64e-6M Pb2+. 
(A) g I' . • <" .. c '" ' c" ... · . , 70";{5 './ 
~on '. . i5bVt mrS"ifPAearanceofd?b(II) Appearance of Pb:DMPS 
(Mx'fff ) 
Potentia'i CUrrent Potential Current 
h .; p %t81~t~ ~ ; . j" ~  / •• "~ .t AfRtt1 (mV) (nA) 
- -389 -220.96 - -
0.48 -387 -118.62 -511 -119.51 
0.96 -391 -59.33 -515 -223 .50 
1.43 -395 -21.12 -518 -335.60 
1.91 -401 -1.21 -518 -376.30 
2.40 -401 0.00 -522 -454.00 
CUrrent 
0.48 -525 -160.07 
0.94 -530 -185.28 
1.40 -534 -167.63 
1.85 -536 -179.62 
2.29 -538 -161.07 
2.72 -539 -164.61 
3.15 -540 -163 .80 
3.56 -541 -147.07 
6.97 -542 -141.58 
The results indicated that one can not rely on the method of Deford-Hume 
for measuring formation constant. This is a consequence of the fact that both Pb2+ 
and DMPS DPP signals appeared at the same potential region. In-addition, they 
both demonstrated comparable sensitivity (8x 106) 
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2.13. Discrimination between the analytical signals of Pb2+ and 
DMPS in plasma and urine (Pilot trial). 
In order to investigate the resulting analytical signal corresponding to Pb:DMPS 
complex in plasma and urine samples after dosing with DMPS, and to establish a 
procedure for evaluating lead chelation, a pilot trial was conducted by dosing a lead 
exposed worker with 3 capsules of 100 mg. Plasma samples were collected prior to 
dosing, and at 0.2, 0.87, 1.42, 1.68, 3.67, 4.7, 6.95, 8.95 and 23.0 hours post dosing. 
Spot urine samples were collected prior to and at 2.7,4.78, 6.2, 7.2 hours after dosing. 
Using the optimized methods, the harvested plasma samples were analyzed for 
DMPS, whereas urine samples were analyzed for lead and DMPS. 
It was concluded that the successful determination of Pb2+ in presence of DMPS 
and/or Pb:DMPS complex in biological matrices depends on the proper choice of both 
(1) the analytical media (test solution) and (2) the voltammetric mode applied. 
The ASV mode was recommended for the analysis of lead in urine after diluting 
a 0.50 ml aliquot with HCI04 (1 M) to make up a final volume of 5.0 ml. Since the lead 
signal demonstrated a much higher sensitivity compared to that ofDMPS. 
CSV mode, however, was chosen for the analysis of DMPS in both plasma and 
urine. For plasma samples, 0.50 ml aliquot was extracted with 0.50 ml (HP03)n (5 M). 
The extracted sample was diluted to a final volume of 5.0 ml with deionized water. This 
was followed by the addition of 5.0/-11 EDTA (O.lM) 
For urine samples, a 50 /-11 aliquot of the urine sample was diluted to a final 
volume of 5.0 ml with deionized water. 
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From the diluted urine sample, a 50 ~l portion was transferred into a 5.0 ml 
acetate buffer solution (PH = 5.6, 0.1 M). This was followed by the addition of 5.0 ~l 
EDTA (O.1M). The results obtained for Pb2+ in urine, DMPS in plasma and DMPS in 
urine are summarized in Figures 2.58 to 2.76. 
It was thus conducted that one can successfully differentiate between the 
analytical signals of Pb2+ and DMPS in biological fluids. 
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Figure 2.58. Anodic Stripping Voltammograms and the 
corresponding data for the standard addition of 
Lead to a 5.0 aliquot HCI04 solution containing 
0.5 ml urine collected prior to dosing with DMPS 
(Zero time). 
The above profiles illustrate the successful determination of lead in urine 
samples collected prior to DMPS administration, using the standard addition 
technique. 
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Figure 2.59. Anodic Stripping Voltammograms and the 
corresponding data obtained during the 
analysis of lead in urine in a sample 
collected 2.70 hr after dosing with DMPS. 
The above profile illustrates that lead signal dramatically increased 
after 2.7 hour of dosing. 
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Anodic Stripping Voltammograms and the 
corresponding data obtained during the analysis 
of lead in a urine sample collected 4.78 hr 
after DMPS dosing. 
The above profile illustrates that chelation persisted 4.78 hour after 
chelation. 
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Figure 2.61. Anodic Stripping Voltammograms and the 
corresponding data obtained during the analysis 
of lead in a urine sample collected 6.2 hr 
after dosing with DMPS. 
The above profile illustrates that the lead signal decreased 6.2 hour after 
dosing. 
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Anodic Stripping Voltammograms and the 
corresponding data obtained during the analysis 
of lead in a urine sample collected 7.2 hr 
after dosing with DMPS. 
The above profile illustrates that the lead signal was still decreasing after 
7.2 hour of dosing. 
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Figure 2.63. Cathodic Stripping Voltammograms and its 
corresponding data obtained during the analysis of a 
plasma sample collected prior to dosing with DMPS. 
The above profiles illustrate that no significant CSV signal appeared in the 
harvested plasma prior to dosing with DMPS. 
160 
DMPS 
concentration 
(added) M 
1 0 
2 1.67E-07 
3 333E-07 
4 5.00E-07 
Figure 2.64. 
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Cathodic Stripping Voltammograms and its 
corresponding data obtained during the analysis 
of plasma sample collected 0.2 hr after dosing 
with DMPS. 
The above profiles illustrate that the CSV signal of DMPS increased in the 
harvested plasma 0.2 hr. after dosing. 
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Cathodic Stripping Voltammograms and its 
corresponding data obtained during the analysis 
of a plasma sample collected 0.87 hr after 
dosing with DMPS. 
The above profiles clearly illustrate that an obvious increase in the DMPS 
signal was measured by CSV 87 minutes after dosing. 
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Cathodic Stripping Voltammograms and its 
corresponding data obtained during the analysis 
of a plasma sample collected 1.42 hr after 
dosing with DMPS. 
The above profiles clearly illustrate that a notable increase in the DMPS 
signal was measured by CSV 1.42 hr. after dosing. 
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after dosing with DMPS. 
The above profiles clearly illustrate that the DMPS signal measured by 
CSV was still persisting 2.08 hr. after dosing. 
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started to decrease4.07 hr. after dosing. 
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Figure 2.69. Cathodic Stripping Voltammograms and its 
corresponding data obtained during the analysis 
of a plasma sample collected 5.10 hr after 
dosing with DMPS. 
The above profiles clearly illustrate that the DMPS signal measured by 
CSV is still decreasing after 5.10 hr. of dosing. 
166 
DMPS 
concentration 
(added) M 
1 0 
2 1.67E-07 
3 3.33E-07 
4 5.00E-07 
Figure 2.70. 
I-
I 
!-
I 
1-~ 
I 
I I I 
• I I 
~ lit 
I I 
Current 
(nA) 
82.84 
193.9 
279.2 
345.1 
I I I I I I I , , , , , , ,~ 
:I 
_ 500 I Y = 5E+08x + 94.395 
~ R2 = 0.9867 
12:~ 
O.E+OO 2.E-07 4.E-07 6.E-07 
DMPS concentration (added) M 
Cathodic Stripping Voltammograms and its 
corresponding data obtained during the analysis 
of a plasma sample collected 7.25 hr after 
dosing with DMPS. 
The above profiles clearly illustrate that the DMPS signal measured by 
CSV was still decreasing 7.25 hr. after dosing. 
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The above profiles clearly illustrate that the DMPS analytical signal was 
still decreasing 9.25 hr. after dosing. 
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Figure 2.72. Cathodic Stripping Voltammograms and its 
corresponding data obtained during the analysis 
of a plasma sample collected 23.0 hr after 
dosing with DMPS. 
The above profiles clearly illustrate that no significant DMPS signal 
appeared 23.0 hr. after dosing. 
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2.14. In-vitro conclusions 
As a conclusion and overview on the analytical signals for the mixture of 
the analytes namely Pb(II), free DMPS and Pb:DMPS complexes) in the three 
matrices including aqueous, plasma or blood inaddition to urine, one may note the 
following: Unfortunately the analytical signals for both lead and DMPS interfere 
together since they both appear at nearly the same potential (- 400 mY). The 
latter observation, pertaining to interference effects, was resolved by the proper 
choice of the media during the analysis of lead and DMPS. 
For the analysis of lead in the three matrices, the ASV mode was chosen 
by virtue of its high sensitivity. Using this mode interference from the DMPS 
signal at relatively high concentrations was negligible. In order to completely 
free lead, however, HCL04 was added to all test solutions. This procedure gave 
the most accurate and precise results compared with DPP and CSV. In contrast, 
however, free DMPS was measured using the CSV mode, which gave high 
sensitivity. Using this mode, the lead signal interfered with the DMPS signal 
consequently EDT A was added. EDT A preferentially complexed with lead and 
free the DMPS. For the latter measurement, an acetate buffer (0.1 M, pH 5.6) was 
optimum in both the urine and the aqueous media. For the analysis of free DMPS 
in plasma, however, metaphosphoric acid was a good reagent for deproteination. 
It is worth noting that the Pb:DMPS complex showed two well resolved 
peaks at ( -280 and - 52 m V) in the DPP and CSV modes which were specific for 
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the resulting complexes). The optimum conditions were by using an acetate 
buffer media coupled with the DPP mode. 
Furthermore, this was only true in the aqueous and dilute urine matrices. 
As a result plasma samples were not assayed for the Pb:DMPS complexes) using 
these techniques. 
In conclusion, optimum results can only be obtained by the correct choice 
of the media coupled with the proper analytical mode. 
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3.1 . Introduction 
CHAPTER III 
IN-VIVO STUDIES 
In the treatment of chronic lead poisoning effective and safe therapy to reduce 
lead body burden remains the most significant step. Chelation treatment for lead 
poisoning decreases lead body burden more rapidly than normal excretory processes. It 
enhances removal of the readily mobile soft tissue fraction(s) of lead, which is potentially 
the most toxic fraction of body lead (Piomelli et aI., 1984). Dimaval® (DMPS) contains 
the active ingredient; (R,S)-2,3 Dimercapto-Qropane-l-~ulfonic acid, sodium salt. DMPS 
has high affinity for many heavy metals and is anticipated to form stable complexes with 
various metal ions (Heyltex, Scientific Monograph, 2000). 
After an in-depth investigation of the complexing properties of lead with DMPS 
(chapter II), in-vivo studies were intended to complement and shed more light into the 
nature and extent of chelation. A single oral dose of DMPS will be given to subjects 
having either low or high lead exposure might demonstrate different disposition. 
No previous work has been conducted on either (1) complexing properties of lead 
DMPS using various polarographic techniques, (2) polarographic investigation of 
biological samples harvested from exposed subjects prior to or after treatment with 
DMPS, or (3) In-vitro/in-vivo comparison using polarographic techniques. 
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In view of the fact that metal ions as well as organic molecules and metal-ligand 
complexes) can be resolved using polarographic techniques, one can potentially correlate 
in-vitro and in-vivo results. 
3.2. Investigation of the disposition of DMPS 
The investigator who planned the study prepared the protocol. 
3.2.1 Subjects 
The provisional study population consisted of sixty exposed, apparently healthy, 
male workers employed at a Lead acid battery manufacturing plant. The workers resided 
in the vicinity of the plant (7 km Northeast of Amman), and were currently working at the 
lead acid battery factory. Their daily working activity (six days/week) commenced at 
07.00 h. and ended at 15:00 h, with a half-hour break at 10:30 each morning and a lunch 
break from 13 :00 h. to 13 :30 h. Biological monitoring was conducted every six months 
with the measurement of blood lead concentrations. 
3.2.2. Ethical and Related Considerations 
Potential subjects were informed of the trial details and that they should sign a 
consent form in accordance with the Helsinki declaration (Appendix II), and approved by 
the Joint committee for clinical investigations at the Jordan University Hospital -The 
Institutional Review Board/Independent Ethics Committee (IRBIIEC). The study was 
initiated by orally explaining the details to all the participants in the investigation. After 
ensuring that the lead exposed workers were fully aware of their role in the study, each 
was requested to sign a consent form. 
177 
Copies were provided to all subjects who were also warned not to donate blood 
, 
or to participate in any other study that required a large quantity of blood to be dra\\TI for 
at least six-weeks prior to and following the study. 
The Institutional Review Board/Independent Ethics Committee (lRBIIEC) of the 
Jordan University Hospital reviewed the submitted documents including: 
1. The final version of the study protocol outlining: the design, conduct and analysis 
for the proposed study of the in-vitro and in-vivo investigation of DMPS 
disposition. 
2. The C.V. of the study chief investigator. 
3. The informed consent form. 
4. The case-report form (CRF). 
5. The protocol for recruitment of subjects. 
The above committee approved the conduct of the above study in compliance with the 
submitted protocol Good clinical practice and the applicable regulatory requirement (s) 
on 18/511999 (Ref. JUH/8/47/3/687). 
All adverse effects occurring during the course of the study, whether or not 
attributed to the drug, were required to be reported to the committee with details of: date, 
time of onset, nature, severity and duration. In case of emergency situations, when the 
well being of the workers is debated, alterations of the protocol and lor protocol 
amendments had to be documented and explained. All clinical and in-vivo investigations 
were conducted at the Jordan University HospitallIntemal Medicine ward. 
178 
3.2.3 Study Design 
a. Screening, selection and classification of the study subjects. 
Screening criteria for subjects participating in the study were based on the 
following: 
a) Occupational history 
b) Medical history (no record of chelation therapy) 
c) Laboratory investigations including: 
1) Blood lead level (BPb) 
2) Zinc protoporphyrin (ZPP) 
Subject screening was initiated by interviewing the subjects to document their 
occupational history including the duration of exposure to lead/years. In addition, clinical 
complaints related to lead poisoning and/or chelation therapy received within the past two 
years were recorded. Blood samples and fingertip puncture were also taken to determine 
lead concentrations and ZPP levels respectively. Subjects were subsequently categorized 
into three groups: 
(1) Control Group 
The control subjects had no prevlOus exposure to lead fumes and or lead 
compounds, and had no record of chelation therapy. Additionally, the subjects were free 
of any symptoms related to lead poisoning. Blood lead concentration and ZPP levels 
were within normal values. 
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(2) Low Lead Exposure Group 
Subjects had duration of exposure to lead between 4-6 years, with no record of 
chelation therapy within the past two years. Subjects were also being free of any clinical 
symptoms related to lead poisoning. Blood lead concentration and ZPP were expected 
within the reference values. 
(3) High Lead Exposure Group 
Subjects with high lead exposure had more than 20 years of exposure, \vith no 
record to chelation therapy within the past two years. Additionally, subjects had some 
clinical symptoms related to chronic lead poisoning. Blood lead concentration and ZPP 
levels were likely to be above the acceptable limits for occupationally exposed workers. 
For practical reasons as described in the discussion chapter (IV) the number of 
subjects was limited to two highly exposed, two with low exposure to lead and one 
control subject. Additionally to these subject a pilot subject was included in the study. 
b. Planned Schedule of the Study. 
Table 3.1. Summarizes the overall design of the in-vivo investigation oflead 
chelation prior to and following a single oral dose (100 mg! 3 capsules) ofDMPS. 
Table 3.1. The over-all design of the in vivo investigation. 
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Table Study Flow Chart 
Study Day Day -30 Day 3 Day 5 
Screening Treatment 1 Discharge 
Medical history & demography X 
Written informed consent X 
Physical examination X X 
Body weight and height X X 
Safety: 
Clinical laboratory tests X X 
(Routine unne, Hematological X 
& Biochemical) X 
Vital signs X X X 
Adverse events X X X 
Drug administration X 
Blood, Plasma harvesting, urine X X 
collection 
Sam~le anal:ysis: 
• Analysis of Lead in X 
whole Blood 
• Analysis of Lead in X 
Plasma 
• Analysis of Lead in X 
Urine 
• Analysis of DMPS in X 
Plasma 
• Analysis of DMPS in X 
Urine 
X = will be completed. 
c. Practical details for the conduct of the study. 
Table 3.2. Summarizes the timing of the study, the time points for administration 
of DMPS and collection of blood and urine specimens. 
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Table 3.2. Specific Details of the Study. 
Table Assessment in Detail 
Time relative Clock time Serious to intake adverse Vital Blood Hospital-
hh:mm (Approximate) events Signs Sampling ization 
7:00 am X X 
0.00 h 8:00 am X X 
0.00 hDRUI ~ ADl~Ul'SI§mRA T ON 
0.50 h X X 
l.00 h X X X 
2.00 h X X 
3.00 h X X 
4.00 h X X 
4.00&ifAND ~~.6~~1'-S r 
5.00 h X X X 
s ANDXRID l-UNC ~ 15.00 pm 
9.00 h X X 
1l.00 h 
14.00 h X X 
48.00 h X 
To assess the extent of metal disposition after DMPS treatment, all subjects were 
admitted to the Internal Medicine ward at the Jordan University Hospital. Two days prior 
to DMPS administration, the study groups were admitted to the hospital for (1) clinical 
observations and sampling of blood and urine in order to record basal lead blood and 
urine levels when subjects were kept away from lead exposure. All subjects received 
standardized diet the night before dosing (Appendix VI). 
On the trial date (day 3 of admission) blood and urine samples were collected 
immediately prior to administration of DMPS (100 mg/capsule, 3 capsules). Blood and 
urine samples were also collected at intervals throughout the triaL which lasted 48 hours 
after dosing (Table 3.2). During each of the five days of hospitalization, 2-+ 'hr urine 
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samples were collected and preserved at 4°C until assay. Plasma and urine D\IPS 
concentrations were analysed immediately after sampling. Aliquots of plasma and urine 
samples were kept frozen at -70 DC for lead analysis. Throughout the duration of the trial, 
blood and urine samples were collected and analysed in accordance with the study 
schedule (Table 3.2). 
The following details of the daily trial activities were: 
Day One: No DMPS Administration. 
Following insertion of a cannula into the forearm, blood samples were collected 
(8 ml). Samples were drawn at the following time points: 
8:00 A.M., 2:00 P.M., and 8:00 P.M. The following steps were taken: 
a) 3 ml whole blood was retained in a lithium heparin tube for the analysis of lead. 
b) 5 ml whole blood was collected, in a plain tube; plasma was harvested after 
centrifugation at 4500 rpm, for 10 min. 
A 24-hour urine samples were collected, of which 10.0 ml aliquot were prepared for 
analysis. 
Day Two: No DMPS Administration. 
The above-mentioned procedures adopted on day one were repeated. 
Day Three: DMPS Administration. 
A Cannula was fixed in the forearm. 
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Blood and urine samples were collected from all subjects prior to DMPS administration 
(Blank samples). DMPS (Dimaval®) 100 mg/capsule (3 capsules) was administered at 
8.00 a.m. Then the following activities were initiated: 
(a) After withdrawing blood samples prior to dosing, samples were collected at 
the following time points 
0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 7.0, 9.0, 11.0 & 14.0 hours post dosing. 
(b) Spot urine samples were collected at the following time points: 
0.0, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, & 14.0 hours post dosing (1 ml/each). 1n-
addition, a 241hr. urine sample was collected from each subject. 
Day Four and Day Five: No DMPS Administration. 
Blood (8 ml) and urine samples (24lhr.) were collected from each subject as described 
earlier. 
3.3 Methods 
All subjects were admitted at the same time, beginning five days after termination 
of exposure to lead. Clinical assessment including: vital signs, basic clinical examination 
of the cardiovascular, pulmonary, abdominal, central and peripheral nervous system and 
genito-urinary systems were performed on day one of admission. Laboratory tests 
including: hematological, biochemical and routine urine analysis as well as urinary 
porphyrins were evaluated prior to the administration of DMPS. 
Blood chemistry data were collected for each subject at the day of admission and 
on the final day following DMPS administration. Blood chemistry testing include 
specific parameters: glucose, urea, BUN, sodium. potasium, creatinine. direct bilirubin. 
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total bilirubin, uric acid, total protein, albumin, calcium, phosphate, alkaline phosphatase, 
lactate dehydrogenase (LDH), aspartate aminotansferase (AST), alanine aminotansferase 
(AL T), and gama glutamyl transferase (GGT). 
Hematological studies included: RBC count, hemoglobin, hematocrit, 
reticulocyte, mean corpuscular hemoglobin volume, mean corpuscular hemoglobin 
concentration, leukocytes, lymphocytes, monocytes, basophils, eosinophiles, neutrophils, 
segments, platelets and differential. Hematological studies were performed prior and 
after the administration ofDMPS. 
Routine urinary analysis included: color, transparency, reaction, protein, sugar, 
WBC, RBC, Epithelial cells, amophours precipitate, bacteria, and casts. Qualitative 
urinary porphyrins were performed prior and after DMPS administration. 
The analytical facilities and equipment of the University of Jordan, School of 
Medicine were used for the determination of the biochemical and hematological tests. 
Other measurements were carried out at the Pharmaceutical Research Unit at the Royal 
Scientific Society Amman-Jordan. 
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3.4. Results of the In-Vivo Studies 
The study was conducted and completed in accordance with the above-mentioned 
protocol. The following summarizes the results obtained. 
3.4.1. Screening Results 
The sixty subjects who entered the screening phase of this study \vere all males 
with a mean age of 39.7 years (range = 23-65 year). The mean period of occupational 
exposure to lead particles was 13.9 years (range = 2-36 year). Within the factory 
exposure to particulate lead and/or lead compounds at a level that is considered in terms 
of possible health effects, is a function of working location. Important sites include areas 
of smelting, pasting and molding while other locations such as management, quality 
control and sales areas do not provide for significant lead exposure. Additionally, blood 
lead concentrations as well as zinc protoporphyrin were determined for all subjects as 
illustrated in the bar diagram (Appendix V). 
The study sample (N = 5) was chosen from the screened workers and was selected 
to participate in the DMPS chelation based on the criteria mentioned earlier. It is worth 
noting that a total of 976 separate analyses were conducted during the five-day 
hospitalization. The five subjects chosen served the objectives of the study and were 
cooperative in spite of the strict control of the study. 
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3.4.2. Demographic Characteristics of the Selected Study Sample 
Eligibility criteria for this study, which was approved by the lordan University 
Hospital Review Board, consisted of apparently healthy male workers from a lead battery 
manufacturing plant in the north east of the capital Amman. Subjects were divided into 
three groups: (1) the control group (n = 1), (51 yr), (2) low exposure group (n = 2) with a 
mean age of 46.5 years (range 53-40 yr), and (3) highly exposed group (n = 2) with a 
mean age of 50 years (range 57-43 yr). 
Additionally, subject's weights and heights v;ere measured upon admission to the 
hospital. Table 3.3. Summarizes the anthropometric data for the subjects included in the 
study. 
Table 3.3. Anthropometric Data for the Selected Subjects. 
Control Low (Ll) Low (L2) High (HI) High (H2) 
Age (Years) 51 40 53 57 57 
Weight (Kg) 75 78 86 84 84 
Height (cm) 167 171 164 165 165 
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(1) Control group (N = 1). 
Table 3.4 illustrates the inclusion parameters for the control subject as indicated 
previously. Additionally, blood lead concentration and ZPP were 1.2 Jlgldl, 52 
Jlmole/mol Hb. respectively. 
Table 3.4. Specific data for the selected Control subject. 
Selection Criteria Control 
• Blood Pb Concentration (Jlgldl) 1.2 
• ZPP Jlmole/mole Hb 52 
• Duration of Exposure (Years) None 
• Clinical Symptoms None 
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(2) Low Exposure Group (N = 2). 
The study subjects were chosen to represent the group having low exposure (n = 
2). Selection was mainly based on their low lead body burden as reflected by their blood 
lead concentration (BPb 7.4 and 7.6 ~g/dl), and unremarkable levels ofZPP (69 and 72 
~mole/mole Hb), despite the seven years exposure. Clinical examination revealed that 
both subjects were free of any symptoms related to chronic lead poisoning as shO\\TI in 
Table 3.5 
Table 3.5. Specific data for the selected subjects in Group 1. 
I Screening Results for Group 1 (Subjects with Low exposure) I 
Selection Criteria Ll L2 
• Blood Pb Concentration 7.4 7.6 
(~g/dl) 
• ZPP ~mole/molelHb 69 72 
• Duration of Exposure 7 7 
(Years) 
• Clinical Symptoms *NS NS 
• NS = No Clinical Symptoms. 
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(3) High Exposure Group (N = 2). 
Subjects with high exposure (HI and H2) were workers at the lead acid battery 
plant for the past 28 and 24 years, respectively. No previous chelation therapy to DMPS 
or any chelating agents was reported. Blood lead concentrations were measured prior to 
the inclusion in the study and there levels were 84.0 ~g/dl and 79.9 ~g/dl respectively. 
ZPP levels were 1421 and 974 ~mole/mole Hb for both subjects. Clinical 
symptomatology ranged from abdominal discomfort, constipation, arthralgias, muscle 
pain, memory loss, loss of appetite, headaches and nervousness as shown in Table 3.6. 
Table 3.6. Specific data for the selected subjects in Group 2. 
I Screening Results for Group 2 (Highly Exposed Subjects) I 
Selection Criteria HI H2 
Blood Pb Concentration (~g/dl) 84.0 79.9 
ZPP ~mole/mole Hb. 1421 974 
Duration of Exposure (years) 28 24 
Clinical Symptoms • Abd. discomfort • Abd. discomfort 
• Constipation • Constipation 
• Arthralgias • Arthralgia 
• Muscle pain • Muscle pain 
• Memory loss • Memory loss 
• Loss of appetite • Loss of appetite 
• Fatigue • Fatigue 
• Nervousness • Nervousness 
• Head ache • Head ache 
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3.5. Results Prior to DMPS Administration 
Physical examination including vital signs was performed pnor to DMPS 
administration and indicated that the subjects appeared to be in acceptable health. All 
subjects were on no medications and no allergies were reported. 
a. Hematological and Biochemical Parameters for the Control and Low 
Exposed Subjects. 
Results of the hematological and biochemical tests for the control subject were 
within normal values as shown in Table 3.7 and 3.8 respectively. Results of the 
parameters for the low exposed subjects were within normal values except for a slight 
decrease in the Mean Corpuscular Volume (MCV = 75) and slight increase in the Red 
Distribution Width (RDW = 18.7%) for subject Ll. Minor increase in Platelets 
Distribution Width (PDW = 17 and 18.8%) was observed in both subjects L 1 and L2, 
respectively. In-addition, dimorphic RBCs were also observed in subject L 1. 
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Table 3.7. Hematological Results Prior to Administration of DMPS for 
the Control subject and the Low Exposed Group. 
Test C Ll L2 Normal 
Values 
• ESR (mmlhr) 18 12 10 0-15 
• WBC x (l212/L) 9.5 5.8 7.l 5.5 + l.0 
• RBC x (l09/L) 4.93 4.89 4.84 4.0-10 
• HOB (g/dl) 14.6 12.3 14.5 16 + 2 
• HCT% 43.1 36.5 43.0 46% + 0.5 
• MeV (fl) 88 75 89 80-100 
• MCH (pg/cell) 29.6 25.1 29.9 26-34 
• MCHC (g/dl) 33.8 33.6 33.7 31-36 
• RDW% 15.2 18.7 16.2 Up to 18% 
• PLT (l091L) 250 250 209 140-440 
• MPV 8.6 9.1 9.9 Up to 10 mlJ 
• PCT% 0.215% 0.227% 0.206% Up to 4% 
• PDW% 15.8% 17.0% 18.8% Up to 16% 
• LYM.% 36.9 37.5 38.0 20-45 
• MON.% 9.9 7.4 9.5 2-10 
• NEU. Seg. 0/0 49.6 50.3 50.4 40-75 
• EOS.% 2.5 3.9 1.3 1-6 
• BAS. % 1.1 0.9 0.8 0-1 
• Reticulocyte. 0.004 0.005 0.005 0.005-0.015 
• Differential RBC's are RBC's are RBC's are 
normochromic Dimorphic. normocytic. 
normocytic. No Blast cells. No Blast cells 
Platelets are Platelets are Platelets are 
normal. normal. normal. 
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Table 3.8. Biochemical Results Prior to Administration of DMPS for 
the Control Subject and the Low Exposed Group. 
Test Control Ll L2 Normal Values Ref. (SIU) (SIU) (SIU) R.SIU 
• Sodium 144 141 139 135-148 (mmolll) 
• Potassium 4.7 4.7 5.0 3.5-5 (mmolll) 
• Fasting Blood Sugar 5.2 4.4 5.5 3.9-6.1 (mmolll) 
• Bilirubin (Total) 10.9 14.6 8.3 8.5-16.9 (umolll) 
• Bilirubin (Direct) 0.5 0.5 1.0 Up to 6.8 (umolll) 
• Urea 4.6 4.8 3.7 2.5-7.7 (mmo!'l) 
• Creatinine 90 118 97 53-123.7 (umo!ll) 
• Calcium 2.2 2.15 2.15 2.1-2.6 (mmolll) 
• Phos2horus 1.1 l.03 0.91 0.77-1.45 (mmolll) 
• Protein (Total) 79 71 72 60-80 (gil) 
• Albumin 48 43 41 35-50 (gil) 
• Alk. Phosphatase 1.2 1.0 0.5 0.5-1. 7 (ukaUI) 
• ALT 0.2 0.2 0.15 Up to 0.67 (ukaUI) 
• AST 0.2 0.2 0.16 Up to 0.67 (ukaUI) 
• LDH 3.1 4.2 2.4 2.33-5.5 (ukat/l) 
• GGT 0.33 0.6 0.5 0.13-0.63 (ukat/l) 
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b. Hematological and Biochemical Results of the Highly Exposed 
Subjects. 
Results of the hematological parameters for the highly exposed group (n =2) were 
within normal values except for an increase in Red Blood Cells (RBC's = 7.12 x 1091L) 
and Red Distribution Width (RDW = 22.2%) in HI subject. Also a decrease in Mean 
Corpuscular Volume (MeV = 57) was observed in HI exposed subject. Basophilic 
stippling was observed in both subjects with high lead exposure with target cells observed 
in subject HI were as shown in Table 3.9. 
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Table 3.9. Hematological Results Prior to Administration of DMPS for 
the Highly Exposed Group. 
Test HI H2 Normal 
Values 
• ESR (mmlhr.) 7 4 0-15 
• WBC x (l212/L) S.9 7.2 5.5 + 1.0 
• RBC x (l09/L) 7.12 5.16 4.0- 6.0 
• HOB (g/dl) 12.9 13.4 16 ± 2 
• HCT% 40.7 41 46% ± 0.5 
• MCV (fl) 57* 79 80-100 
• MCH (pg/cell) lS.2 ** 26 26- 34 
• MCHC (g/dl) 3l.S "J S j-. 31-36 
• RDW% 22.2 lS.l Upto 18% 
• PL T x (l09/L) 184 311 140- 440 
• MPV% 9.0 9.7 Up to 10 m1
3 
• PCT% 0.165 0.302 Up to 4% 
• PDW.% 1l.6%- 13% Up to 16% 
• LYM.% 34.S 32.S 20- 45 
• MON.% 9.1 10.4 2-10 
• NEU. Segt.% 53 51 40-75 
• EOS.% 2.5 3.9 1- 6 
• BAS.% 0.6 1.4 0-1 
• Reticulocyte 0.005 0.005 0.005- 0.015 
• Differential RBC's are RBC's are 
hypochromic normochromic RBC's are 
microcytic with normocytic. normochromic 
target cells seen. No blast cells. normocytic. 
Platlets are Platelets are Platelets are 
normal. Basophilic normal. Basophilic normal. 
stippling. Stippling. 
* 
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Results of the biochemical parameters for the highly exposed group were within 
normal values as shown in Table 3.10. 
Table 3.10. Biochemical Results Prior to Administration of DMPS for 
the Highly Exposed. 
Test Hl (SIU) H2 (SIU) Normal Values Ref. 
R. SIU 
• Sodium 142 138 135-148 (mmolll) 
• Potasium 4.5 5.0 3.5-5 (mmolll) 
• Fasting Blood Sugar 4.9 5.2 3.9-6.1 (mmolll) 
• Bilirubin (Total) 10.7 9.8 8.5-16.9 (umolll) 
• Bilirubin (Direct) 1.0 1.1- Up to 6.8 (umolll) 
• Urea 7.5 5.8 2.5-7.7 (mmol!l) 
• Creatinine 76 90 53-123.7 (umolll) 
• Calcium 2.10 2.15 2.1-2.6 (mmolll) 
• Phosphorus 0.95 1.2 0.77-1.45 (mmolll) 
• Protein (Total) 73 72 60-80 (gil) 
• Albumin 42 42 35-50 (gil) 
• Alk. Phosphatase 1.0 0.7 0.5-1.7 (ukat/l) 
• ALT 0.1 0.1 Up to 0.67 (ukat/l) 
• AST 0.1 0.1 Up to 0.67 (ukat/l) 
• LDH 2.9 1.9 2.33-5.5 (ukak/l) 
• GGT 0.25 0.20 0.13-0.63 (ukat/l) 
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c. Results of routine urme analysis and urinary Porphyrins for all 
selected subjects. 
Routine urinary analysis for all the selected subjects (control, low, and high) was 
performed prior to DMPS administration. Results showed a nonnal urine examination 
for the control subject. Results for low exposed group were not significant. Calcium 
oxalate crystals were seen in the highly exposed subjects to lead. Additionally qualitative 
tests of urinary porphyrins were strongly positive in subjects having high exposure as 
shown in Table 3.11. 
Table 3.11. Routine Urinary Analysis for all Selected Subjects 
Prior to DMPS Administration. 
Test Control Ll (SIU) L2 Hl H2 
Color Yellow Yellow Yellow Yellow Yellow 
Transparency Turbid Clear Clear Clear Clear 
Reaction Alkaline Acid Acid Acid Acid 
Gravity 1.015 1.019 1.020 1.020 1.0018 
Protein Nil Nil Nil Nil Nil 
Sugar Nil Nil Nil Nil Nil 
W.B.CIHPF 0-1 0-1 0-1 1-2 1-2 
R.B.C/HPF Nil Nil 0-1 1-2 0-1 
Ep. Cells 0-1 1-2 Nil 0-1 2-3 
Crystals Nil Nil Nil Ca -Oxalate Ca- Oxalate 
Bacteria Nil Nil Nil Nil Nil 
Cast Nil Nil Nil Nil Nil 
Porphyrins Negative Negative Negative Positive Positive 
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3.6. Results following to DMPS Administration 
a. Clinical Observation 
All subjects tolerated DMPS well and no difficulties were encountered with the 
administration of DMPS. Subjects were carefully observed for evidence of possible 
adverse drug reactions. No nausea, vomiting, abdominal pain and rashes or other signs 
and symptoms of possible reactions were seen. Vital signs were recorded and they were 
within normal range. Slight mood changes were observed in one subject during the study 
period. Although this did not affect the study protocol, subjects were anxious to be 
released from the hospital. 
b. Hematological and Biochemical Parameters for the Control and Low 
Exposed Subjects. 
Complete blood count and differential were obtained following to DMPS 
administration. Unremarkable hematological, biochemical and urinary changes were 
observed for the control subject. Subjects with low exposure (L 1) showed slight decrease 
in the Mean Corpuscular Volume (MCV = 75) and slight increase in the Red Distribution 
Width (RDW = 18.7) with dimorphic RBC's suggesting that subject Ll might have iron 
deficiency anemia (Table 3.12). Total iron and total iron binding capacity were carried 
out and the result confirmed the diagnosis of mild iron deficiency anemia. The subjects 
were instructed to improve his diet and iron supplement was provided to alleviate this 
condition. Furthermore, insignificant hematological changes \vere observed prior and 
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after DMPS administration for subject L2. Results of the biochemical parameters were 
within normal values as shown in Table 3.13. 
Table 3.12. Hematological Results Following to DMPS Administration for 
The Control Subject and Low Exposed Group. 
Test C Ll L2 Normal Values 
• ESR (mmlhr.) 14 10 10 0-15 
• WBC x (l2 121L) 10.9 6.1 7.4 - - + 1 0 ).) - . 
• RBC x (l09/L) 4.57 4.98 4.87 4.0-6.0 
• HOB (g/dl) 13.6 12.7 14.9 16 ± 2 
• HCT% 40 37.3 42.8 46% ± 0.5 
• MCV (fl) 88 75 88 80-100 
• MCH (pg/cell) 29.8 25.5 30.6 26-34 
• MCHC (g/dl) 34.1 34.1 34.8 31-36 
• RDW% 14.8 18.7 15.9 Up to 18% 
• PLT. x (l09/L) 250 239 238 140-440 
• MPV 9.0 8.6 10 Up to 10 ml
3 
• PCT% 0.224 0.205 0.237 0.4% 
• PDW% 15.8 14.5 18.5 Up to 16% 
• LYM. % 28.6 36.8 35.9 20-45 
• MON. % 9.9 9.1 8.7 2-10 
• NEU. Seg. 0/0 58.3 49.2 52.4 40-75 
• EOS. % 1.8 4.4 2 1-6 
• BAS. % 1.4 0.5 1 0-1 
• Retc.% 0.003 0.002 0.012 0.005--0.015 
• Differential RBC's are RBC's are RBC's are 
normochromic dimorphic. normochromic 
normoytic. No blast cells. normocytic. 
No blast cells. Platelets are No blast cells. 
Platelets are normal. Pate lets are 
normal. normal. 
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Table 3.13. Biochemical Results Following to DMPS Administration for 
the Control Subject and the Low Exposed Group. 
Test Control Ll L2 Normal Values Ref. (SIU) (SIU) (SIU) R.SIU 
• Sodium 136 142 134 135-148 (mmol/I) 
• Potasium 4.1 5.2 5.2 3.5-5 (mmol/I) 
• Fasting Blood Sugar 4.4 5.6 5.7 3.9-6.1 (mmol/I) 
• Bilirubin (Total) 6.1 12.2 8.8 8.5-16.9 (umol/I) 
• Bilirubin (Direct) 0.8 1.0 0.9 Up to 6.8 (umol/I) 
• Urea 6.8 7.0 5.6 2.5-7.7 (mmol/I) 
• Creatinine 85 122 109 53-123.7 (umol/l) 
• Calcium 2.1 2.18 2.3 2.1-2.6 (mmol/I) 
• Phosphorus 1.08 1.04 0.95 0.77-1.45 (mmol/I) 
• Protein (Total) 75 73 74 60-80 (gil) 
• Albumin 45 44 42 35-50 (gil) 
• Alk. Phosphatase 1.1 0.9 0.6 0.5-1. 7 (ukat/I) 
• ALT 0.1 0.2 0.1 Up to 0.67 (ukat/l) 
• AST 0.1 0.1 0.1 Up to 0.67 (ukat/l) 
• LDH 2.5 2.5 2.0 2.33-5.5 (ukak/I) 
• GGT 0.3 0.7 0.5 0.13-0.63 (ukat/I) 
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c. Hematological and Biochemical Parameters for the High Lead Exposed 
Subjects. 
No changes were observed in the hematological parameters for the highly exposed 
group following to DMPS administration, however, the Mean corpuscular Volume 
remained below normal levels (MCV = 57; normal values 80-100 £1) and the presence of 
high Red Cell Distribution Width (RDW =22%; normal values up to 18%) were observed 
for subject HI (Table 3.14). This condition might be due to either iron deficiency anemia 
or thalassemia. An in depth investigation (total iron, iron binding capacity, Vitamin B 12, 
ferritin and hemoglobin electrophoresis) were carried out and concluded that subject HI 
might be a thalassemia patient which require further genetic investigation which was not 
the scope of this study. Additionally, differential blood film shO\ved the presence of 
basophilic stippling for both subjects HI and H2. Also target cells were observed and this 
may be due to the fact that both subjects were exposed for longer period of time to lead 
fumes and or its compounds. Furthermore, a slight increase in Red Blood Cells (RBC's 
7.15 x 1091L) and slight decrease in Red Cell Distribution Width (RDW = 19.3%) in HI 
subject were also observed as shown in Table 3.14. 
201 
Table 3.14. Hematological Results Following to DMPS Administration for 
the Highly Exposed Group 
Test HI H2 Normal Values 
• ESR (mmlhr.) 6 8 0-15 
• WBC x (12 121L) 8.6 5.9 5.5 + 1.0 
• RBC x (1091L) 7.15 5.09 4.0-6.0 
• HOB (g/dl) 13.5 l3.7 16 + 2 
• HCT% 40.9 40.1 46% ± 0.5 
• MCV (fl) 57 * 79 80-100 
• MCH (pg/ceU) 18.9 ** 26.9 26-3.:1-
• MCHC (g/dl) 33 34.9 31-36 
• RDW% 19.3 *** 16.6 Up to 18% 
• PLT x (1091L) 150 289 140-440 
• MPV% 9.2 9.7 Up to 10 ml3 
• PCT% 0.138 0.250 0.4% 
• PDW% 16 18 Up to 16% 
• LYM.% 26.4 35.5 20-45 
• MON. % 10.4 11.1 2-10 
• NEU. Segt.% 59.7 45.7 40-75 
• EOS.% 3 .1 4.5 1-6 
• BAS.% 0.4 1.5 0-1 
• Retc. % 0.011 0.017 0.005-0.015 
• Differential RBC's are 
hypochromic RBC's are 
microcytic. normochromic 
Target cells are normocytic. 
seen. Basophilic Basophilic stippling. 
stippling Platelets are normal. 
Platelets are normal. 
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Results of biochemical parameters were within normal values as sho\\-TI in Table 3.15. 
Table 3.15. Biochemical Results Following to DMPS Administration for 
the Highly Exposed Group 
Test Hi (SIU) H2 (SIU) Normal Values Ref. 
R. SIU 
• Sodium 139 138 135-148 (mmol/I) 
• Potasium 4.4 5.4 3.5-5 (mmol/I) 
• Fasting Blood Sugar 5.4 5.2 3.9-6.1 (mmol/l) 
• Bilirubin (Total) 16.5 9.0 8.5-16.9 (umol/l) 
• Bilirubin (Direct) 1.0 1.0 Up to 6.8 (umol/l) 
• Urea 8.9 5.8 2.5-7.7 (mmol/l) 
• Creatinine 85 90 53-123.7 (umol/l) 
• Calcium 2.16 2.25 2.1-2.6 (mmol/l) 
• Phosphorus 1.03 1.34 0.77-1.45 (mmol/l) 
• Protein (Total) 76 72 60-80 (gil) 
• Albumin 42 42 35-50 (gil) 
• Alk. Phosphatase 1.1 0.7 0.5-1. 7 (ukatll) 
• ALT 0.1 0.1 Up to 0.67 (ukatll) 
• AST 0.1 0.1 Up to 0.67 (ukatll) 
• LDH 2.5 1.9 2.33-5.5 (ukak/l) 
• GGT 0.24 0.27 0.13-0.63 (ukatll) 
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d. Results of routine urine analysis and urinary porphyrins for all 
selected subjects following DMPS administration. 
Results of the routine urinary analysis prior and post DMPS administration for 
both subjects showed significant urinary porphyrins and the presence of calcium oxalate 
crystals for subject H2 and the disappearance in subject HI ( Table 3.16). It is well 
known that lead exerts its inhibitory effects on the enzymatic activity of the heam 
biosynthetic pathway. Therefore, it is evident to observe that the presence of urinary 
porphyrins even after the administration ofDMPS. 
This could be explained that the dose was insignificant to cause any changes at the 
cellular level. The presence of calcium oxalate \vas attributed to dietary and geographic 
factors. 
Table 3.16. Routine Urinary Analysis for all Subjects Following 
DMPS Administration. 
Test C Ll L2 Hl H2 
Color Yellow Yellow Yellow Yellow Yellow 
Transparency Turbid Clear Clear Clear Clear 
Reaction Alkaline Acid Acid Acid Acid 
Gravity 1.020 1.020 1.022 1.021 1.019 
Protein Nil Nil Nil Nil Nil 
Sugar Nil Nil Nil Nil Nil 
W.B.C.lHPF 0-1 0-1 0-1 1-2 1-2 
R.B.C/HPF Nil Nil Nil 1-2 0-1 
Ep. Cells 0-1 1-2 2-3 Nil 2-3 
Crystals Nil Nil Nil Nil Ca oxalate 
Bacteria Nil Nil Nil Nil Nil 
Cast Nil Nil Nil Nil Nil 
Porphyrins Negatiye Negative Negatiye Positive Positi\'c 
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3.7. A Pilot Trial 
A pilot trial was conducted prior to investigation of the disposition of D\lPS in 
the selected study groups in an attempt to assess the proposed anal)1ical methodologies 
and the effectiveness of chelation therapy with DMPS. 
A lead exposed subject was chosen for the pilot trial, the choice was based on (l ) 
his blood lead level, which was 72.6 /J.g/dl, (2) clinical complaints which include: general 
weakness, arthralgias, constipation (3-4 days), lack of appetite, and behavioral changes. 
After a 12 hr fast the subject was given 3 capsules of D~lPS 100 mg each. DMPS in 
plasma was monitored 23 hours after dosing, \vhereas urine levels of lead and D~IPS 
\vere monitored 8 hours after dosing (spot urine samples were collected). The results are 
summarized in Tables 3.17 to 3.19 and illustrated in Figures 3.2 to 3.5. 
Table 3.17 summarizes the concentration-time data for DMPS m plasma 
measured at the specified time points previously mentioned. These are also illustrated in 
Figure 3.2. 
Figure 3.3 and Table 3.18 illustrate the DMPS concentrations in urine versus time, 
after dosing with DMPS. Figure 3.4 and Table 3.19 illustrate the lead concentrations in 
urine versus time, after dosing with DMPS. 
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Table 3.17. The concentration-time data for DMPS measured at 
different time points following to dosing with DMPS (300 
mg) for the Pilot subject. 
Time (hr) *DMPS Concentration in plasma (ng/ml) 
0.00 15.18 
0.20 17.21 
0.60 46.04 
0.87 70.46 
1.42 282.91 
1.68 410.66 
2.72 409.75 
3.67 19l. 73 
4.70 79.31 
6.95 4l.07 
8.95 38 .79 
23.00 7.11 
'* Duplicate samples 
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Figure 3.1. Concentration of DMPS (Plasma) vs. time after dosing for 
the Pilot subject. 
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Table 3.18. The concentration-time data for DMPS in Urine 
measured at different time points following to 
dosing with DMPS (300 mg) for the Pilot subject. 
Time (br) DMPS (ng/ml) 
0.00 -
2.70 42.9 
4.75 98.7 
6.20 23.1 
7.20 14.5 
100 
75 
,,--
-E 
-eL c:: 50 
--\./J. 
0... 
~ 
0 
25 
O~--------~---------r---------'---------' 
o 2 468 
Time (hour) 
Figure 3.2. Concentration of DMPS (Urine) vs. time after dosing for 
the Pilot subject. 
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Table 3.19. The Concentration-time data for Pb2+ in urine measured at 
different time points following to dosing with DMPS (300 
mg) for the Pilot subject. 
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-0 
ro 
Q) 
...J 
Time (hr) Pb
2+ 
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0.00 12.9 
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4.75 251.9 
6.20 188.8 
7.20 171.3 
400 
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Figure 3.3. Concentration of Pb2+ (Urine) vs. time after dosing for the 
Pilot subject. 
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Figure 3.4. Concentration vs. time profiles for the Pilot subject: 
(A) DMPS concentration in plasma (ng/ml) 
(B) Lead concentration in urine (ug/dl) 
(C) DMPS concentration in urine (ng/ml) 
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3.8. In-Vivo Results of the samples harvested in the actual trial 
(e, L1 and L2, H1 and H2) 
After the successful evaluation of the experimental procedures detailed earlier for 
the determination of DMPS in plasma and urine as well as for the determination of lead 
in blood and urine the study was conducted in accordance with the protocol (section 3.3). 
The collected samples were subsequently analysed using the validated methods. 
3.8.1. Results of DMPS in Plasma and Urine. 
The DMPS levels in plasma vs. time measured prior to and post dosing \vith 
DMPS for the study groups C, Ll, and L2, HI and H2 are summarized in Tables 3.20 to 
3.24 and illustrated in Figures 3.6 to 3.10. DMPS concentrations vs. time were also 
measured after dosing with DMPS to all trial subjects. The data of the DMPS 
concentrations in urine harvested at the following time points 2, 4, 6, 8, 10, 12, 14, 24, 30 
and 48 hours after dosing is summarized in Table 3.25 and illustrated in Figures 3.11 to 
3.15. 
3.8.2. Results of Lead in Blood and Urine. 
Lead concentrations (~g/dl) vs. time (hour) In blood measured after the 
administration of a single oral dose of DMPS to all study subjects are summarized in 
Table 3.26 and illustrated in Figures 3.16 to 3.19. Lead levels (~g!dl) vs. time (hours) in 
urine were also measured after the administration of DMPS to all subjects. 
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It was noted that the control subject as well as subjects having low lead exposure 
(L I and L2) chelated lead to a very small extent, which was regarded as insignificant 
difference from the base levels (Zero time levels). 
A notable increase in the lead urine levels was measured in the samples collected 
within 48 hr after dosing with DMPS for the highly exposed group (HI and H2). The 
resulting data are summarized in Table 3.27 and illustrated in Figures 3.20 and 3.2l. 
A summary of the results obtained from HI and H2 subjects are illustrated in 
Figure 3.22. 
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Table 3.20. DMPS concentration (ng/ml) vs. time (hr) in plasma 
measured after a single oral dose of DMPS (300 mg) 
for the control subject. 
-'..J 
E 
-
; C) 
c: 
-c: 
0 
-~ ~ 
-c: Q) 
U 
c: 
0 
'C,) 
Time(hr) Concentration (ng/ml) 
usinJl standard addition 
0.0 10.00 
0.5 205.33 
l.0 267.25 
2.0 532.0 
3.0 172.18 
4.0 106.93 
5.0 70.58 
7.0 66.18 
9.0 58.25 
11.0 174.08 
14.0 43.85 
24.0 70.90 
30.0 36.15 
36.0 -
48.0 70.00 
------- ----------------- ------------------
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Figure 3.5. DMPS concentration (ng/ml) vs. time (hr) in plasma measured 
after a single oral dose of DMPS (100 mg) for control subject. 
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Table 3.21. DMPS concentration (ng/ml) vs. time (hr) in plasma measured 
after a single oral dose of DMPS (300 mg) for the LI subject. 
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1l.0 
14.0 
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36.0 
48.0 
10.00 
Concentration (ng/ml) 
using standard addition 
9.73 
210.50 
389.00 
428.00 
238.75 
14l.18 
70.88 
14.90 
49.25 
11l.98 
63.58 
130.88 
38.88 
28.93 
20.28 
Ll 
--tr- Standard addition 
20.00 30.00 
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60.00 
Figure 3.6. DMPS concentration (ng/ml) vs. time (hr) in plasma measured 
after a single oral dose of DMPS (300 mg) for the low lead 
exposed subject (LI). 
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Figure.3.7. DMPS concentration (ng/ml) vs. time (hr) in plasma measured 
after a single oral dose of DMPS (300 mg) for the low lead 
exposed subject (l2). 
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Table 3.23. DMPS concentration (ng/ml) vs. time (hr) in plasma measured after 
a single oral dose of DMPS (300 mg) for the high lead exposed 
subject (HI). 
Time(hr) Concentration (ng/ml) 
using standard addition 
0.0 15.35 
1.0 310.50 
2.0 791.25 
3.0 210.85 
4.0 106.45 
5.0 58.70 
7.0 0.00 
9.0 0.00 
11.0 84.25 
14.0 3.85 
24.0 0.00 
30.0 0.00 
36.0 0.00 
48.0 63.00 
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DMPS concentration (ng/ml) vs. time (hr) in plasma measured 
after a single oral dose of DMPS (300 mg) for the high lead 
exposed subject (HI). 
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Table 3.24. DMPS concentration (ng/ml) vs. time (hr) in Plasma 
measured after a single oral dose of DMPS (300 mg) 
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Figure 3.9. DMPS concentration (ng/ml) vs. time (hr) in plasma 
measured after a single oral dose of DMPS 
(300 mg) for the high lead exposed subject (H2). 
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60.00 
Table 3.25. DMPS concentration (~g/ml) vs. time (hr) In urine 
measured after administering a single oral dose of 
DMPS (300 mg) for the trial subjects. 
Time DMPS Concentrations (~glml) 
(hr) C LI 
0 0.00 0.00 
2 3.44 37.86 
4 16.29 27.64 
6 4.83 7.01 
8 3.64 12.45 
10 6.48 5.73 
12 3.17 10.75 
14 3.28 11.12 
24 0.19 1.60 
30 1.86 7.55 
48 0.30 0.90 
c: Control 
LI: Subject with low lead exposure 
L2: Subject with low lead exposure 
HI: Subject with high lead exposure 
H2: Subject with high lead exposure 
L2 HI 
0.00 0.00 
18.2 53.11 
16.79 32.20 
25.60 3.64 
2.52 3.73 
10.63 11.23 
28.52 0.65 
18.67 10.93 
1.73 0.61 
11.54 3.15 
3.80 6.83 
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Figure 3.10. DMPS concentration (Ilg/ml) vs. time (hr) in urine 
measured after the administration of a single oral 
dose of DMPS (300 mg) to a control subject. 
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Figure 3.11. DMPS concentration (J.lg/ml) vs. time (hr) in urine measured 
after the administration of a single oral dose of DMPS (300 
mg) to a low exposure subject (L1). 
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Figure 3.12. DMPS concentration (J.lg/ml) vs. time (hr) in urine measured 
after the administration of a single oral dose of DMPS (300 
mg) for the low exposed subject (L2). 
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(300 mg) to a subject having high lead exposure (HI). 
---- ~ -~---------. 
E 
....... 
tn 
c 
....... 
c 
0 
'Zi 
ns 
100 
~ 
c 
Q1 
U 
C 
0 
u 
25 -: 
20 1 
I 
15 I 
I 
10 I 
1 
5 -
o ----
o 
H2 
------~.---.-- ---------- -~ ._------ - -_. 
10 20 30 40 50 60 
Time (hr) 
Figure 3.14. DMPS concentration (~g/ml) vs. time (hr) in urine measured 
after the administration of a single oral dose of DMPS (300 
mg) for a high lead exposed subject (H2). 
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Table 3.26. Lead concentration (ug/dl) vs. time (hr) in Blood measured 
after the administration of a single oral dose of DMPS 
(300 mg) for the trial subjects. 
Time 
(hr) Lead Concentration (.ug/dl) 
LI L2 HI H2 
0.0 13.88 15.65 71.23 95.2 
0.5 13.20 16.51 65.86 82.55 
l.0 12.28 14.45 78.56 87.99 
2.0 11.09 13.54 72.75 85.70 
3.0 12.27 12.26 70.16 78.12 
4.0 11.67 l3.89 85.25 83.46 
5.0 12.78 15.39 76.28 82.12 
7.0 9.42 11.77 63.01 81.32 
9.0 12.51 14.42 71.23 81.86 
11.0 11.84 12.20 75.65 80.26 
14.0 13.48 l3.29 75.65 98.40 
24.0 11.63 16.14 84.93 89.91 
30.0 14.29 17.25 76.53 9l.73 
36.0 11.13 13.68 76.16 72.47 
48.0 14.09 15.15 75.45 66.81 
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Figure 3.15. lead concentration (Jlg/dl) vs. time (hr) in whole blood measured 
after the administration of a single oral dose of DMPS (300 mg) 
for the low lead exposed subject (ll). 
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Figure 3.16. lead concentration (,ug/dl) vs. time (hr) measured in whole Blood 
after the administration of a single oral dose of DMPS (300 mg) 
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Figure 3.17. Lead concentration (ug/dl) vs. time (hr) measured in whole Blood 
after the administration of a single oral dose of DMPS (300 mg) 
to a subject with high lead exposure (H1). 
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Figure 3.18. Lead concentration (ug/dl) vs. time (hr) measured in whole 
Blood after the administration of a single oral dose of DMPS 
(300 mg) to a subject with high lead exposure (H2). 
Table 3.27. Lead concentration (ug/dl) vs. time (hr) in Urine measured 
after the administration of a single oral dose of DMPS 
(300 mg) to highly exposed subjects. 
Time Lead Concentration tug/dl) 
(hr) HI H2 
0 0.00 16.12 
2 56.65 33.72 
4 10.78 7.31 
6 0.00 30.52 
8 7.725 38.67 
10 18.48 58.00 
12 10.58 46.00 
14 19.06 151.50 
24 5.50 25.20 
36 10.58 82.33 
48 2.20 68.20 
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Figure 3.19. Lead concentration (ug/dl) vs. time (hr) measured in Urine 
after the administration of a single oral dose of DMPS (300 
mg) to a highly exposed subject (H1). 
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Figure 3.20. Lead concentration (ug/dl) vs. time (hr) measured in Urine after 
the administration of a single oral dose of DMPS (300 mg) to a 
highly exposed subject (H2). 
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CHAPTER IV 
DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS 
The search for effective metal chelating agents has continued for the past 50 
years (Domingo, 1994; Jones and Basinger 1982). Research is still underway to 
develop an ideal chelating agent which: 
(l) Selectively and specifically competes with negatively charged bioligands 
containing sulfhydryl, carboxyl and imidazole residues present in enzymes and 
other proteins, 
(2) Does not bind avidly to essential metal ions such as copper and zinc, 
(3) Does not form insoluble precipitates with metal ions, 
(4) Effectively mobilize metal ions from body depots, 
(5) Forms soluble species to eliminate metal ions via the kidney and 
(6) Demonstrates low toxicity to the biological system. 
Clinical efficacy of a lead chelating agent has been assessed by high rate 
elimination of lead with a consequent reduction of blood levels. The stability of the 
resulting complexes formed between each of the proposed chelating agents and lead 
may not be as crucial as it was initially thought. For the successful mobilization of 
metal ions from target organs, labile complexes (with low Kf values) may be as 
effective as those with high formation constant (strong complexes). 
Mercapto-chelating agents have been employed for the treatment of or 
reversing the toxic effects of metals such as mercury, arsenic, cadmium and lead 
(Jones, 1994). The correlation between chemical investigations and in-vivo studies 
has rarely been published (Cichini, et aI., 1989). 
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Shortly after the development of dimercapto chelating agents, it became clear 
that the nature of metal complexes formed, as well as their relative stabilities is 
important parameters in the development of newer and more effective chelating 
agents. Although BAL proved to be successful in the treatment of heavy metal 
toxicity, its use has been limited due to its redistribution of metals in the brain 
(Hoover and Aposhian, 1983). 
DMSA has been used extensively for the treatment of lead pOIsonmg m 
children and adults. However, the physicochemical properties have not been fully 
elucidated (Rivera, et aI., 1989). DMSA has been shown to be a strong chelating 
agent for lead, but it is well established that it is not specific as compared to other 
chelating agents mainly due to its simultaneous binding to essential metal ions such as 
zinc and copper (Mc Neil Consumer Products, 1992). 
More recently, DMPS gained much popularity after its successful use for the 
treatment of heavy metal poisoning in China and Russia. Experimental as well as 
clinical evidence demonstrated that DMPS is a safe oral chelating agent for the 
treatment of chronic mercury, arsenic and lead poisoning (Chisolm, 1990). DMPS 
forms stable complexes with heavy metal ions including mercury, copper, cadmium 
and zinc (Parr, et al 1983). It forms two complexes; a 1: 1 and 2: 1 complexes having 
Kf values of 2.5 x 1017 and 1 x 1025 respectively (Ospanov, et aI., 1987). It is noticed 
that mercapto compounds have not been comprehensively investigated particularly by 
using analytical techniques that facilitate the simultaneous measurement of (a) the 
free metal ion (b) the free ligand and (c) and their resulting complexes. Thus, the 
present study was initiated with several objectives in mind including: 
1. Utilization of the physicochemical characteristics of mercapto chelating agents 
such as DMPS as an electroactive species. 
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The present work made use of the adsorptive characteristics of the sulfur atom 
of the mercapto group onto a mercury electrode. Hence, electro analytical techniques 
were employed to investigate the complexing properties of DMPS with lead. 
2. Investigation of the pharmacokinetic characteristics of DMPS given to lead 
exposed subjects while they are in a fasting state 
3. From the above conclusions on the efficacy and safety of DMPS for the 
management of lead toxicity will be drawn. 
2,3 Dimercaptopropane-l-sulfonic acid (DMPS). 
Metal-binding substances, many of which form chelates constitute a class of 
compounds, which have provided many useful drugs of value. Although mercapto 
compounds received particular attention for their efficacy in the treatment of mercury 
poisoning, increased interest have been noted in the water soluble analogues of BAL, 
DMPS and DMSA for lead chelation (Aposhian, 1983). In the present study, DMPS 
was chosen because of the relative ease by which the sulfhydryl compound can be 
investigated by electroanalytical techniques. In-addition, its complex and rapid 
biotransformation following dosing may be similar to the other sulfhydryl containing 
drugs such as captopril (Maiorino 1996). 
The sulfur linkage responsible for forming disulfide bond with blood proteins 
suggests that the active free drug may be released slowly from the protein complex 
the fact which may aid in the therapeutic benefits of the drug. Previous work 
identified the presence of major cyclic polymeric metabolites in addition to other 
minor metabolites believed to be mixed disulfides. 
In contrast to BAL, 2,3-Dimercaptopropane-l-sulfonic acid, sodium salt (DMPS) was 
claimed to have less toxicity, greater water solubility, and limited lipid solubility 
when given orally. 
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By virtue of the fact that carbon 2 in DMPS is asymmetric, it exists in two 
enantiomers and therefore DMPS use for therapeutic purposes is prepared as a 
racemic mixture. The chemical and pharmacological properties of the racemic 
mixture have been investigated in spite of the fact that neither LDso nor EDso values of 
individual enantiomers, administered to mice were found to differ significantly 
(Apohsian et aI., 1984; Nukhin et aI., 1992)). 
DMPS belongs to the vicinal dithiol group of chelating agents; its two SH 
groups have strong affinity for many metal ions, it is thus expected to form stable 
complexes with most heavy metals. In addition, the two-sulfhydryl groups give rise to 
the reductive properties of DMPS. Like all dithiols, DMPS is sensitive to oxidation, 
particularly in solutions having pH values higher than 7. Oxidation occurs 
spontaneously in the presence of Cu2+ and Fe3+ to form either cyclic or acyclic 
products (Maiorino et aI., 1985). It was believed that because of the sulfhydryl 
groups, equilibrium processes are complicated by interactions with other sulfur 
containing bioligands such as cysteine. 
Furthermore, the polar sulfonic acid group influences its physicochemical 
properties, and is responsible for both its water solubility as well as its low lipid 
. 2+ 2+ 2+ N·2+ H 2+ d Z 2+ 
solubility. Although complexes of DMPS WIth Cd ,Co ,Cu , I , g an n 
are water soluble, it is believed that lead complexes) form precipitates in aqueous 
media (PH < 7). In contrast to other findings this work demonstrated that the 
mechanism of action of the DMPS might be totally different that of the other well 
established chelating agents, which forms complexes with most metal ions such as 
EDT A. Figure 2.50 clearly illustrate that while Pb-EDTA forms a very stable 
complex lead, DMPS did not at pH 5.6. 
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Addition of DMPS to lead in an aqueous solution clearly illustrated that the lead 
analytical signal decreased due to its interaction with DMPS, and this was 
simultaneously accompanied by the appearance of another signal corresponding to the 
newly formed species. The resulting species were also water-soluble but may have 
low formation constants. 
In-Vitro Studies 
Electroanalytical techniques were chosen in the present study because of the 
following inherent advantages: 
(A) Electroanalytical techniques are highly sensitive. 
(B) Electroanalytical techniques require minimum sample pretreatment. 
(C) Electroanalytical permit the determination of several analytes simultaneously 
including organic and inorganic analytes. 
It is worth noting that one can couple HPLC with an electroanalytical detector for 
isolating and detecting trace levels of many analytes. The principles of detection 
remain the same, as explained in the introduction (page 35). 
Method Development and Validation for the Determination of Lead In 
Biological Samples. 
U sing the optimized instrumental settings (section 2.4.1), Pb2+ signals were 
measured in the following matrices: 
(1) Aqueous test solution 
(2) Extract of blood samples 
(3) Dilute urine samples 
Using the ASV mode, analytical signals for Pb2+ were measured in an aqueous 
HCI04 media using the standard addition technique (Figure 2.1 & 2.2; Table 
2.1). 
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This experiment was designed initially to establish linearity and linear 
working range in the test solution, assuming no interference's or matrix effect are 
present. High correlation coefficients between peak heights or peak areas (0.9999, 
0.9998) were measured in the concentrations ranging from 0.999 to 7.937 ~g/dl. 
Similarly lead signals were measured in an extract of a whole blood sample in 
accordance with the developed procedure (section 2.4.2.b) (Figure 2.3 & 2.4; Table 
2.2). In contrast to the results obtained from the aqueous HCI04 media, the slope of 
the calibration graph measured from the blood extract was significantly lower. The 
obvious loss in sensitivity is due mainly to matrix effects. 
Organic molecules are expected to adsorb at the surface of the mercury electrode 
(at the employed reduction potentials), this may partially block the active sites of the 
working mercury electrode. By increasing the plating time, higher analytical signals 
will be obtained. This may compensate for the loss in sensitivity and render the 
technique sensitive enough for the determination of lead in biological fluids. It is 
worth noting that linearity was demonstrated despite the reduction in sensitivity 
(Figure 2.8 & 2.12). Further comparison for the lead signals measured from different 
matrices was extended to a urine matrix. Measurement of lead in urine necessitated 
dilution of the original sample (dilution factor of 10). This dilution reduced the effect 
of matrix components and slightly enhanced the sensitivity compared with that 
obtained from the blood matrix. 
In conclusion, it was observed that the employed method demonstrated 
significant matrix effects, which did not adversely affect the linearity or the recovery. 
It was also noted that the calibration sensitivity, measured from the blood matrix, 
decreased four times compared with that measured from the aqueous media. 
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In contrast, however, the calibration sensitivity measured from the urine matrix 
was 2.6 times lower than that measured from the aqueous media (Figure 2.8). 
The developed method, therefore, was successfully applied to the proposed 
work. Prior to the application of the developed method to the analysis of lead in 
authentic samples harvested during the proposed clinical trial, the method was further 
validated by comparing the analytical concentrations in spiked samples with those 
measured using the optimized and developed method. Correlation coefficients 
between spiked and measured lead in whole blood was 0.9867 (Figure 2.7). 
The corresponding correlation coefficient measured from the urine matrix was 
0.9908 (Figure 2.11). It is believed therefore that the developed and validated method 
proposed is recommended for the analysis of lead in biological matrices. 
An acceptable relative error for the determination of lead in blood that ranged 
from 2.32 to 25.50% was demonstrated as shown in Table 2.5 and Figure 2.7. The 
method also demonstrated good precision with a CV% ranging from 3.51 to 15.09 for 
peak heights as seen from Table 2.8 and Figure 2.9. Furthermore, accuracy was also 
demonstrated during the measurement of Pb2+ in urine as depicted from the relative 
error of 1.89 to 10.01 % evaluated from peak heights as shown in Table 2.9. The 
CV% ranged from 2.65 to 8.27 from peak heights as shown in Table 2.12 and 
illustrated Figure 2.13. 
Method Development and Validation for DMPS in Biological Fluids 
using Electroanalytical Techniques. 
Experiments designed to develop and validate an electrochemical technique for 
the determination of DMPS in biological fluids were initiated by investigating the 
electrochemical behavior of DMPS. 
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Cyclic voltammogram for DMPS was recorded using the hanging mercury drop 
electrode clearly demonstrates that the cathodic potential wave appeared at - 486 
mY, whereas the anodic wave appeared at - 445 mY giving a difference in the 
potential (~E) of 41 mY. This indicates that the oxidation-reduction ofDMPS seems 
to be an irreversible one. While this observation may help in the explanation of the 
electrode process, it might not be directly related to the purpose of the work. One may 
also note that several authors believe that electrode reactions may closely simulate the 
in-vivo oxidation-reduction processes. Consequently, the resulting cyclic 
voltammogram suggests the formation of a reduced species that was more difficult to 
oxidize. 
DMPS signals were investigated in three different matrices including: 
(l) In an aqueous acetate buffer. 
(2) In a diluted urine samples. 
(3) In a plasma extract. 
(1) DMPS in an aqueous media. 
Figures 2.18 to 2.20, illustrate the determination of DMPS in aqueous solution 
(acetate buffer media) using different voltammetric modes namely DPP, ASV and 
CSY. Linearity was clearly demonstrated using the DPP and ASV when 
measurements were made either at the SMDE or HMDE. Deviation from linearity 
was observed when the CSY mode was employed. The results may be explained in 
terms of the mechanism of the electrode process, which seems to be a complex one. 
Both oxidation-reduction and adsorption seem to be involved in the electrode process. 
Unlike DPP and ASY, the electrode process in CSV is predominated by adsorption 
prior to oxidation-reduction at the mercury electrode. 
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(2) DMPS in diluted urine samples 
A 50 ~l aliquot of a previously diluted urine sample 1: 100 (urine: acetate buffer 
media) was spiked into a 5.00 ml acetate buffer solution (PH 5.6, 0.1 M). The test 
solution was individually recorded using DPP, ASV and CSV modes prior to and 
after the successive additions of DMPS (Figures 2.27, 2.28 and 2.29). The results 
indicate that DMPS shows a signal at - 462 m V and gave a linear curve with a slope 
of 6.29x 1 06 nAlM from the DPP mode. A lower sensitivity was obtained using the 
ASV mode (slope 4.7xl06 nAlM). CSV shows a DMPS signal at - 397 mY. 
Linearity was demonstrated in the low DMPS concentration range 10-8 to 10-7 M 
(Figure 2.32), however, deviation occurred at a relatively high concentration (l0-6M). 
This may again be due to the complex electrode process, which involves an 
adsorption process of DMPS onto the mercury electrode. This observation has been 
previously noted in most sulfur containing molecules prior to electron transfer (Galus 
1994). 
In order to investigate more complex solutions containing a mixture of analytes 
III the presence of DMPS, further investigations were carried out for the 
determination of lead in a urine matrix (under the same conditions used for the 
determination of DMPS in urine matrix). The results showed that a lead peak 
appeared at - 400 mY, and the slope of the calibration graph was 7.65xl06 nAlM 
using DPP mode. These values were - 404 mV and 3.88xl08 nAiM, when ASV 
mode was used, and - 410 mV and 7.82xl06 nAlM, when CSV mode was used 
respectively. These are illustrated in Figures 2.14, 2.15 and 2.16. In addition to 
DMPS one can simultaneously determine lead in the urine matrix using the ASV 
mode. 
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(3) DMPS in plasma extract 
In order to determine DMPS in plasma, sample preparation was performed by a 
protein precipitation method using (HP03)n. EDTA was added to mask lead signals 
in the CSV mode. 
The results were linear over the range 10-8 to 10-7 M. In order to test for linearity 
in the investigated electro analytical modes, the above procedures were repeated for 
aqueous and blank plasma samples. Linearity was demonstrated in the aqueous 
media (r = 0.9999). This linearity was maintained when plasma extracts were 
investigated giving r = 0.9805 (Figure 2.22). 
In order to examine other extraction procedures from plasma, acetonitrile was 
employed for protein precipitation and gave a relation coefficient r = 0.9948, linearity 
was again demonstrated (Figure 2.23 to 2.26). However, the results showed that 
despite the high signal enhancement, low recovery was recorded. 
Specificity of the Pb2+ I DMPS and Pb: DMPS analytical signals 
In order to discriminate between lead and DMPS signals in urine matrix, further 
experiments were carried out. Two test solutions were investigated; an acetate buffer 
solution in the presence of EDTA (PH 5.6, O.lM), and a perchloric acid solution (1 
M). The results demonstrate that one can successfully measure DMPS in the 
presence of lead using the CSV mode in the first solution. By changing the media to a 
solution containing perchloric acid, lead was successfully determined in the presence 
of DMPS using the ASV mode. Each of the above experiments is specific for the 
determination of one analyte only. Unfortunately the two analytes cannot be 
determined simultaneously. 
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Complexometric titrations of DMPS versus lead and vice versa were employed 
to study Pb:DMPS signal in the presence of free lead and lor free DMPS. These 
titrations were investigated using DPP, ASV and CSV modes as illustrated in the 
voltammograms shown in Figures 2.38 to 2.43. 
Three experiments were carried out, each employed a different mode for signal 
recording, namely: DPP, ASV and CSV (Figures 2.38, 2.39 & 2.40). Using DPP 
mode, the lead signal was clearly decreasing after each successive addition of DMPS. 
Two other peaks appeared at - 515 m V and - 290 m V during the titration. The 
new peaks probably correspond to the formation of new Pb:DMPS complexes. The 
above observation was further confirmed by the signal observed at - 515 m V which 
persisted despite the addition of excess DMPS; since there was no free lead available 
for complexation. 
Using the ASV mode, the same titration was repeated as illustrated in Figure 
2.39. It was clear that after the successive additions of DMPS, the ASV signals of 
lead were decreasing upon the addition ofDMPS. 
U sing the CSV mode, the titration of lead with DMPS was not specific enough 
to depict the decrease in the lead signal, since it was overlapping the DMPS signal. 
Only one new signal was recorded at - 540 m V (Figure 2.40). It was also interesting 
to note that by titrating DMPS versus lead, using the DPP, no significant lead signal 
was recorded until a 1: 1 molar ratio was exceeded (Figure 2.41). 
This indicates that the species formed was a 1: 1 Pb:DMPS complex. The 
appearance of the two new DPP peaks may also indicate that two complexes were 
possibly forming, initially a 1: 1 and later on as more lead was added, a 2: 1 Pb:DMPS 
complex. 
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Figure 2.42 which illustrated the ASV profiles during the complexometric 
titration showed that only one peak appeared, this might correspond to both lead and 
lor DMPS. It may well be that the formed complex was labile at the potential and 
time windows employed in the ASV mode. 
Figure 2.43, which, illustrates the CSV during the titration of DMPS with Pb2+ 
clearly demonstrates the formation of new complexes with lead, as evident from the 
two new peaks appearing at - 260 m V and - 400 m V. 
Optimization of the Electroanalytical signals for the Lead: DMPS 
Complex (1: 1) 
Figure 2.44 illustrates that the DPP profile for Pb:DMPS complex showed two 
peaks, one appeared at - 280 m V and the second at - 520 m V. One may differentiate 
these peaks from those corresponding to the free lead, which appeared at - 400 m V 
(Figure 2.14), while the free DMPS appeared at - 460 m V (Figure 2.27). 
Consequently, using DPP, one can simultaneously detect free lead, free DMPS 
and the Pb:DMPS complex from the acetate buffer media or in a dilute urine sample 
(PH = 5.6). 
Figures 2.45, 2.28 and 2.15 illustrate ASV voltammograms after the successive 
b2+ additions of (1) aliquots of 1:1 (Pb:DMPS) complex, (2) free DMPS and (3) free P . 
These figures clearly demonstrate that analytical signals overlap since free Pb2+ 
appeared at - 400 mV while free DMPS appeared at - 460 mV and Pb:DMPS 
complex appeared at - 400 m V. Therefore, one cannot utilize ASV mode for the 
simultaneous recording of the three analytes as anticipated, in urine samples collected 
during chelation therapy. 
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Figure 2.46, which shows the CSV profiles recorded after the successive 
additions of aliquots containing 1: 1 Pb:DMPS complex, clearly illustrates that the 
three analyte peaks were simultaneously recorded at - 260, - 400 and - 540 m V s. 
Furthermore, it was also observed that only the peak recorded at - 540 m V was 
sensitive enough and exhibited linearity. After comparing the ASV and DPP with the 
CSV profiles for free lead (Figure 2.16) and for free DMPS (Figure 2.29), it became 
obvious that the peak that appeared at - 400 m V could be due to the free lead ions; 
however DMPS might have overlapped since it appeared at - 397 m V (Figure 2.29). 
Tables 2.14 to 2.16 which are illustrated in Figures 2.47 to 2.50 clearly 
demonstrate that Pb:EDT A complex is a stable complex having a dissociation 
potential at about - 1300 mV versus the Ag/AgCI reference electrode. In contrast, 
Pb:DMPS behaved as if no complex formed, possibly because of the formation of 
labile complex. 
Determination of Formation Constant of Lead: DMPS Complex. 
Most dimercapto compounds form metal complexes, which are insoluble at low 
pH values, however, their solubility increases by increasing pH and consequently it 
becomes difficult to evaluate formation constant(s) at high pH values since most 
metal ions precipitate as hydroxides. 
Dimercapto complexes do not possess physicochemical characteristics that 
qualify them to absorb UV radiation, or to fluorescence; as a result 
spectrophotometric techniques for the determination of stability constants have not 
been suggested. Attempts have been made to evaluate formation constants of the 
mercapto compounds with heavy metals. However, as a result of the weak 
endogenous absorption fluorescence characteristics, these attempts focused only on 
the evaluation of relative formation constants (Schubert, 1981). 
239 
Direct measurement of the formation constants of Cd-DMPS complexes has 
also been studied potentiometrically using glass electrode. This method showed that 
species ML, and ML2 were found to be present in the system at equilibrium (Fisher, et 
aI., 1985). Furthermore, it has been found that Cd2+ ions interact with DMPS to form 
a range of polynuclear protonated species, such studies concluded that the greater the 
stability constant for a specific complex, the greater the mobilization of the ions 
observed after dosing with the chelating agent (Trinus, et aI., 1984). 
1. Shuman and Woodward's technique for evaluating 
conditional formation constants. 
It was assumed that if the following conditions were met namely: 
(1) formation of a 1: 1 complex of Pb:DMPS (2) the formed complex has a relatively 
high Kr values, and (3) the kinetic dissociation was not too high, one can easily 
evaluate formation constants using Shuman and Woodward's method (section 2.12. aI 
Appendix I). 
The profiles illustrated in Figure 2.54 showed that in spite of the overlapping 
lead and DMPS peaks, the analytical signal of lead was 50 times more sensitive than 
that of DMPS. Analytical measurements may thus be successfully carried out. The 
results of the titration of lead versus DMPS, which covers the two important regions 
in the titration curve namely: (1) the region before the equivalence point and (2) the 
region after the equivalence point, are summarized in Tables 2.17 and 2.18. and 
illustrated in Figures 2.55 and 2.56. From the slopes of the two graphs, the formation 
constant was evaluated in accordance with section 2.12. a. The average value of the 
measured conditional formation constant was Kr = 2.66 x 104. 
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The low conditional formation constant value could be due to either of the 
following reasons: 
(a) Very high kinetic dissociation. 
(b) Formation of a labile complex between Pb2+ and DMPS. 
It is worth noting that the high values reported for the formation constant of 
Pb:DMPS complex 10gKI and logK2 17.4 and 25.0 respectively (Ospanov et aI., 
1987) are not justified. 
2. Deford - Hume Method. 
An attempt was made to investigate whether a shift in the reduction potential 
of lead occurs upon titrating lead with DMPS. From the shift in the observed 
potential, one can evaluate the consecutive formation constants if more than one 
complex results. It was observed that the reduction potential shifted cathodically (to a 
more negative cathodic potential). Application of Deford and Hume's method 
becomes unreliable (Table 2.20, Figure 2.57). 
This is a consequence of the fact that both Pb2+ and DMPS signals appeared 
at the same potential region and demonstrated comparable sensitivity (8x 106) when 
the DPP mode was used. 
It is worth noting that the Pb:EDT A formation constant was successfully 
measured using both Shuman and Woodward's as well as Deford and Humes 
methods, this resulted in Kf values which compared well with literature values 
(1.25 xl 0 18). It is interesting to note that when measurement of the dissociation 
potential of Pb:DMPS was compared with that of the Pb:EDT A, the Pb:EDTA 
demonstrated the formation of a strong complex which dissociated at 1.0 volts, 
whereas it was not evident that a Pb:DMPS complex was strong (Figure 2.50). This 
finding demonstrates further that in spite of the strong evidence which suggests the 
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formation of Pb:DMPS, the complex may have high kinetic dissociation after 
elimination via the kidney. The above observation may explain the efficacy ofDMPS 
in removing metal ions from depots. 
Relative stabilities of Pb:EDTA and Pb:DMPS 
Relative stabilities of both Pb:EDT A and Pb:DMPS were investigated by initially 
recording the signals from a solution of a 1: 1 Pb:DMPS complex in a urine matrix. 
Two peaks appeared at - 310 mV and at - 515 mY, these correspond to the Pb:DMPS 
complex (Figure 2.51). After the addition of an equimolar amount of EDT A, 
however, it was demonstrated that EDTA formed a complex with Pb2+, even though 
the Pb2+ ions were associated with DMPS after forming the more stable Pb-EDT A 
complex. DMPS was freed, consequently, the peak that appeared at - 415 m V clearly 
demonstrated that it corresponds to the free DMPS signal. 
Thus, Pb:EDTA complex, which has a formation constant of 1.13 x 1018 is 
more stable than that of Pb:DMPS. This was clearly demonstrated when EDT A was 
added to a 1: 1 Pb:DMPS complex and DMPS was freed. One therefore, confirms a 
very low stability constant for the Pb:DMPS (Figures 2.52 and 2.53), as demonstrated 
both by the ASV and CSV profiles obtained. It is worth noting that this observation 
has never been suggested before. 
In-Vivo Studies 
The efficacy of a chelating agent is based on the clinical outcome of the 
intoxicated patient. This is true particularly in the case of the chronically lead 
exposed workers. 
Sodium 2,3-dimercapto-l-propanesulfonic acid (DMPS), (DIMA V AL ®), was 
introduced for the treatment of heavy metal toxicity (Petrukin, 1959). 
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Later this drug gained popularity in the western world particularly in Eur ope. 
and in Japan. Like meso-2,3 dimercaptosuccinic acid (DMSA), DMPS is an orally 
effective chelating agent readily available, with low toxicity in animals (Aposhian et 
aI., 1984). 
Eley, et aI., (1987) investigated the diagnostic use of DMPS for the urinary 
excretion of mercury in subjects with dental amalgam toxicity. Since then, DMPS has 
been utilized for the diagnosis of mercury body burden in humans resulting from 
exposure to dental amalgam. 
Furthermore, Gabard (1976) concluded that DMPS is effective for the 
removal of both inorganic and methyl mercury probably because it is not lipophilic 
like BAL and does not penetrate tissues but removes extracellular metal. 
Additionally, Buchet and Lauwerys (1989), suggested that both DMSA and 
DMPS could be used to treat mercury poisoning, but DMPS was found to mobilize 
mercury at a faster rate than DMSA. Additionally, both DMSA and DMPS have been 
suggested for the treatment of chronic lead intoxication. Experiments in rats suggest 
that DMPS can be used to estimate the renal burden of lead (Twarog and Cherian 
1984) and inorganic mercury (Cherian et aI., 1988). 
The absorption of DMPS after oral administration from the gastrointestinal 
tract is rapid (Wiedemann et aI., 1982). As the absorbed fraction remained the same 
over a large dose range, uptake is presumably by means of passive diffusion through 
the intestinal mucosa (McGown et aI., 1984). In humans, the peak concentration was 
achieved after 3.7 hours following oral administration (Maiorino et aI., 1991). 
Following intravenous dose, DMPS was found in the plasma for as long as 60 hours 
and 96 hours in the urine (Hurlbut et aI., 1994). 92.4% and 94.8% of the total plasma 
DMPS was found at 0.5 and 8 hours respectively (Maiorino et aI., 1990). 
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It has been suggested that the formation of the DMPS-albumin complex is 
dose dependent. When given to normal volunteers to determine whether DMPS is 
stable and provides for "metabolic reservoir" the results showed that a different time 
profile was observed (Maiorino et aI., 1996). This could be explained by the fact that 
DMPS contains two sulfhydryl groups. If both react with albumin, the DMPS 
albumin complex will be doubled. This suggests that DMPS is reduced to some of the 
17-disulfide bonds of albumin (Meloun et aI., 1975). 
Furthermore, in human plasma DMPS rapidly forms a non-protein disulfide 
linkages, which indicates that DMPS is more reactive than DMSA (Maiorino et aI., 
1990). 
DMPS is rapidly excreted in the urine (Luganskii & Loboda 1961; Golota 
1980). In humans the plasma half-life of DMPS was reported to be 0.9 as the 
distribution half-life and 19 hours as the elimination phase following intravenous 
administration (Kemper et aI., 1990). 
Reports indicate that after 6 hours, more than half of the administered dose 
was excreted (Gabard 1978), and after 24 hours about 90% (McGown et aI., 1984). 
In humans, the highest DMPS concentration in the urine was measured two or 
three hours after oral administration (Maiorino et aI., 1987 and 1991). The 
predominant urinary metabolites have been identified as a cyclic polymeric disulfide 
(97%), mixed disulfide (2.5%) and acyclic disulfide (0.5%) following an oral dose of 
DMPS (Maiorino et aI., 1996). 
Orally administered DMPS IS presumably absorbed unchanged from the 
gastrointestinal tract in humans. 
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In blood and plasma it is relatively rapidly oxidized to cyclic and acyclic 
polymeric sulfides (Maiorino et aI., 1987; McGown et aI., 1984; Stewart & Diamond 
1988). The acyclic metabolites are presumably intermediate products in the formation 
of cyclic compounds (Maiorino et aI., 1988). 
Furthermore, in rats pretreated with HgCh, 92% of the injected dose of DMPS 
was recovered in the bile as the cyclic polymeric disulfide (Zheng et aI., 1990). It 
appears that DMPS enters the liver cells where it is believed to decrease mercury 
levels in the liver and in the cellular fraction of the blood. This indicates that the 
rapid biotransformation of DMPS to predominantly cyclic polymeric disulfides 
explains the need for large doses of DMPS in the treatment of lead poisoning. It is 
well known that the disulfide and the sulfonic groups seem to be very poor chelators 
of lead; the sulfhydryl groups of DMPS, however, are necessary for chelation 
(Maiorino et aI., 1996). 
It is thus expected that chelation of DMPS will be delayed because of the slow 
in vivo reduction reaction of DMPS disulfide linkages to the parent drug which occurs 
in the kidney (Stewart and Diamond 1988). This suggests that the metabolic 
formation of DMPS disulfide is an important step in its pharmacological action 
perhaps by prolonging its in-vivo activity. 
In humans, the distribution of DMPS metabolites depends on the route of 
administration. After oral administration only 0.5% of the DMPS monomer was 
excreted, but 20% after an intravenous administration (Maiorino et aI., 1996). 
In animals with acute lead poisoning, DMPS increases lead excretion in the 
urine (Llobet et aI., 1990) and reduces lead levels in most organs, especially in the 
kidneys (Flora et aI., 1996; Llobet et aI., 1990 and Xu et aI., 1988). 
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The present work aimed at consolidating the understanding of the interaction 
between lead and DMPS both in-vitro and in-vivo. The present study screened sixty 
workers employed by the lead acid battery manufacture in the north east of 
Amman/Jordan. The workers were assessed qualitatively for their lead body burden, 
by measuring blood lead and zinc protoporphyrin levels. 
Their blood lead concentrations ranged from 85 ~g/dl to 3.6 ~g/dl. Only six 
subjects were chosen to participate in the present study. Several factors contributed to 
the choice of the sample size (n = 6), among others, these have included: 
1. The large number of biological samples which needs to be collected. 
2. The principal investigator was solely responsible for sample collection, 
preservation and analysis keeping in mind that DMPS is not stable, fast analysis 
of the samples was necessary. 
3. The high cost of hospitalization, which includes offering standardized food, 
precluded involvement of a large sample size. 
With regards to the disposition of DMPS, the concentration-time profiles 
illustrate the results obtained after dosing the subjects while in a fasting state (Figures 
3.5, 3.6, 3.7, 3.8 and 3.9). The concentration-time profiles were comparable for most 
of the investigated subjects including: the control subject (C), subjects with low 
exposure (L1 and L2) as well as the subject having high exposure (HI). 
Except for H2, all subjects showed Cmax, values which ranged between 500 
and 1000 ng/ml, and a tmax of about 2 hours. It was difficult however to conclude 
from the concentration-time profiles whether the patterns observed can be related to 
lead body burden. 
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It is interesting to note that the urinary concentration-time profiles of DMPS 
of the control subject (C) subjects Ll and HI showed almost the same elimination 
patterns (Figures 3.10, 11, 12, 13 and 14). A Cmax of 16.29 ng/ml appeared at a tmax 
of 4 hours for the control subject. Much higher Cmax values were observed for 
subjects Ll and HI since a 37.86 and 53.11 /-lg/ml were determined, these values 
occurred at shorter tmax of 2 hours. 
DMPS is an organic acid, its solubility may have diminished at the normal pH 
of the urine (5.0), but became more soluble when the Pb:DMPS complex formed. 
Consequently, this may explain the variation in the results of Pb2+ and DMPS for 
subjects Ll and HI. 
One may add that when the complex was formed in the presence of lead, it 
was a labile one (low formation constant with high kinetic dissociation). Hence 
DMPS appeared in the urine collected after dosing. One would also expect DMPS to 
be present as a disulfide or as a cyclic disulfide. The investigator tried to analyze the 
collected samples immediately after sampling so as to minimize the formation of 
disulfides prior to analysis. Upon the addition of dithiotriol to reduce the disulfide, 
the signal remained constant. This clearly showed that the measured signal was due 
to the free DMPS. 
A sulfur-sulfur bond is expected to form between two DMPS molecules or 
between a cystein and a DMPS molecule. 
The above observation shed more light on the possibility of utilizing a single 
oral dose of DMPS for the diagnosis of chronic lead poisoning. In contrast however, 
the concentration-time profiles of urinary DMPS for subjects L2 and H2 were more 
difficult to interpret, since no predictable pattern was observed particularly in the case 
ofL2. 
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Lead concentrations (Figure 3.15, 16, 17and 18) in the blood of the 
investigated subjects at Zero time and at 14 time points after dosing may also be 
interpreted as follows: 
1. The control subject showed low and unremarkable lead levels throughout the 
investigation (up to 48 hours post dosing), such level remained constant. 
2. For subjects with low exposure Ll and L2, the lead levels in whole blood 
were almost constant throughout the study duration. A similar observation 
was also noted for the highly exposed subjects (HI and H2). 
The above observations may be a consequence of the reduced dose; a single oral dose 
of 300 mg of DMPS was not significant enough to alter the equilibrium between the 
free ionized lead in plasma and the lead depots of the body (bone and soft tissues). 
Additionally, a competitive complexation between the DMPS and the already fonned 
complexes) between lead and blood proteins might have occurred. This work showed 
evidence that the Pb:DMPS is a labile complex. 
The investigator believes that DMPS may be able to mobilize lead by competitive 
binding if it forms a Pb:DMPS complex that has a higher formation constant 
compared with that of the lead bioligand complex. 
An important observation is illustrated in Figures 3.19 and 3.20, which shows the 
amount of lead excreted in the urine post dosing with 300 mg of DMPS. The lead 
excretion pattern for subject HI was closely similar to that of DMPS in the urine. 
This observation clearly confirm the formation of Pb:DMPS complex of the previous 
in-vitro findings ( Figure 2.50 ). 
One may therefore, conclude that a 1: 1 lead-DMPS complex forms prior to 
urinary excretion. 
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The labile complex formed is soluble in the aqueous media as a result it was 
excreted via the kidney where it may have dissociated to give the same profile for 
both lead and DMPS in the urine matrix. The above observation was also confim1ed 
by the elimination pattern for H2. Since both lead and DMPS concentration-time 
profiles showed similar patterns again. This observation have never been reported in 
the literature since electroanalytical techniques have not been utilized for this 
application. 
This important observation is clearly demonstrated in the in-vitro investigation, 
which compared the complexing properties of the Pb:DMPS with that of Pb:EDT A. 
Unfortunately, the investigator was unable to detect high levels of lead in the urine in 
both subjects Ll and L2 that may be due to the lower lead body burden(s). 
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Conclusions 
1. Novel electro analytical methods and procedures were developed and validated 
for the determination of: Lead, DMPS and Lead DMPS complex in biological 
fluids. 
2. The developed procedures were simple, accurate and precise for their 
application to the present investigation. Simple, direct and cost effective 
sample preparation techniques were suggested. It was also possible to assay 
free lead, free DMPS and Pb:DMPS complexes) in biological matrices. 
3. The developed procedures were employed for investigating the in-vitro 
complexing behavior of DMPS with lead. 
4. In-vitro results demonstrated the formation of Pb:DMPS complexes), however 
these complexes) were not as stable as Pb:EDTA. 
5. The present work estimated the conditional stability constant for Pb-DMPS 
complex using the Shuman-Woodward methods. A value of KF 2.66 x 104 
was obtained. 
6. In-vivo studies demonstrated that DMPS might be used for the diagnosis of 
lead body burden. 
7. DMPS was not an aggreSSIve chelator for lead; this was regarded as an 
advantage for its use orally. Treatment of lead exposed subjects may require 
longer treatment duration without causing adverse effects due to the presence 
of high lead levels in the blood during treatment. 
8. Disposition of DMPS was not affected by the extent of lead body burden. 
9. DMPS was well tolerated by the study subjects. None demonstrated adverse 
events during the study duration. 
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10. The in-vitro observation pertaining to the formation of a labile complex 
compared well with in-vivo results, as demonstrated both by the 
concentration-time profiles of DMPS and lead in urine. 
Recommendations 
1. Electroanalytical techniques may be successfully employed for the 
determination of free lead, free DMPS and Pb:DMPS complex during therapy. 
Their individual determinations however, require slight modifications of the 
media and the measurement mode. 
2. DMPS may be used successfully as a diagnostic test for estimating lead body 
burden. 
3. DMPS seems to be safe, efficacious chelating agent, however a long regimen 
is recommended. 
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Appendix I 
Conditional Formation Constants 
Conditional or effective formation constants are pH-dependent equilibrium 
constants that apply to a single pH only. K' ML, for example, is the conditional formation 
constant, which describes equilibrium relationships only at a certain pH value. 
The following therefore, can be derived: 
M2+ + L4- ¢ ML2-
[ML2-] 
[M 2+ HL4-] 
Eq.l 
Eq.2 
One can thus evaluate the relative amounts of different ligand species that vary as 
a function of solution pH. For an H2L ligand one can derive the Uo, Uland U2 which refer 
to the different mole fractions of H2L, HL- and L2- respectively. Therefore, their 
magnitude varies with pH. 
CT = [H2L] + [HL-] + [L2-] ........................... Eq. 3 
[H2L] _ [H30+ ]2 
U - -
0- [H2L]+[HL-]+[L-2] [H30+]2 +Ka) [H30+]Ka) Ka2 
= [H2L] ............................................. Eq. 4 
Cr 
[HL-] .............................................................. Eq. 5 
Cr 
_ [L2-] 
--C .................................... Eq6 
··········· ..... 0..... . 
T 
Lo + LJ + L2 = 1 ................................................. Eq. 7 
Thermodynamic formation constant are obtained from the conditional fonnation 
constant of the complex, and the all of the ligand (at a certain pH value). 
Eq.8 
Where K'ML is the measured conditional fonnation constant. 
KML is the thermodynamic formation constant. 
all is the mole fraction ionized species calculated at a specific pH. 
d. DPP in the Determination of Formation Constants. 
It has been shown experimentally that the half-wave potential for the reduction 
reaction of the metal complex species is always more negative than that for the reduction 
of the aqua metal ion. The shift in the reduction potential of the complexed ion, E, 
(negative direction) increases with increased stability of the complex and is further 
related to the free energy change of the reaction; 
-~G = nF~E = RT Ln p .................... Eq. 9 
This phenomenon may be attributed to the bulky complexed species requiring 
more energy during its transport to the working electrode. The rate of electron exchange 
process, however, remains relatively faster than the diffusion, which is the rate-
determining step. 
From the knowledge of the free ligand concentration and the shift in the half-
wave potential, it is possible to calculate the formation constant and coordination 
numbers of complexed species provided that the electrode reaction is reversible. 
A reversible system is a system that is always at equilibrium. For such a system 
the electrode must have a potential that obeys Nemst equation: 
E = E1/2 - RT Ln i .... ................... Eq. 10 
nF (id -i) 
E1/2 = half-wave potential (m V) 
Id = diffusion current 
= current at time t 
2.303 x RT = 59.2 .......... at 25 DC ............ Eq. 11 
nF n 
Prior to the intended application, it is important to establish reversibility of the 
electrode reaction, by plotting E vs. Log (id-it liD. A straight line is obtained with a slope 
of (59.2/n) mV for a reversible system (Crow, 1969). 
Reversibility can also be tested using Tomes criterion according to which EII4-E3/4 
equals (56.4/n) m V for a reversible system (Riley et aI., 1987). 
Lingane, (1941) reported the first method for determination of formation 
constants by polarographic techniques. He derived an equation describing a shift in half-
wave potential as a function of excess ligand in a test solution. 
This method was developed for a ligand-metal system, where a single complex 
species is formed, to virtual exclusion of all others over the entire ligand concentration 
range. 
Ten years later, Deford and Hume, (1951) reported an equation that was based on 
the same assumption as that reported by Lingane. 
Their method has an advantage over the Lingane method, since it allowed the 
calculation of the formation constants for the ligand-metal system when several 
complexes are formed in stepwise reactions. 
The method of Schap and McMasters, (1961) is a logical extension of the Deford-
Hume's, by applying the latter to the ligand-metal system where two ligands compete in 
complex formation reactions with the same metal ion. 
All of the above methods require the presence of large ligand excess, 
consequently the concentrations of the ligand at the electrode surface and in the bulk 
solution are considered constant. 
Evaluations of formation constants for partly reversible systems were reported by 
Momoki and Ogawa, (1971), in which the method of Deford-Hume was developed. 
Cukrowski, (1966) reported another method for evaluating of formation constants 
from polarographic data at fixed ligand to metal ratio with varying pH solutions. The 
method depends on the shift in peak potential and a decrease in polarographic peak height 
caused by the formation of metal complexes. The free metal ion concentration IS 
calculated from mass-balance equation written for the assumed metal-ligand model. 
The following limitations should be considered when measuring formation constants 
by DPP: 
(A) DPP cannot be applied to ligands such as thiocyanate, which are strongly adsorbed 
onto the mercury working electrode (Bond, et a1.1971). 
It has been found that polarographically determined formation constants suffer from 
positive determinate errors when strongly adsorbed ligands are involved. 
(B) There are many systems of complexes whose polarographic behavior is complicated 
by kinetic factors (Crow, 1969) such as the rate of dissociation of complexes being 
faster than their diffusion rates. The effect of kinetic dissociation on the magnitude of 
the formation constant would be larger for weaker and labile complexes. 
e. Mathematical Treatment for Formation Constants using DPP 
Two methods have been suggested for the calculation of formation constants 
calculation from polarographic data, the first is Lingane's method, and the second is 
Deford and Hume's method. 
f. Lingane Method for the Determination of Stability Constants and 
Coordination Number 
For the reactions 
Mn+ + ne- + Hg ~ M(Hg) 
And Mn+ + p L ~ MLp n+ 
Lingane derived the following relationship that relates to the molar concentrations 
fth 1· d C d the shift in half-wave potential (provided that the electrode reaction o e 19an, L, an 
is reversible and only one species of the complex ion present in the solution) 
0.0592 0.0592 
(El/2 )c -El/2 =- n LogKf - n p LogC L .... Eq.12 
Where (E lI2)c and (ElI2)M are the half-wave potentials for the complexed ion and 
free metal ion respectively, Kf is the stability constant for the complex, and p is its 
coordination number. 
Consequently, a plot of the half-wave potential (V) against Log CL for several 
ligand concentrations is given as: 
.Eq 13 
and 
-n 
p= 0.0592 s. 
............................ Eq.14 
Where (int.) and (s) are the intercept and slop of the straight line plotted. 
g. The Deford and Hume's Method for Determining Consecutive Overall 
Formation Constants 
Deford and Hume presented their approach to investigate formation constants in 
1951. The starting point of their work was the expression describing the electrode 
potential 
................. Eq.15 
Where EO a is the standard potential of the electrode system consisting of Mn+ ions 
and its mercury amalgam. The r M n + and r M are the activity coefficient of the reduced 
ion, and the metal in the amalgam, respectively. 
The concentration of each MLt+ complex in the bulk of the solution is given by 
the expression: 
.............. Eq.16 
The concentration of the MLt+ complex at the electrode surface is described by a 
relationship similar to equation (26), in which the concentrations are labeled with the 
subscript 0, except for [L] the ligand concentration, which is assumed to be high and 
effectively constant. Moreover, it is assumed that the activity coefficients have the same 
values both at the electrode surface and in the bulk. 
By adding the surface concentration of the complex ion in the solution from j = ° 
to j = p one obtains: 
P P fJ [L]j 
'"' n+ [Mn+] "j LJML j L = oYMn+L.J---
)=0 j=O Y MC+ 
.................... Eq.17 
Introducing [Mn+] into Eq. (25) from Eq. (27) gives the relationship: 
.................... Eq.18 
On the basis of Ilkovic equation the reduction current due to ML n+ can be expressed as: 
iJ. = J K II ([ ML nJ+ ] 0 - [ML nJ+ ] 0 ) ........... Eq.19 
and the total current as: 
.................... Eq.20 
Introducing the experimental Ilkovic constant exp Kn into Eq. (20) gives: 
i="'P Kll ~ [uL/+ r -[ML/+ JJ .................................. Eq. 21 
The concentration of the metal in the amalgam is given by: 
1 = K;/ [ML ................................................... Eq. 22 
Combining this equation with Eq. (18) and Eq. (19) gives the relationship: 
E = E: + RT Inr KII (it=- ill + RT In 
nF exp K11rM i nF 
....!--. r MLn + ~ [LY Pi .......... Eq.23 
p 
where It =exp KI/ L[ML~+] 
j=O 
From Eq. (23) an expression for half-wave potential is obtained: 
E c _ EO RT L [ K;I ] RT L ~ Y ML"/ 1/2 - a + n + n ~ J 
nF expKIlYM nF j=O [L] Pj 
..... Eq.24 
The half-wave potential for the reduction of a complexed ion is shifted with 
respect to the reduction of the free metal ion. This shift is given by the expression: 
.......... Eq.25 
Equation (25) can be rewritten in the form: 
The right-hand side of Eq. (26) can be determined experimentally. The function 
can also be described by the expression: 
Eq.27 
Where Bo is the formation constant of the complex having coordination number O. and 
equal to unity. The terms B 1, B2, B3, are the consecutive stability constants. To 
determine the formation constants graphically. The function Fp(L) is introduced: 
F (L)-/3 
Fp(L)= p-l p-l 
CL 
...................... Eq.28 
A plot Fo(L) vs. CL yields a curve with intercept l. When Fp_I(L) is plotted vs. CL 
a straight line that has a slope of pp and intercept of Pp_1 is obtained. 
The final function Fp(L) is independent of CL, therefore plotting Fp(L) vs. CL 
results in a straight line parallel to the CL axis. The intercept of this line with the Fp(L) 
axis gives a confirmative value for pp. 
Formation constants for many complexes were measured by DPASV. Values 
reported for the formation constant of Cd-EDTA were consistent (Shuman, et aI., 1979). 
Furthermore, the formation constants of copper fulvic and humic complexes have been 
determined using the same method (Shuman, et aI., 1979). 
When ASV is used for determining stability constant, some precautions must 
be considered. (l) The complex formed must be a 1: 1 complex. (2) Rapid 
dissociation of the metal complex that forms during titration is unfavoured, since this 
causes inaccuracy in determination of stability constants. (3) The dissociation 
potential of the complex must be more negative than that of the non-complexed 
metal ion. Therefore, to obtain accurate measurement of the conditional stability 
constant ~ 1 using DP ASV, many assumptions must be considered. 
h. Mathematical treatment of the determination of formation constant 
by DPASV (Shuman and Woodward, 1979) 
In an aqueous solution, the formation constant of the metal complex ML +n 
proceeds according to the equation: 
M+n + L ¢. ML+n ......................................... Eq.29 
With conditional formation constant, K 1 ML defined as: 
KIML = [MLn+] / [Mn+] [L] ............................. Eq. 30 
Where, [L] is the total concentration of the ligand not associated with M and is either a 
molecule or charged ion, [Mn+] is the total metal ion concentration not associated with L. 
[ML +n] is the equilibrium concentration of the complex. Kf and Kb are the kinetic rate 
constants of the forward and backward reactions, respectively. 
Provided that K 1 ML is large or Kb is small, a pre-concentration potential can 
usually be found at which Mn+ is reduced and not MLn+ , according to the reaction: 
Mn+ + ne- ~ M(Hg) ..................................... Eq. 31 
The anodic stripping current ia is proportional to the equilibrium concentration of the 
uncomplexed metal ion. 
ia = K [Mn+] ................................................... Eq. 32 
Where K is a constant that depends on the mercury electrode geometry and its volume, 
stirring efficiency, length of pre-electrolysis time, scan rate and diffusion coefficient of 
the metal both in solution and mercury. 
By a mass balance: [MLn+] = CM - ia IK ................................... Eq. 33 
Where, C is the analytical concentration of the metal M in the solution, and 
[L] = CL - CM + ia/K ........................................ Eq. 34 
Where, CL is the analytical concentration of the ligand in the solution. Substitution in 
equation (11) gives the following equation: 
Eq.35 
With reference to a titration of ligand concentration CL with the metal 
concentration CM, two useful regions of the titration curve can be identified. The region 
before equivalence, when CL > CM and for reasonably large formation constant, 
[Mn+] = (ia/K)« CM < CL so, equation (29) becomes: 
KIML = CM I [(ia/K). (CM - Cd] ............................... Eq. 36 
Thus ia, is plotted vs. [CM / (CL - CM )] should give a slope SI = KI KIML . The second 
region is the region after the equivalence point, when CM » CL 
ia = K (CM - Cd ............................................... Eq 37 
The quantity K can be obtained from the slope Su of a plot ia vs. CM. Consequently, the 
conditional formation constant KIML can be calculated from Su lSI. 
I. Formation Constant from the polarographic behavior of the ligand 
A modified form of the Deford-Hume technique can be used to calculate the 
stability constant of a complex when the organic ligand are reducible at more positive 
half-wave potentials than that of the metal ions with which they complex. The method 
consists of determining a set of half-wave potentials of a fixed concentration of the ligand 
in the presence of increasing concentration of the metal ion. The situation is thus 
essentially reversed from that of the normal Deford-Hume application, i.e. the 
complexing process is now to be written as: 
x + jM "¢ XMj ................................. Eq.38 
Where j = 1, 112, 113,. lIN. 
Casassas and Eek defined a "pseudo stability constant, Pj*", defined by the following 
equation: 
p*j = axMj / axaiM ........................... .. .Eq. 39 
Because a large excess of M is present, the only 1: 1 complex predominates and the 
following equation can be used to calculate the formation constant of a 1: 1 complex. 
i1EII2 = 0.059 log (l +~I[MD .................... Eq. 40 
It is evident that the method is particularly useful for obtaining pseudo stability constants. 
Casassas and Eek applied the method to the complexes of cobalt and nickel with 
1-nitroso-2-naphthol and obtained good agreement with the values of BI obtained by 
established methods (Crow, 1969). 
j. Ligand number and degree of Formation 
The ligand number or degree of formation, n, of a metal ligand system M, X, is 
defined by: n = (total concentration of X bond to M) / (total concentration M) 
n = (Cx -[XD / CM .............................. Eq. 41 
Where, Cx, CM represent the analytical concentration of the ligand and metal, 
respectively, and [X] is the free ligand concentration. Thus, n may also be expressed in 
the following way: 
n = ([MX]+ 2[MX2]+ 3[MX3]+ ... ) / ([M]+ [MX]+ [MX2]+"') 
The degree of formation of the /h complex, uj is given by: 
Uj= [MXj]/ C= [MXj] / ([M] + [MX] + [MX2] + ..... ) 
Eq.42 
Eq.43 
It may be readily calculated in the systems where the free ligand concentration is 
directly (or indirectly) measured, when n, [X] data are available. 
Appendix II 
Consent Form 
To all subjects who agreed to participate in this study, the following infonnation 
is provided to explain to you the details of the research project you are involved in. 
- Please read this form carefully. 
- Any question you may have about this study will be answered. 
Please feel free to ask any question you may have about this study and/or 
about information given below. 
Item 1. Purpose, Procedure and Study duration. 
a- The purpose of this study is to investigate the disposition of DMPS. 
b- The procedures followed are explained in the attached protocol and explained by 
the investigators. 
c- The approximate duration of this study is a 5 days with 2 days admission prior to 
the dosing with DMPS. 
d- After screening and eligibility I understand that I will be hospitalized for one 
week, of which I will have to fast for 11 hours prior to drug administration. 
e- I understand that qualified medical personnel will assist in securing a cannula in 
my forearm and blood samples will be drawn at several times set by the 
investigator. 
f- I accept the dose of DMPS (300 mg). 
g- I accept that blood samples (about 10 ml each) will be harvested at different time 
set by the investigator. 
h- I accept that urine samples will be collected during my stay at the hospital and the 
technical team will collected the samples at times set by the investigator. 
1- I accept that the investigator will measure my vital signs before and after dosing 
and at any time set by the investigator. 
J- I understand that all results of chemistry, hematology and urine will be given to 
me. 
Item 2. The discomforts inconveniences and/or risks that can reasonably 
be expected are: (None). 
Item 3. The possible benefits to you from this study are: 
a- I understand that the study involves research for the benefit of the investigator as 
well as myself. 
b- To evaluate the efficacy ofDMPS. 
B. Future use of DMPS as a new therapeutic agent for the treatment chronic lead 
pOIsomng. 
C. To chelate some of your lead body burden. 
D. A complete check-up. 
Item 4. Your rights of privacy will be maintained in the following 
manner: 
a- All data obtained to your participation in this study will be kept confidential and 
accessible only to you and the investigator. 
b- Should the results of this study project be published, your code number will refer 
you to. 
Please note the following: 
-Y ou are free to discontinue participation in this study at any time. 
-Any complaints should be addressed to the investigator(s). 
Statement by person agreeing to participate in this research project. 
I agree to enroll in this study as a participant in the present research 
project. 
VVorker Signature 
Date 
VVitness Signature 
Date 
VVitness Signature 
Date 
Data reporting and case report form. 
CASE REPORT FORM (CRF) 
FOR 
AN IN-VIVO INVESTIGATION 
OF 
Appendix III 
Study: Investigation the Disposition of DMPS. 
Date: 1--1 --I 1--1--1 1--1--1 
Day month year 
Part I: SUbjects details 
A. Demography: 
SUbject Initials: ~- ~- ~- I Subject I.D: ..................................... . 
Sex: M 0 
Age (years): 
......................................... 
Height (cm): 
Weight (Kg): 
......................................... 
Status: Healthy 0 Patient 0 
Date: 1--1 --I 1--1--1 1--1--1 
Day month year 
Subject Initials: 1--1--1--1 Subject ID: ···· .. ·······...........HH .............................. . 
B. Physical Examination and Medical History 
BP (mm Hg): 
Cardiovascular 
···System····································· ............. . 
·Respiratory··· ........ · ...... · ............ . 
.Sy.stem ................................................. . 
"'Gisff'oIrilestinar" ........... .. 
···T·ra-et·········· .. · .... · ..................................... . 
Temp 
(OC): 
Genito-
Urinary System 
Heart rate: 
(beats/min ): 
Central Nervous 
System 
Ear, Nose and 
Oropharynx 
..... , .............................................................................................................................. . 
Physician's Geriera .................................................. H ............. ·.·········H ....... . ................................................................................. 
Comme'nts' ............................................................................................................................ 
Physician's Signature: .................................... 
............................................ 
Date: 1--1 --I 1--1--1 1--1--1 
Day month year 
Subject Initials: 1--1--1--1 Subject ID: 
E. Inclusion Criteria: 
Body weight within ± 10% of ideal weight. 
1. Age between 25 and 60 years. 
2. Physical and physiological properties to fulfill the study. 
3. Signed and written informed consent (s). 
4. Known to be complaint with the study. 
5. Non-smoker. 
6. Previously exposed to lead or lead fumes. 
F. Exclusion Criteria: 
1. A known hypersensitivity to any drug 
2. Gastrointestinal diseases. 
3. Positive HIV I. 
4. Renal transplantation, disease or dysfunction 
5. Cardiovascular diseases of any type 
6. Pancreatic disease including diabetes 
7. Hepatic disease 
8. Brain tumor 
9. History of alcoholism or drug abuse 
10. Other serious psychological illness 
11. Abnormal (out of range) laboratory values 
12. Subjects who have taken any medication: Rx. within two weeks or OTC within 
one week of the trails starting date. 
13. Subjects who donated blood (more than 500 ml) or who participated in other 
bioequivalence studies (within two months prior to this trail) 
Conclusion: The subject fulfills the eligibility criteria: 
Yes 0 No 0 Physician's Signature: ......................... . 
Date: 1--1 --I 1--1--1 1--1--1 
Subject Initials: 1--1--1--1 SUbject ID: 
E. Vital Signs Monitoring Sheet: 
A. Pre-Trail Monitoring: 
Temp. (OC) : .................... '.H ... "'''''''''''''''''''''''''''''''''''' H·····B .. ood Pressure (mm Hg): .. 
Heart rate (beats/min): 
Physician's Signature: ." ..................................................... HH .. H ............................................. . 
E. During-dosing Monitoring: 
Protocol Actual time Blood Pressure Heart Rate Comments 
Time{hl lmmHg) (beats/min) 
0.00 
1.00 
5.00 
.................................................................................................................................... 
Date: / /1999 Signatures: 
Principal 
Investigator (M.D) 
Subject Initials: 1--1--1--1 Subject ID: 
................................... _ ..... -... _ .................. . 
F. Safety Assessment: 
Post Dosing 
.............................................................................................. 
.... , ....................................................... . 
............................. . ............•............•........... 
Adverse Event (AE): Adverse Event (AE): 
Subject ID: Subject ID: 
Date of onset: 1--1 --I 1--1--1 1--1--1 
day month year 
Date of onset: 1--1 --I 1--1--1 1--1--1 
day month year 
Description of the adverse event Description of the adverse event 
Seriousness: Not serious 0 Seriousness: Not serious 0 
Serious 0 Serious 0 
Severity: Mild 0 Severity: Mild 0 
Moderate 0 Moderate 0 
Severe 0 Severe 0 
Action: No action 0 Action: No action 0 
Dose reduction 0 Dose reduction 0 
Discontinuation 0 Discontinuation 0 
Not applicable 0 Not applicable 0 
Causality: Unlikely 0 Causality: Unlikely 0 
Possible/probable 0 Possible/probable 0 
Not classified 0 Not classified 0 
Outcome: Recovered 0 Outcome: Recovered 0 
Not Recovered 0 Not Recovered 0 
Unknown 0 Unknown 0 
...... " ........... ..................... 
............................................................... 
Signature: Date: 1--1 --I 1--1--1 1--1--1 
Day month year 
Principal Investigators (M.D): 
Table: Blood, Plasma and Urine Sampling Schedule 
Protocol 
Time (h) Sampling Signature Time (h) 
0.00 
0.50 
1.00 
1.50 
2.00 
3.00 
4.00 
5.00 
6.00 
8.00 
10.0 
12.0 
----,. 
24.0 
48.0 
Date: 1--1 --I 1--1--1 1--1--1 
Day month year 
Appendix IV 
Demographic data of workers in the lead acid battery 
manufacturing (n = 60). 
Subjects Age (Year) Working Exposure Working Area I.D. (years) 
1. 62 35 Smelting 
2. 55 2 Smelting 
3. 27 8 Smelting 
4. 28 5 Smelting 
*5. 50 28 Smelting 
*6. 42 24 Smelting 
7. 58 17 Smelting 
8. 58 26 Grinding 
9. 31 7 Grinding 
10. 30 13 Pasting 
11. 52 10 Pasting 
12. 33 14 Pasting 
13. 43 6 Pasting 
14. 30 9 Pasting 
15. 29 5 Pasting 
16. 23 5 Pasting 
17. 40 18 Cutting 
18. 26 5 Cutting 
19. 35 5 Cleaning 
20. 37 11 Molding 
21. 37 10 Molding 
22. 61 20 Molding 
23. 28 5 Assembling 
24. 50 18 Assembling 
25. 30 6 Assembling 
26. 55 28 Assembling 
27. 28 9 Assembling 
28. 39 19 Assembling 
29. 31 11 Assembling 
30. 44 27 Assembly Supervs. 
Continued Appendix IV 
Subjects Age Working Exposure 
I.D. (Year) (Years) 
Working Area 
31. 58 32 Assembly Supervs. 
32. 42 3 Testing 
33. 28 3 Testing 
34.* 31 7 Quality Control 
35. 30 8 Quality Control 
36. 52 36 Rubber Dept. 
37. 53 25 Rubber Dept. 
38. 55 28 Rubber Dept. 
39. 32 8 Casing 
40. 41 20 Casing 
41. 55 15 Casing 
42. 25 4 Casing 
43. 28 7 Electrical Main. 
44. 30 13 Electrical Main. 
45. 29 6 Maintenance 
46. 48 3 Maintenance 
47. 29 8 Maintenance 
48. 35 13 Management 
49. 39 24 Management 
50. 65 31 Management 
51. 33 7 Management 
52. 38 4 Management 
53. 49 35 Management 
54. 23 5 Driver 
55.* 37 7 Driver 
56. 27 4 Packing 
57. 25 2 Packing 
58. 45 7 Packing 
59. 54 34 Packing 
60. 56 34 Sales Officer 
Appendix V 
Blood lead concentration (Ilg/dl) and Zinc Protoporphyrin levels 
(ZPP) for workers in the acid lead battery manufacturing (n = 
60). 
Subjects Blood Lead Level Zpp 
I.D. (/-lg/dl) i!!mol/moleHb) 
1. 56.15 106 
2. 34.62 77 
3. 62.85 98 
4. 37.70 157 
*5. 79.00 652 
*6. 84.00 876 
7. 27.30 253 
8. 59.80 1436 
9. 62.20 54 
10. 62.80 808 
11. 62.10 876 
12. 63.00 588 
13. 58.00 1159 
14. 62.40 1191 
15. 49.20 236 
16. 60.60 1182 
17. 58.00 615 
18. 38.80 275 
19. 26.20 586 
20. 53.80 526 
21. 61.00 76 
22. 60.20 128 
23. 34.80 89 
24. 62.80 208 
25. 42.80 279 
26. 57.20 255 
27. 62.70 1039 
28. 57.20 659 
29. 28.60 945 
30. 24.50 558 
Continued Appendix V 
Subjects Blood Lead Level Zpp 
I.D. (/-lgldl) (Jlmollmol Hb) 
31. 31.30 77 
32. 28.60 79 
33. 15.60 156 
34. 07.90 138 
35. 22.20 75 
36. 58.90 83 
37. 31.40 311 
38. 46.00 68 
39. 62.00 67 
40. 28.70 119 
41. 40.70 68 
42. 61.30 112 
43. 19.70 141 
44. 16.90 291 
45. 33.80 200 
46. 18.70 58 
47. 17.90 51 
48. 10.40 83 
49. 14.20 146 
50. 03.60 68 
51. 10.50 55 
52. 09.80 79 
53. 20.30 202 
54. 07.40 90 
55. 07.60 88 
56. 35.20 66 
57. 19.70 150 
58. 27.60 1255 
59. 32.80 610 
60. 24.00 89 
Appendix VI 
Diet and Fluid Intake. 
Time Meal Details 
6:30 A.M. Breakfast Jam, labaneh, white cheese, bread, juice, 
tomatoes, cucumber 
12.30 P.M. Lunch Yz chicken, yogurt, soup, one loaf of bread, 
1 apple, juice 
15.30 P.M Light Meal 1 piece of cake, juice 
20.00 P.M Dinner 2 Hamburgers, orange, juice, one banana 
WORLD MEDICAL ASSOCIATION 
DECLARATION OF HELSINKI 
Appendix VII 
Recommendations Guiding Medical Physicians in Biomedical Research Involving 
Human Subjects 
Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 
amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975 
and the 35th World Medical Assembly, Venice, Italy, October 1983 
and revised 41st World Medical Assembly Hong Kong, 1989 
and by the 48th World Medical Assembly, South Africa, October 1996 
INTRODUCTION 
It is the mission of the physician to safeguard the health of the people. His or her 
knowledge and conscience are dedicated to the fulfillment of this mission. 
The Declaration of Geneva of the World Medical Association binds the physician with 
the words, "The health of my patient will be my first consideration", and the International 
Code of Medical Ethics declares that, "A physician shall act only in the patient's interest 
when providing medical care which might have the effect of weakening the physical and 
mental condition of the patient". 
The purpose of biomedical research involving human subjects must be to improve 
diagnostic, therapeutic and prophylactic procedures and the understanding of the 
aetiology and pathogenesis of disease. 
In current medical practice most diagnostic, therapeutic or prophylactic 
procedures involve hazards. This applies especially to biomedical research. 
Medical progress is based on research that ultimately must rest m part on 
experimentation involving human subjects. 
In the field of research a fundamental distinction must be recognized between 
medical research in which the aim is essentially diagnostic or therapeutic for a patient, 
and medical research, the essential object of which is purely scientific and without 
implying direct diagnostic or therapeutic value to the person subjected to the research. 
Special caution must be exercised in the conduct of research that may affect the 
environment, and the welfare of animals used for research must be respected. 
Because it is essential that the results of laboratory experiments be applied to 
human beings to further scientific knowledge and to help suffering humanity, the World 
Medical Association has prepared the following recommendations as a guide to every 
physician in biomedical research involving human subjects. They should be kept under 
review in the future. 
It must be stressed that the standards as drafted are only a guide to physicians all 
over the world. Physicians are not relieved from criminal, civil and ethical 
responsibilities under the laws of their own countries. 
I. BASIC PRINCIPLES 
1. Biomedical research involving human subjects must conform to generally 
accepted scientific principles and should be based on adequately performed 
laboratory and animal experimentation and on a thorough knowledge of the 
scientific literature. 
2. The design and performance of each experimental procedure involving human 
subjects should be clearly formulated in an experimental protocol which 
should be transmitted for consideration, comment and guidance to a specially 
appointed committee independent of the investigator and the sponsor provided 
that this independent committee is in conformity with the laws and regulations 
of the country in which the research experiment is performed. 
3. Biomedical research on human subjects should be conducted only by 
scientifically qualified persons and under the supervision of a clinically 
competent medical person. The responsibility for the human subject must 
always rest with a medically qualified person and never rest on the subject of 
the research, even though the subject has given his or her consent. 
4. Biomedical research involving human subjects cannot legitimately be carried 
out unless the importance of the objective is in proportion to the inherent risk 
to the subj ect. 
5. Every biomedical research project involving human subjects should be 
preceded by careful assessment of predictable risks in comparison with 
foreseeable benefits to the subject or to others. 
Concern for the interest of the subject must always prevail over the interests of 
science and society. 
6. The right of the research subject to safe guard his or her integrity must always 
be respected. Every precaution should be taken to respect the privacy of the 
subject and to minimize the impact of the study on the subject's physical and 
mental integrity and on the personality of the subject. 
7. Physicians should abstain from engaging in research projects involving human 
subjects unless they are satisfied that the hazards involved are believed to be 
predictable. Physicians should cease any investigation if the hazards are found 
to outweigh the potential benefits. 
8. In publication of the results of his or her research, the physician is obliged to 
preserve the accuracy of the results. Reports on experimentation not in 
accordance with the principles laid down in this Declaration should not be 
accepted for publication. 
9. In any research on human beings, each potential subject must be adequately 
informed of the aims, methods, anticipated benefits and potential hazards of 
the study and the discomfort it may entail. He or she should be informed that 
he or she is at liberty to abstain from participation in the study and that he or 
she is free to withdraw his or her consent to participation at any time. The 
physician should then obtain the subject's freely-given informed consent, 
preferably in writing. 
10. When obtaining informed consent for the research project the physician 
should be particularly cautious if the subject is in a dependent relationship to 
him or her or may consent under duress. In that case the informed consent 
should be obtained by a physician who is not engaged in the investigation and 
who is completely independent of this official relationship. 
11. In the case of legal incompetence, informed consent should be obtained from 
the legal guardian in accordance with national legislation. Where physical or 
mental incapacity makes it impossible to obtain informed consent, or when the 
subject is a minor, permission from the responsible relative replaces that of 
the subject in accordance with national legislation. 
12. Whenever the minor child is in fact able to give a consent, the minor's consent 
must be obtained in addition to the consent of the minor's legal guardian. 
13. The research protocol should always contain a statement of the ethical 
considerations involved and should indicate that the principles enunciated in 
the present Declaration are complied with. 
II MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE 
(CLINICAL RESEARCH). 
1. In the treatment of the sick person, the physician must be free to use a new 
diagnostic and therapeutic measure, if in his or her judgment it offers hope of 
saving life, reestablishing health or alleviating suffering. 
2. The potential benefits, hazards and discomfort of a new method should be 
weighed against the advantages of the best current diagnostic and therapeutic 
methods. 
3. In any medical study, every patient - including those of a control group, if any 
- should be assured of the best proven diagnostic and therapeutic method. This 
does not exclude the use of inert placebo in studies where no proven 
diagnostic or therapeutic method exists. 
4. The refusal of the patient to participate in a study must never interfere with the 
physician-patient relationship 
5. If the physician considers it essential not to obtain informed consent, the 
specific reasons for this proposal should be stated in the experimental protocol 
for transmission to the independent committee. 
6. The physician can combine medical research with professional care, the 
objective being the acquisition of new medical knowledge. only to the extent 
that medical research is justified by its potential diagnostic or therapeutic 
value for the patient 
III NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING 
HUMAN SUBJECTS (NON-CLINICAL BIOMEDICAL RESEARCH) 
1. In the purely scientific application of medical research carried out on a 
human being, it is the duty of the physician to remain the of the life and 
health person on whom biomedical research is being carried out. 
2. The subject should be a volunteer - either healthy persons or patients for 
whom the experimental design is not related to the patient's illness. 
3. The investigator or the investigating team should discontinue the research if 
in his/her or their judgment it may, if continued, be harmful to the 
individual. 
4. In research on man, the interest of science and society should never take 
precedence over considerations related to the well-being of the subject. 
Appendix VIII 
Bar Diagrams representing (A) Blood lead levels (ug/dl) vs 
Frequency. (B) ZPP (Ilmol/mol Hg) vs Frequency in the Lead 
acid battery plant. 
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